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Abstract	  
The global pandemic of obesity continues to escalate worldwide and results in severe multi-
system metabolic dysfunction in the expanding population of its sufferers. It is associated 
with the concurrent pathologies of type 2 diabetes, cardiovascular disease, cancer and sleep 
apnoea, which have also increased in prevalence over the past decade. Obesity can be mapped 
in social networks and is recognised as a fundamental element of the metabolic syndrome 
contributing to the global burden of diabesity and oncobesity. Its impact on global health has 
resulted in a massive burden on healthcare services and is among the most prominent 
contributors to mounting healthcare costs. Despite its pathological impact, the non-surgical 
management of obesity through behavioural, lifestyle and pharmacotherapies has not offered 
dependable benefits in severely obese patients. Bariatric surgery has demonstrated consistent 
weight loss in morbidly obese subjects and is increasingly performed worldwide to treat 
morbid obesity. Furthermore, these operations may produce beneficial metabolic effects 
especially with respect to improvement in type 2 diabetes and the metabolic syndrome.  
 
Understanding surgical weight loss mechanisms and metabolic modulation is required to 
enhance patient benefits and operative outcomes. A surgical model of Roux-en-Y gastric 
bypass (RYGB) was developed as an experimental platform to investigate the metabolic 
effects of bariatric surgery. The model was studied through a systems biology approach to 
characterize systemic and gastro-intestinal surgical metabolic modulation. Analysis of post-
operative faecal samples from this rodent model revealed a powerful shift in gut microbial 
ecology and also highlighted the role of RYGB surgery in regulating the cross-talk between 
the gut microbiome and its mammalian host. Similar metabolic changes were also identified 
in human subjects undergoing bariatric surgery. Analysis of plasma and cardiac tissue 
revealed shifts in metabolic activity, reflected by enhanced cardiac energy metabolism. 
Overall, the results of this work identify some of the potential mechanisms behind bariatric 
surgical weight loss and systemic metabolic enhancement. This study not only supports the 
term metabolic surgery but also identifies the global multi-systemic benefits of bariatric 
surgical procedures. As such, the findings presented in this thesis may in future contribute to 
the enhancement of current bariatric procedures and the development of the next-generation 
of innovative metabolic therapies. 	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Chapter	  1	  -­‐	  General	  Introduction	  
1.1	  The	  Impact	  of	  Excess	  Body	  Weight	  and	  Obesity	  
1.1.1	  Energy	  Regulation	  and	  Adiposity	  
The human body exhibits physiological and biochemical capabilities to offer effective 
wide-ranging environmental adaptability. Energy regulation is a core component of 
environmental adaptability and can be classified into two principal elements, (i) long-
term and (ii) short-term energy regulation. The ability to effectively regulate these 
processes is recognised as a fundamental component of human evolutionary success 
where the ability to lay down long-term energy stores with the concomitant capacity 
to rapidly present processed fuel offered a survival advantage at key evolutionary 
time periods such as the ice age.[1] 
 
Biomolecular mechanisms of long-term energy storage have been achieved through 
the accumulation of essential and nonessential lipids in the form of triglycerides 
(triacylglycerols) stored in adipocyte cells or adipocytes. Rapid energy release has 
also been achieved through the universal cellular mediator of glucose regulated by an 
endocrine insulin-glucagon system.[2] An accumulation of triglycerides in adipocytes 
offers the potential advantages of enhanced temperature regulation and thermogenesis 
that may protect from the biological extremes of cold whilst offering energy release in 
periods of nutritional insufficiency and famine. An excess of adipocytes is however 
associated with localized and systemic inflammation and metabolic toxicity[3] that 
can lead to metabolic dysfunction resulting in multi-systemic diseases such as Type 2 
diabetes and the metabolic syndrome.[4-6] Furthermore, an excess of adipocytes and 
their contents is also associated with tumourigenesis and cancer development.[7]  
 9 
1.1.2	  Classification	  of	  Adiposity	  –	  The	  Body	  Mass	  Index	  (BMI)	  	  
The classification of degree of adipose accumulation is complex as adiposity is not a 
continuous trait and there are no clear-cut dichotomies between ‘excess’ and ‘normal’ 
adipose levels.[8] The first attempts to normalize for levels of adiposity came from 
mortality risk tables derived from the Insurance industry in the United Sates derived 
from the Metropolitan Life Insurance Company in 1959. Belgian statistician Adolphe 
Quetelet[9] first introduced the concept of weight according to the body dimension of 
height (weight-height index) in the early nineteenth century, providing an improved 
measure of normal and excess body weight known as ‘Quetelet's index’.  
 
Quetelet's index was a measure of an individuals weight in kilograms divided by the 
square of their height in meters (mass[Kg]/height[m]2 or weight divided by height 
squared). This was subsequently termed the Body mass index or BMI in 1972,[10] 
and was validated as a reliable measure of fatness.[11] Although there are now 
numerous methods by which to classify obesity (such as anthropometry, dual-energy 
X-ray absorptiometry, computed tomography, magnetic resonance and skin fold 
thickness), BMI remains the most widely used measure of excess weight[12, 13] due 
to its simplicity of calculation, wide international acknowledgment and minimal 
requirement for additional instrumentation. 
 
A BMI value of 25kg/m2 was consistent with the upper end of the weight range for an 
individual with a large frame according to the 1959 Metropolitan Life Insurance 
Company tables and as a result, the World Health Organization applies this value as 
reference point to define the state of being overweight. From this point, an overall 
classification of obesity was developed to categorize fatness into normal, 
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underweight, overweight and obese individuals. These include a cut-off for 
overweight (BMI > or = 25), underweight (BMI<18.5), normal weight (BMI 18.5-
24.9). Obesity is categorized into obesity class I (BMI 30-34.9), obesity class II (BMI 
35-39.9) and morbid obesity or class III obesity (BMI>40) (Table 1-1).[14, 15] 
 
The accuracy of BMI in predicting mortality has been assessed in large-scale studies 
and systematic reviews. Pooled analysis of 19 prospective studies encompassing 1.46 
million white adults, ranging 19 to 84 years revealed that during a median follow-up 
of 10 years, there was a J-shaped relationship between BMI and all-cause mortality. 
Overweight and obese individuals with BMI ≥25 demonstrated increased all-cause 
mortality when compared to normal weight individuals (BMI 20 to 24.9) with a 
hazard ratio of 1.31 (95% CI 1.29-1.33) per 5-unit increase in BMI.[16] Similarly, 
meta-analysis of 97 studies with a combined sample size of more than 2.88 million 
individuals revealed that relative to normal weight individuals, all grades of obesity 
and specifically class II and III obesity were associated with significantly higher all-
cause mortality.[17] These studies therefore highlight that beyond its application as a 
marker of obesity, BMI carries clinical relevance through its association with all-
cause mortality outcomes. 
 
BMI (kg/m2) Classification 
< 18.5 Underweight 
≥ 18.5 and <25.0 Normal Weight 
≥ 25.0 and <30.0 Overweight 
≥ 30.0 Obese (in general) 
≥30.0 and <35.0 Obese Class I (moderate obesity) 
≥35 and <40.0 Obese Class II (severe obesity) 
≥40.0 Obese Class III (morbid obesity) 
 
Table 1-1 – Classification of Obesity according to World Health Organization (WHO) criteria. 
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1.1.3	  Epidemiology	  of	  Obesity	  
Mankind has recognized obesity since the Palaeolithic era[18] where sculptural 
evidence of heavily obese figurines exist at sites such as Hohle Fels[19] in Germany 
dated to approximately 35,000 years ago and Willendorf[20] in Austria dated to 
approximately 28,000 years ago (Figure 1-1). Obesity was typically seen as a sign of 
wealth, fertility and abundance so that it was notable and celebrated in anthropologic 
deities, leaders and individuals in the highest socioeconomic classes.[21] However, 
since the industrial availability of refined sugars and high caloric foodstuffs in the 
context of increasingly sedentary lifestyles the prevalence of obesity has been steadily 
increasing since the end of the Second World War in 1945.[22] The extent of obesity 
has now become a major global healthcare concern. According to the World Health 
Organization (WHO),[23] the global burden of obesity has nearly doubled since 1980. 
In 2008, more than 1.4 billion adults (aged 20 and older) were overweight. Of these 
over 200 million men and nearly 300 million women were obese. 35% of adults aged 
20 and over were overweight in 2008, and 11% were obese. 65% of the world's 
population lives in countries where overweight and obesity kills more people than 
underweight. Furthermore, more than 40 million children under the age of five were 
overweight in 2011 (Figure 1-2) 
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Figure 1-1 – Depictions of Obesity in the Paelolithic era. (a) Venus of Hohle Fels (© University of 
Tübingen), (b) Venus of Willendorf (© The Bridgeman Art Library). 
 
Overall, more than 10% of the world’s adult population is obese. Whereas this was 
traditionally considered a high-income country issue, overweight and obesity are now 
on the rise in low- and middle-income countries, particularly in urban settings. More 
than 30 million overweight children are living in developing countries and 10 million 
in developed countries.[23] The development of genetic technologies such as 
genome-wide linkage scans and the more recent genome wide association (GWA) 
studies has revealed several gene candidate mutations associated with obesity 
including those of FTO, Leptin (LEP), Leptin Receptor (LEPR), proopiomelanocortin 
(POMC) pro-hormone convertase subtilisin/kexin type 1 (PCSK1), MC4R and an 
increasing number of array-identified targets.[24] Based on twin studies however, 
genetics and inheritance account for between 25 and 40% of obesity,[25] so that the 
 13 
environmental factors of eating behavior, sedentary lifestyle and diet account for 
approximately 60-75% of modern obesity rates. 
 
Figure 1-2 – 2005 Worldwide prevalence of obesity in adults over 20 years old (upper=overweight, 
lower= obese)  
 
Figure 1-3 – Obesity and overweight in OECD and non-OECD countries (adults). OECD Health Data 
2010, and WHO Infobase for Brazil, Chile, China, India, Indonesia, Russian Federation and South 
Africa.[26] 
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The conditions of overweight and obesity are the fifth leading risk for global deaths. 
In addition, 44% of the diabetes burden, 23% of the ischaemic heart disease burden 
and between 7% and 41% of certain cancer burdens are attributable to overweight and 
obesity. According to the OECD (Organisation for Economic Co-operation and 
Development (OECD),[26] obesity has climbed to the top of the global public health 
policy agenda. Before the 1980s, obesity prevalence was typically below 10%. Since 
that time, obesity rates have doubled or tripled in many countries worldwide and over 
50% the population in these countries are overweight with figures estimated to rise 
(Figure 1-2, 1-3, 1-4 and 1-5). OECD estimate that when employment and industrial 
production losses are added to health care costs, obesity accounts for over 1% of GDP 
in the United States. Furthermore, by 2030 the number of overweight individuals 
worldwide is projected to be 1.35 billion with 573 million being obese without 
adjusting for secular trends. If recent secular trends are to continue then the absolute 
numbers were projected to total 2.16 billion overweight and 1.12 billion obese 
individuals.[27] 
Figure 1-4 – Past and projected future overweight rates (OECD figures based on self-reported 
data).[26] 
 
 15 
 
Figure 1-5 – Projected obesity in selected areas. [World Bank] & [27] 
	  
1.1.4	  Morbidity	  and	  Mortality	  Associated	  with	  Obesity	  
The impact of obesity on increasing all-cause mortality has been addressed in several 
large systematic reviews that classify obesity according to BMI.[17] There is large-
scale prospective epidemiological evidence to support an increased risk of death with 
increased BMI,[28] particularly secondary to obesity-related metabolic dysfunction. 
Furthermore, obesity has been linked to a higher risk of death from indirect lifestyle 
causes including motor vehicular accidents.[29] In the paediatric population obesity 
can result in a significantly increased risk of long-term obesity and obesity-related 
disease[30-33] whilst also increasing mortality and morbidity in young oncology 
patients[34] in addition to raising the likelihood of traumatic rib and pelvic injuries 
and their complications in this patient cohort.[35] Furthermore, evidence suggests that 
maternal obesity can result in poor neonatal outcomes. One large multivariable 
analysis of 27 national datasets studying neonatal deaths from a population cohort of 
over 80,000 sub-Saharan Africans identified maternal obesity with an increased risk 
 16 
of early neonatal death (adjusted odds ratio 1·46, 95% CI 1·11–1·91).[36] The 
increased risk of mortality from obesity in the neonatal population was considered to 
derive from obesity-related prematurity, intrapartum events, or infections. 
Furthermore, recent evidence from a UK population of 37 709 people followed up for 
50 years suggests that maternal obesity is also associated with increased risk of all 
cause death in adult offspring.[37] 
 
Adipose tissue affects nearly every body system, so that the downstream effects of 
obesity that lead to early mortality may occur any anatomical location. The large 
prospective Renfrew and Paisley (Scotland) Study in 1972-6 offered important data 
on obesity co-morbidities for its female obese population who were non-smokers.[38] 
It demonstrated that obesity rates were highest in lower occupational classes (based 
on the registrar general’s classification of occupations) and that obese women in this 
socio-economic class had the highest mortality. 
 
1.1.5	  Obesity	  and	  the	  Impact	  of	  its	  Co-­‐Morbidities	  
The Prospective Studies Collaboration group performed a collaborative analysis of 57 
prospective studies with the aim of stratifying cause-specific mortality according to 
BMI.[39] They reported data from approximately 900,000 adults mostly in Western 
Europe and North America and identify that a BMI of 22·5–25 kg/m² is associated 
with the lowest overall mortality. Above this value a sequential increase of BMI by 
5kg/m² was associated with approximately a 30% higher overall mortality, 40% 
higher cardio-vascular mortality, 60–120% higher diabetic, renal, and hepatic 
mortality, 10% higher neoplastic mortality and 20% higher respiratory and other 
mortality. From this large prospective series, it can be identified that the most 
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significant co-morbidities associated with increased BMI (as a measure of obesity) are 
diabetes, cardiovascular, hepatic, renal, respiratory and neoplastic disease.  
 
1.2	  Obesity	  Co-­‐Morbidities,	  Diabetes,	  Metabolic	  Syndrome	  and	  Cancer	  	  
The global increase in the prevalence of obesity has been associated with a concurrent 
rise in global diabetes.[40] Currently more than 371 million people are diagnosed 
with diabetes worldwide although it is estimated that half of all diabetics remain 
undiagnosed. It is projected that the global total of diabetics will rise to 552 million 
by 2030.  80% of these patients live in low- and middle-income countries. Although 
the International Diabetes Federation (IDF) estimates a global healthcare spend of 
over 471 billion USD on diabetes, 4.8 million people die annually due to diabetes. 
The majority of the increase noted in global rates are for type 2 diabetes mellitus.[40] 
The term ‘diabesity’ has thus been coined as a result of the epidemiological rise in 
both obesity and type 2 diabetes mellitus, supported by mechanistic data linking 
defective insulin resistance and poor insulin release in both these disorders.[6, 41] 
 
Both obesity and diabetes (including impaired glycaemic control) have been clustered 
together with hypertension and dyslipidaemia to represent one condition that is 
associated with increased cardiovascular risk and mortality. This is known as the 
‘metabolic syndrome’. There are currently 16 various classifications of this condition 
and the common underlying mechanism is currently the subject of active research. 
This concept of a metabolic syndrome has led both clinicians and policy makers to 
focus on global therapeutic strategies for these disorders in order to decrease both the 
population risk and mortality of metabolic syndrome patients. A World Health 
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Organization Expert Consultation on the metabolic syndrome concluded that this was 
a pre-morbid condition as opposed to a clinical diagnosis, and they therefore 
suggested that this should exclude patients with established diabetes or known 
cardiovascular disease (CVD).[42] 
 
The rise in global obesity has also been associated with a concurrent rise in 
worldwide cancer rates.[43] The Million Women Study[44] in the United Kingdom 
studying over one million female subjects for over a 5 fear follow-up revealed a 
significant association between increased weight and cancer risk, particularly in the 
post-menopausal group. Furthermore, collaborative analysis of 900,000 adults has 
now confirmed a consistent association between body mass index, mortality and a 
number of male and female cancers including Breast, Ovarian, Cervical, Prostate, 
Oesophagus, Pancreas, Hepato-biliary, Colorectal, Renal, Thyroid, Epidermal 
(Melanoma) and Immunological malignancies (Leukaemia, Lymphoma, Myeloma). 
The World Cancer Research Fund systematically reviewed the data from nine 
international centers to study the relationship between seventeen different cancers and 
lifestyle factors including food, nutrition, physical activity, weight gain and obesity. 
The results of this study highlighted the association between obesity and cancer, and 
concluded that patients should aim to “Be as lean as possible within the normal range 
of body weight”.[45]  
 
1.3	  Bariatric	  Surgery	  
1.3.1	  The	  History	  of	  Bariatric	  Surgery	  
Anecdotal evidence from patients demonstrating weight loss from “short gut 
syndrome” after peptic, traumatic or cancerous bowel resection led surgeons to 
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believe that surgical weight loss could be achieved through so-called “malabsorption” 
or stomach size “restriction”. In 1954 three surgeons (Drs Kremen, Linner and 
Nelson) performed the first jejuno-ileal bypass in dogs, demonstrating significant fat 
malabsorption and weight loss,[46] thus heralding the birth of bariatric surgery. 
 
 
Figure 1-6 – Timeline of the development of bariatric operations 
 
 
Amongst the most common bariatric operations of the current era (Figure 1-6) 
include those were a stomach-bowel anastomosis is created (gastroenterostomy) 
where the stomach and the bowel characteristically follow a ‘Y” configuration. This 
was first performed by César Roux (1857–1934) who was a student of Emil Kocher 
and Chief of Surgery at the Hospital of Lausanne in Switzerland. Famed for having 
accomplished several ‘firsts’ in abdominal surgery including the first adrenelectomy 
for phaeochromocytoma in 1926, he performed the first Y gastroenterostomy 
(“ANSA-EN-Y”) for gastric outlet obstruction in 1888.[47] Roux credited Anton 
Wölfler (1850-1917) as initially conceiving the idea of a ‘Y’ configuration, as he had 
been the first to perform a gastroenterostomy in 1881, although he is not reported in 
ever having performed the Y gastroenterostomy operation. The Y configuration 
prevented the complications of primary bile reflux gastritis after primary 
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gastrojejunostomy seen after partial gastrectomy typically noted in the Billroth I and 
II procedures.[48] Although Roux’s original Y gastroenterostomy procedure was 
abandoned for many years due to high rates of marginal ulceration at the gastrojejunal 
anastomosis, it was rapidly re-adopted for managing post-gastrectomy problems and 
when the concept of a partial gastrectomy to achieve weight loss was introduced, 
Mason and colleagues implemented its use for bariatric surgery in 1967 (Figure 1-6) 
[49, 50] where it is eponymously entitled the Roux-en-Y gastric Bypass. 
 
1.3.2	  Current	  Status	  and	  Types	  of	  Bariatric	  Surgery	  
The first surgical weight loss procedures were derived independently in the mid-
1950’s by Richard Varco[51, 52] and Arnold Kremen.[46] The subsequent use of the 
term ‘bariatric surgery’ designates an umbrella term to account for all surgical 
procedures that are used to help in the reduction of excess weight. The word 
‘bariatric’ now used to describe these procedures stems from the combination of two 
Greek words, namely ‘baros’ and ‘iatrike’ that combine to literally mean ‘weight 
treatment’. 
 
These operations are further subdivided by surgeons into three groups; restrictive 
surgery, pure bypass operations (or traditionally named ‘malabsorptive surgery’) and 
combinative procedures. Technically a fourth category would include other 
procedures such as jaw wiring and fat-debulking surgery that includes 
abdominoplasty, liposuction and omentectomy, although these are not generally 
considered as purely bariatric operations. They can however mildly reduce weight in 
their own right, and can be used in conjunction with more conventional bariatric 
procedures.   
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Restrictive surgery literally restricts or decreases the size of the stomach and causes 
reduced hunger or earlier satiety with smaller volumes of food. Procedures within this 
category include gastric banding (GB) where an adjustable band is placed below the 
cardia of the stomach to create a small upper gastric pouch. Alternative restrictive 
techniques include a sleeve gastrectomy (SG), a procedure initially designed to form 
the restrictive component of the biliopancreatic diversion-duodenal switch 
operation.[53] With the advent of laparoscopic surgery in the late 1990s, sleeve 
gastrectomy was subsequently adopted as a first step in high risk patients undergoing 
Rou-en-Y gastric bypass, only later being performed as a standalone procedure.[54]  
Sleeve Gastrectomy literally involves resecting a large ‘sleeve’ of stomach leaving a 
small gastric tube with an intact pylorus. Older methods of restriction include 
gastroplasty, which partitions the stomach with the use of a stapler (either 
horizontally or vertically), limiting the area of the stomach to which food enters. Both 
procedures can be performed laparoscopically and can be carried out concurrently as 
in a vertical banded gastroplasty (VBG), where both banding and stapling take place.  
 
Pure Bypass Operations or the traditionally named ‘Malabsorptive Surgery’ 
were initially designed with the aim of decreasing the absorption of nutrients by 
excluding food from segments of the alimentary tract by either shortening tract length, 
bypassing anatomical segments of the gastrointestinal system, or even inter-
transposing various segments of bowel. Examples of this are the first described 
bariatric procedure of jejunoileal bypass (JIB),[46] the duodenojejunal bypass 
(DJB),[55] and biliopancreatic diversion[56] with or without duodenal switch.[57] 
Although these procedures can successfully induce weight loss, the term 
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‘malabsorptive’ can be misleading, as there is no clear evidence that ‘malabsorption’ 
accounts for the dramatic weight loss observed.[58-60]   
 
Combination surgery aims to join the benefits of both restrictive and malabsorptive 
procedures. Examples include Roux-en-Y Gastric Bypass (RYGB).[49, 61] Here a 
small stomach pouch is created and subsequently anastomosed to the jejunum (gastro-
jejunostomy). Bypass is then achieved by anastomosing the stomach remnant to a 
segment of jejunum, which creates an alimentary limb. The small bowel continues 
from the larger stomach remnant and is anastomosed to the jejunum via jejuno-
jejunostomy to create a bilio-pancreatic limb, which completes the ‘Y’ configuration 
of the Roux-en-Y bypass (Figure 2-2). Chyme now passes from the small stomach 
pouch directly to the jejunum, bypassing a large area of the stomach and the 
duodenum. As a result RYGB procedure can be summarised to result from five 
components: (1) small stomach pouch, (2) bypassed stomach and proximal small 
bowel, (3) alterations in the flow of bile, (4) manipulation of the vagus nerve (that can 
vary) and (5) distal small bowel being brought more proximally and thus allow earlier 
contact with food.  
 
Due to their dramatic effects on the resolution of diabetes, metabolic syndrome and 
the cardiovascular system,[62, 63] bariatric surgical procedures are now often 
considered as ‘metabolic operations’. Historically, ‘metabolic surgery’ was defined as 
‘the operative manipulation of a normal organ or organ system to achieve a biological 
result for a potential health gain’.[64]	   In modern practice however, ‘metabolic 
surgery’ or ‘metabolic operations’ represent the operative manipulation of the 
gastrointestinal system to achieve a biological result from a change in systemic and 
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local metabolism for potential health gain. With growing recognition of the potential 
metabolic benefits of bariatric surgical procedures, their study has become the focus 
of increasing mechanistic research, particularly as many of these actions occur before 
any noticeable weight loss.[65] 
 
Current Indications for Bariatric Procedures 
The National Institutes of Health (NIH), The American College of Surgeons (ACS), 
The Society of Gastrointestinal Endoscopic Surgeons (SAGES), The American 
Society of Metabolic and Bariatric Surgeons (ASM&BS) and the United Kingdom’s 
National Institute for Health and Clinical Excellence (NICE) have similar guidelines 
that identify patients who could be considered for bariatric surgery. In general 
bariatric surgery is indicated in morbidly obese patients (Body Mass Index (BMI) > 
40 kg/m2), or those with BMI > 35kg/m2 who suffer with significant comorbidities. 
Surgery should only be considered in these patients in the event that non-surgical 
treatment has been unsuccessful, and that all patients are reviewed and followed up 
within in a multi-disciplinary specialist obesity unit. 
 
Annually, approximately 340,768 procedures are performed worldwide, 101,645 of 
which take place in the USA/Canada and 10,000 of which are performed in the 
UK.[66] Of the multitude of surgical operations available, three are most widely 
accepted by the majority of bariatric surgeons. Each procedure (Roux-en-Y gastric 
bypass, Adjustable gastric band and Sleeve gastrectomy) offers distinctive effects on 
the resolution of obesity, however surgery also carries healthcare costs both in its 
operative expenses and long-term follow-up. Although some units report a 1-year 
mortality of 4.6%,[67] a meta-analysis of 361 studies on 85,048 patients undergoing a 
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wide spectrum of bariatric procedures revealed a perioperative (≤30 days) mortality of 
0.28% and 2-year postoperative mortality of 0.35%,[68] which is further corroborated 
by a recent multicentre prospective study focusing on the perioperative safety of 
bariatric surgery.[69] 
 
1.3.3	  Weight	  Loss	  and	  Clinical	  Benefits	  of	  Bariatric	  Procedures	  
Sustained long-term weight loss is rarely achieved with intensive lifestyle 
intervention alone. Indeed, weight loss in diabetic patients with a body mass index of 
30kg/m2 has been shown to be approximately 2kg at two years[70] and only 1.5kg at 
ten years.[71] This may be even less in patients when their starting body mass index 
is above 35kg/m2.[72] Bariatric surgery can offer sustained weight loss of 25-35kg or 
25-27% weight loss at 15 years (Table 1-2).[73, 74] 
 
	   Excess	  Weight	  Loss	  (%)	  –	  Data	  from	  
systematic	  review	  reporting	  weighted	  
mean	  results	  (excluding	  sleeve	  
gastrectomy)[75]	  
Actual	  Weight	  Loss	  (%)	  –	  Data	  from	  
prospective	  study[72,	  76]	  
Procedure	   2	  Years	   5	  Years	   7	  Years	   10	  Years	   15	  Years	  
Gastric	  Banding	   52.7	   55.2	   51.0	   14.0	   13.0	  
Biliopancreatic	  
Diversion	  with	  
Duodenal	  Switch	  
75.1	   73.3	   69.0	   NA	   NA	  
Roux-­‐en-­‐Y	  Gastric	  
Bypass	  
67.5	   58.2	   55.0	   25.0	   27.0	  
Sleeve	  
Gastrectomy[77]	  
67.42	   NA	   NA	   NA	   NA	  
 
Table 1-2. Metabolic surgical weight loss over time. NA=Not Available. Actual Weight Loss has only 
recently been calculated in surgical weight loss studies. Older studies consider Excess weight loss 
(EWL) = (weight before - weight after [kg]/excess body weight before) where excess body weight = 
(total body weight - ideal body weight). Ideal body weight refers to the weight if BMI = 25 kg/m2 
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Author Study Type 
Surgery 
subjects 
(n) 
Mean 
Follow 
Up 
(Years) 
Surgical 
weight 
loss 
Overall Mortality Cancer 
Surgery 
group 
mortality 
Non-
surgical 
obese 
mortality 
Reduction 
in the 
relative 
risk of 
death 
Surgery 
group 
cancer 
Non-
surgical 
obese 
cancer 
Reduction 
in the 
relative 
risk of 
cancer 
MacDonald 
[78] 1997 
Retro 154 9  
50% 
EWL 9% 28% 68% 
0% 
(mortality) 
0.6% 
(mortality) NS 
Christou 
[79] 2004 
Retro 1035 2.5 35% 0.68% 6.17% 89% 2.03% (incidence) 
8.49% 
(incidence) 
76% 
(incidence) 
Flum [80] 
2004 
Retro 3328 4.4 (median) NS 11.8% 16.3% 27.6% NS NS NS 
Adams et 
al.[81] 2007 
Retro 9949 7.1 NS 2.89% 4.41% 34.5% 0.42% (mortality) 
1.06% 
(mortality) 
60% 
(mortality) 
Adams [81] 
2007 
Retro 7925 7.1 NS 2.69% 4.05% 33.6% (40.0%)* 
0.39% 
(mortality) 
0.92% 
(mortality) 
57.6%  
(mortality) 
Sjostrom 
[72] 2007 
Pros 2010 10.9 (median) 13-27% 5.0% 6.3% 20.6% 
1.4% 
(mortality) 
2.35% 
(mortality) 
42.5% 
(mortality) 
Peeters [82] 
2007 
Retro 966 4.3 (median) 27Kg 0.41% 10.62% 
96% 
(82%)* 
0.2% 
(mortality) NS NS 
Sowemimo 
[83] 2007 
Retro 
908 4.5  NS 2.9% 14.3% 
79.7% 
(50%-
85%)* 
NS NS NS 
Busetto [84] 
2007 
Retro 821 5.6  
37.2% 
EWL 0.97% 4.38% 
77.9% 
(60%)* NS NS NS 
Christou 
[85] 2008 
Retro 
1035 2.5 35% NS NS NS 
2.03% 
(medical 
visits) 
8.49% 
(medical 
visits) 
76% 
(medical 
visits) 
Adams [86] 
2009 
Retro 
6596 12.5 NS NS NS NS 
3.85% 
(incidence) 
 
0.62% 
(mortality) 
5.05% 
(incidence) 
 
1.13% 
(mortality) 
24% 
(incidence) 
 
46% 
(mortality) 
Sjostrom[87
] 2009 
Pros 2010 10.9 (median) 19.9Kg NS NS NS 
5.8% 
(incidence) 
8.3% 
(incidence) 
30% 
(incidence) 
 
Table 1-3. Comparative overall mortality and cancer mortality/incidence rates between obese and 
metabolic surgical groups. NIDDM = non-insulin-dependent diabetes mellitus, NS= Not Specified, 
*=covariate adjusted figure. EWL = Excess Weight Loss(see Table 1.) Retro= Retrospective Study, 
Pros=Prospective Study. 
 
Bariatric surgery demonstrates a clear overall all-cause mortality benefit when 
compared to non-surgical obese matched controls (Table 1-3). Although reported 
studies vary as to the magnitude of reduction in relative risk of mortality, obese 
patients who have undergone bariatric surgery have been shown to achieve 
significantly lower long-term death rates than non-operated obese patients. Such a 
decrease however does not necessarily achieve a mortality comparable to that of 
normal-weighted individuals,[88] although surgery can significantly reduce several 
obesity-related co-morbidities including the resolution of diabetes[63] in 78.1% and a 
decrease in diabetes-related death by 92% and coronary-related death by 56%.[81] 
These findings have been supported by three recent randomized controlled trials 
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(RCTs) comparing bariatric surgery to conventional or intensive medical therapy 
revealing the significantly beneficial effect of these procedures on diabetes 
control.[70, 89, 90] A number of recent studies demonstrate that some of the mortality 
benefits from surgery are derived from a decreased incidence of cancer. Although 
intentional weight loss through lifestyle, diet and pharmacotherapy can all achieve 
improvements in glucose homeostasis and diabetes, these effects are difficult to 
maintain in the long-term[71]. Medical weight loss can reduce diabetes-related 
mortality in overweight patients by one-third[91] and overall mortality in diabetic 
patients also by one-third[92], whereas one observational study of metabolic surgical 
patients demonstrated a relative risk reduction of overall mortality by 89% when 
compared to non-surgical controls[79]. 
 
1.3.4	  Understanding	  the	  Mechanisms	  of	  Bariatric	  Procedures	  
Neither the surgical nor the scientific community had initially expected the profound 
effect of bariatric operations in providing metabolic effects independent to weight 
loss. As these operations provided novel disease management in endocrine diseases 
such as type 2 diabetes mellitus early investigators hypothesized that these operations 
may offer endocrine actions, which may work through systemic hormones. In 1975 it 
was revealed that gastrointestinal bypass operations could modulate some gut 
hormones.[93, 94] Many of these surgically modulated hormones demonstrate 
anorectic actions, and their post-operative weight-loss effects can be significant, even 
when confronted with severe underlying metabolic dysfunction.[95] Furthermore, 
some hormones may have a concurrent effect on the resolution of type 2 diabetes and 
systemic metabolism. These hormonal effects can be classified according to the 
embryological site of their release, the foregut (derivatives of which are supplied by 
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the Coeliac axis), the midgut (supplied by the superior mesenteric artery) and the 
hindgut (supplied by the inferior mesenteric artery). Two gut hormones that have been 
well described as being modulated after bariatric surgery include peptide-YY and 
glucagon-like peptide-1 (GLP-1).[73] The latter has been identified as offering both 
appetite regulating, cardiovascular and incretin activity, so that agonists at the GLP-1 
receptor have been developed as treatments for type 2 diabetes.[96] 
 
Not all bariatric patients achieve ‘good weight loss’. Approximately 10-15% of 
gastric bypass patients experience ‘poor weight loss’ which is commonly associated 
with a greater starting Body Mass Index, male sex, and diabetes.[97, 98] This may 
represent a diminished gut hormone release or response, with increasing evidence 
demonstrating augmentation of weight loss with external gut hormone therapy. 
Similarly, gut hormonal blockade by antibodies or pharmacological agents (such as 
Octreotide) can diminish the weight loss seen in these operations.[59]  
 
1.5	  Unexplained	  effects	  not	  accounted	  for	  by	  Gut	  Hormones	  
 
Gut peptides may be a major contributor through which the gastrointestinal tract can 
communicate with the brain to regulate feeding behaviour and energy balance. This 
gut-brain axis has developed a sophisticated collection of peptides with which to relay 
its messages. These can travel via the nervous system, the systemic circulation or both 
to deploy energetic information to the brainstem and higher food regulatory centres. 
Bariatric (or ‘metabolic’) surgical procedures are not all the same, with each 
procedure transmitting a characteristic hormonal profile to the brain. Anatomical 
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variations in surgery can result in distinct metabolic message that ultimately leads to 
an improvement in both obesity and metabolic status. 
 
Whilst gut hormones represent one powerful mechanism through which bariatric 
operations offer successful effects, gut hormones alone do not reflect the entire 
metabolic activity offered by these procedures. Traditionally it has been considered 
that the effects of bariatric surgery can be replaced by a pharmacological mix to 
reflect post-bariatric changes, a so-called “pharmacological gastric bypass” or “drug 
bypass”. One large recent systematic review and meta-analysis of randomised 
controlled trials on the effects of glucagon-like peptide-1 receptor agonists revealed 
significant weight loss 2.9Kg and glycaemic enhancing effects (reduction of 
glycosylated haemoglobin HbA1c –0.63%) by these medications.[99] However these 
effects are not so pronounced when studied against to a large systematic review of 
bariatric surgery revealing over 38kg of weight loss, a reduction of HBA1c by 2.24% 
and 78.1% resolution of diabetes mellitus[63] in a comparable period. 
 
The mechanisms through which bariatric operations carry out their beneficial actions 
remain unclear. The traditional bottom-up hypothesis testing of peptide modulations 
derived from clinical trials has offered some insights (such as the role of gut 
hormones), however leaves many mechanistic questions unanswered. More recently, 
advances in top-down systems biology methodologies have provided an added 
dimension to studies of disease pathogenesis through metabolic profiling. It is 
therefore possible that the application of such methodologies to bariatric surgical 
operations may offer new insights into the mechanism by which they carry out their 
beneficial actions. 
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Metabolic profiling may be defined as ‘measurement of the dynamic multiparametric 
metabolic response of living systems to pathophysiological stimuli or genetic 
modification’.[100] Practically, this involves characterization of the low-molecular 
weight metabolites and their intermediates that reflect the dynamic response of a cell 
or multicellular system to genetic modification, physiological, pathophysiological 
and/or developmental stimuli.[101] 
 
In order to overcome the complex array of human patient variables after surgery, an 
experimental model of bariatric surgery can offer increased robustness and precision 
of data assessment. By combining this model with top-down metabolic profiling, this 
work strives to better elucidate and quantify the specific chemical and metabolic 
changes associated with bariatric surgical procedures.  
 
1.6	  Project	  Aims	  
 
1. Develop an experimental (animal) model of bariatric surgery. The procedure 
should be anatomically equivalent human bariatric surgery (Roux-en-Y Gastric 
Bypass) 
2. Identify the systemic metabolic activity of bariatric surgery (using my 
experimental model) applying a top-down systems biology approach. 
3. Identify the organ-specific effects of bariatric surgery. I will focus on cardiac 
specific changes to discern whether these operations offer targeted beneficial cardiac 
effects. 
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Chapter	  2	  –	  Development	  of	  a	  Surgical	  Model	  of	  Bariatric	  
Surgery	  
 
2.1	  Introduction	  
2.1.1	  Multifactorial	  variables	  in	  assessing	  bariatric	  patients	  
 
Bariatric surgery demonstrates clear metabolic benefits for the reduction of obesity 
and the management of its co-morbidities such as type 2 diabetes mellitus. However 
the physiological effects demonstrated by each bariatric operation has rendered the 
understanding of operative mechanisms as complex and incomplete. Amongst the 
many confounding factors that contribute to difficulties in analyzing the benefits of 
surgery are significant variations in patient pre- and post-operative eating patterns and 
disease-load, lifestyle activity, behavior, healthcare support, pharmacotherapy and 
environmental exposure to high caloric foods and social networks.[102] These 
elements (Table 2-1) confound research comparisons so that between-subject 
variation is high and the subsequent identification of cause and effect variables 
becomes inaccurate.  
 
Patient Variables Confounding the 
Assessment of Bariatric Surgical Mechanisms 
 
Eating Pattern 
Bariatric 
Surgery 
Metabolic 
Enhancement 
and Disease 
Resolving 
Mechanisms 
Toxic Environment 
Lifestyle activity 
Pharmacotherapy 
Healthcare Support 
Behaviour 
Social Networks 
 
Table 2-1 – Patient Variables Confounding the Assessment of Bariatric Surgical Mechanisms 
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In order to minimize many of these confounding variables in the assessment of 
bariatric surgical mechanisms, the application of a representative model of surgery 
can be applied to control for experimental variables and enhance the robustness and 
precision of results. One successful technique to model surgery in this way has been 
through the use of animal models.[103] 
 
My aim was to apply an appropriate model of bariatric surgery to assess for the 
metabolic activity of these operations. Although a translational study in human 
patients is a critical element of identifying the metabolic activity of surgery, this alone 
would not offer adequate control of the multifactorial elements in bariatric patient 
management to discern any clear scientific mechanistic answers. I therefore decided 
to investigate the potential for a physiologically representative animal model of 
bariatric surgery.  
 
2.1.2	  Animal	  Models	  in	  the	  Development	  of	  Bariatric	  Surgery	  
A significant proportion of our knowledge in bariatric surgery was derived from the 
study of animal models. For over half a century they have contributed to the 
continuing evolution of bariatric surgery. A variety of models have been used in 
several animal species (Figure 2-1), ranging from rodents, where microsurgical 
techniques are necessary, to large pigs, which have body dimensions concordant with 
human obese body types and are often applied as training models for modern in-vivo 
laparoscopic surgical training.  
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Figure 2-1 – Overview of Animal Models Applied to Study Bariatric Surgical Mechanisms 
 
The first generation of operations included the jejuno-ileal bypass and partial-ileal 
bypass that led to the development of the current procedures including Roux-en-Y 
Gastric Bypass, Biliopancreatic Diversion, Adjustable Gastric Banding and Sleeve 
Gastrectomy (Figure 1-6). These operations carry significant metabolic benefits and 
can reduce the risk of diabetes, heart disease and cancer. Further insights from these 
animal models can reveal genetic, molecular and systemic effects that can enhance 
and develop the next generation of metabolic operations. 
	  
Roux-­‐en-­‐Y	  Gastric	  Bypass	  (RYGB)	  
Roux-en-Y Gastric Bypass has been considered as the ‘gold standard’ bariatric 
procedure for three decades. Its effects of successful weight loss and low morbidity 
with improved quality of life have ensured its continued use in the modern era. As a 
result, it remains to be the standard against which other metabolic operations are 
compared. 
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Gastric bypass (without a ‘Y’ anastomosis) was first performed in the late 1960’s by 
Mason and Ito [49] and combined the lessons learned from jejuno-ileal bypass, 
Billroth II operations and Y anastomoses from ulcer surgery. Griffen subsequently 
modified the procedure in 1977 with a retro-colic Roux-en-Y anastomosis (gastro-
jejunostomy)[104, 105] so that the complications of biliary reflux were significantly 
decreased. The current procedure, which has been performed laparoscopically since 
1994,[106] is described on Pages 23-24 and shown in Figure 2-2.  
 
 
 
Figure 2-2 – Anatomical rearrangement in Metabolic Roux-en-Y Gastric Bypass 
 
Canine Models of RYGB 
Gastric bypass in dogs with Pavlov pouches demonstrated better secretory acid 
elimination when compared to the older gastric antral exclusion operations used in 
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peptic ulcer disease.[49] Mongrels with pancreatic and duodenal catheters revealed 
that although there is a decrease in pancreatic protein enzymes after gastric bypass, 
there is no significant decrease in pancreatic bicarbonate secretion.[107] These studies 
also sparked off the interest of the role of caloric stimulation in gut hormonal 
modulation after bypass.[108]  
 
Porcine Models of RYGB 
Gastric bypass in pigs revealed that surgery might result in some deleterious effects 
on the preservation of smooth muscle and on interstitial cell of Cajal (ICC) continuity 
when compared to the ‘uncut’ Roux procedure.[109] These animals of larger size 
offer a larger degree of anatomical equivalency to humans, but also carry a 
considerable expense. Other porcine models have been applied to discern the 
feasibility of newer surgical techniques such as the banding of stomach bypasses for 
preventing pouch dilation,[110] or assessing newer laparoscopic instrumentation for 
these procedures including surgical staplers[111] and Nitinol Compression 
Anastomosis Clips.[112] Some of the porcine models have been used to demonstrate 
of the applicability of Natural Orifice Transluminal Endoscopic Surgery (NOTES) to 
bariatric procedures. However, among the most important uses of these large animal 
models resides in their use as models for laparoscopic surgical training.[113] 
 
Rodent Models of RYGB 
Rodent models of gastric bypass have only recently been introduced (Table 2-2), and 
were set-up to investigate human surgical observations, heralding a new age in 
metabolic surgical science. However, the operations can be technically demanding 
and the required microsurgery does not accurately represent the same skills used in 
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laparoscopic human gastric bypass. The weight loss seen in rodents after RYGB 
closely follows the changes seen in humans,[114-118] and this is also substantiated by 
a parallel change in gut hormones.[119] These models have revealed hypothalamic 
neurochemical changes (NPY, alpha-MSH, serotonin)[120], genetic profiles[121] and 
a role for peripheral endocannabinoids and mitochondrial complexes in the 
mechanism of sustained weight loss after gastric bypass.[122] They also suggest that 
there is no increased risk of Helicobacter pylori infection[123] or gastric cancer in 
rodents undergoing these procedures.[124] 
 
Successful weight loss in the rat gastric bypass model is associated with a rise in the 
satiety hormone PYY, GLP-1 and decrease in ghrelin and a concurrent drop in 
gastrin.[125-127] A failure in weight loss is associated with a failed rise in PYY.[126] 
These operations may work partially through the reduction of food intake,[128, 129] 
an increased preference for lower fat foods and taste changes (our unpublished data) 
but may also work through the increase of energy expenditure.[130, 131] Early data 
suggest, that gastric bypass may alter sodium and water handling leading to a greater 
urine output, water intake and sodium excretion (unpublished data from our unit) 
which may account for the early improvement in arterial hypertension in post-bypass 
patients.[132, 133] A recent mouse model of gastric bypass has revealed that these 
procedures improve disorders of glucose homeostasis through an increase in the gut  
hormone GLP-1, intestinal gluconeogenesis and its detection via the gut GLUT-2 
hepatoportal sensoring.[134] Interestingly, the Roux-en-Y anastomotic geometry 
protects against Barrett’s oesophagus and subsequent invasive adenocarcinoma 
induced by duodeno-oesophageal reflux in a rat model of adenocarcinoma[135]. The 
metabolic nature of RYGB has led some units to perform these procedures on human 
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patients purely to treat diabetes mellitus. In some cases, these have been applied to 
patients with body mass indices of 25 Kg/m2[136]. 
 
Author and 
Institution Rodent Pouch Formation 
Pouch 
Size 
Small 
intestinal 
Division 
Placement 
of Roux 
Limb 
Anastomoses 
Young et al.[129] 
1984 (University of 
Texas Health Science 
Center, San Antonio, 
Texas) 
Rat Stainless steel stapler 
(Auto Suture TA 30-4.8) 
(Non-cutting), separating 
stomach at glandular area 
(not divided). 
Not 
specified 
10-12 cm 
distal to 
pylorus 
10-12 cm 
downstream 
of gastro-
jejunostomy 
Not specified, 
however 
reinforced with 
3-0 silk 
Xu et al.[137] 2002 
(University of 
Syracuse, New York, 
USA) 
Rat Transverse transection with 
linear-cutting stapler  
20% 16 cm 
distal to 
ligament 
of Treitz 
10 cm 
downstream 
of gastro-
jejunostomy 
Interrupted 5-0 
polyglactin 
Stylopoulos et 
al.[116] 2005 
(Harvard Medical 
School, USA)  
Rat Gastric transection at ridge 
that separates the fore-
stomach and glandular 
stomach 
Not 
Specified 
15-18 cm 
distal to 
ligament 
of Treitz 
Not 
Specified (10 
cm Roux 
limb) 
Running 6-0 
silk 
Stenström et al.[118, 
123] 2005 & 2006 
(University Hospital 
of Trondheim, 
Norway) 
Rat 
 
& 
 
Mouse 
No Pouch, Anastomosis of 
first bulb of duodenum 
directly to oesophagus. 
Removal of whole stomach 
0% 2-3 cm 
distal to 
ligament 
of Treitz 
 
Shorter 
for mice 
Directly at 
level of 
gastro-
jejunostomy 
Not specified 
Inoue et al.[124] 2007 
(IRCAD, Strasbourg, 
France) 
Rat Gastric division 5mm distal 
to gastro-oesophageal 
junction 
Not 
specified 
10 cm 
distal to 
ligament 
of Treitz 
15 cm 
downstream 
of gastro-
jejunostomy 
Interrupted 6-0 
Maxon 
Tichansky et al.[115] 
2008 (University of 
Tennessee, USA) 
Rat Transverse transection with 
linear-cutting stapler and 
partial removal of excluded 
stomach  
(2-3 ml) 
10% 
Division 
10 cm 
distal to 
duodenu
m 
15 cm 
downstream 
of gastro-
jejunostomy 
Running 5-0 
prolene 
Troy et al.[134] 2008 
Universite Paris and 
Lyon, France 
Mouse No Pouch. Anastomosis of 
Stomach to small bowel 
excluding the duodenum 
and jejunum 
0% Not 
specified 
No Roux 
limb 
Not specified 
Lee et al.[138] 2009 
Seoul St. Mary’s 
Hospital, Republic of 
Korea 
Rat Not specified 20% 16 cm 
distal to 
ligament 
of Treitz 
10 cm 
downstream 
of gastro-
jejunostomy 
Not specified 
Hernandez et al.[139] 
2009 
University Hospital of 
Sant Joan. Rovira i 
VirgiliUniversity, 
Reus, Spain 
Rat Transverse transection 33% 15 cm 
distal to 
ligament 
of Treitz 
10 cm 
downstream 
of gastro-
jejunostomy 
Not specified 
Our Institution 
(Imperial College 
London, UK) 
Rat Gastric division by 
microsurgical scissors to 
leave ‘sliver of gastric 
tissue’ as a pouch. Gastric 
remnant left in situ 
<5% 10 cm 
distal to 
the 
pylorus 
28 cm 
proximal to 
caecum 
Interrupted 7-0 
prolene  
 
Table 2-2 – Rodent Models of Gastric Bypass 
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This operation improves quality of life in the majority of patients[140] and carries a 
30-day mortality of 0.3% [69, 141]. It is recognised as a leading metabolic procedure 
in view of its low morbidity compared to other bypass procedures such as 
biliopancreatic diversion [142, 143] and its metabolic superiority compared to non-
bypass procedures such as gastric banding [144]. 
 
2.1.4	  Aims	  in	  Developing	  a	  Rodent	  Model	  of	  Roux-­‐En-­‐Y	  Gastric	  Bypass	  
 
My aim was to develop an appropriate experimental animal model of the Roux-En-Y 
Gastric Bypass surgery. I chose this procedure, as it is the most common bariatric 
operation that demonstrates immediate weight loss-independent metabolic effects (in 
addition to subsequent weight loss-dependent metabolic effects). Other common 
bariatric procedures, such as the adjustable gastric band, achieve their metabolic 
activity primarily through weight-dependent effects and thus are not considered here. 
 
The goal of my model was to demonstrate: 
1. Anatomical equivalence to human Gastric Bypass 
2. Analogous Physiology in terms of weight loss 
3. Develop an appropriate sham operation – to reflect the Roux-En-Y Gastric 
Bypass Procedure (consisting of a laparotomy and two enterotomies) 
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2.2	  Methods	  
2.2.1	  Developed	  rodent	  model	  of	  Roux-­‐En-­‐Y	  Gastric	  Bypass	  
 
Preparation 
Before embarking on developing my animal model of Roux-En-Y Gastric Bypass 
surgery, I ensured I had trained in animal husbandry and microsurgical techniques. I 
had obtained the appropriate licenses in according with the Animals (Scientific 
Procedures) Act of Parliament (United Kingdom) in 1986. I had communicated with 
my university veterinarians and central biological services facility regarding my 
proposed operative plans. Furthermore I performed my technique of Roux-En-Y 
Gastric Bypass in 156 rodent cadavers before commencing this on live subjects. 
 
Overview of the Developed Roux-En-Y Gastric Bypass Technique 
The procedure involves the creation of a sliver of stomach tissue to form a direct 
equivalent of gastric pouch in adult human surgery, a single layer interrupted-suture 
gastrojejunostomy (prolene), a 10cm antecolic, antegastric Roux-limb, and an 
interrupted-suture end-side jejuno-jejunostomy. This technique begins with the 
creation of the Roux-limb, followed by the gastrojejunostomy, and to end with the 
jejuno-jejunostomy. 
 
Set-up and Positioning 
All procedures are performed under the Animals (Scientific Procedures) Act of 
Parliament (United Kingdom) in 1986. Furthermore Universal/Standard surgical 
precautions are applied throughout the procedure. The surgeon prepares for the 
operation by employing surgical loupes or surgical microscope. 
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After the induction of general anesthesia and the administration of prophylactic 
antibiotics and analgesia, the subject is placed supine on a microscopic operating table 
and is strapped in above and below the waist. Drapes are placed to cover the torso and 
limbs, excluding the abdominal skin. Animal monitoring (visual and 
electrophysiological) is commenced to ensure subject safety at all times. 
 
The abdomen is shaved and prepped with anti-septic solution. 
A midline laparotomy is performed with McIndoe Scissors. 
 
Jenunostomy with the creation of Roux and Biliopancreatic Limbs 
With the animal in the supine position, the omentum is advanced toward the upper 
abdomen to expose the ligament of Treitz. The jejunum is measured 10cm distal to 
the pylorus. 
 
Microsurgery scissors are applied perpendicular to the jejunum and parallel to the 
mesenteric vascular arcade to create the biliopancreatic limb (in continuity with the 
anatomical stomach) and the Roux-limb which will be in continuity with the eventual 
stomach pouch (Figure 2-3). 
 
Advancement of the Roux-limb 
The omentum is divided with microsurgical scissors from the transverse mesocolon to 
its inferior edge. Dividing the omentum reduces tension on the Roux-limb as it passes 
in front of the colon up towards the stomach (at the site of the eventual gastric pouch). 
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Careful attention is paid to ensure that the Roux-limb mesentery is not twisted and its 
vascular supply is not compromised. 
 
Creation of the Gastric Pouch 
The upper stomach is exposed by manually retracting the liver anteriorly. A window 
is created in the “bare area” of the gastrohepatic ligament immediately anterior to the 
caudate lobe of the liver. Microsurgery scissors are used to divide the lesser omentum 
2-3 mm distal to the gastroesophageal junction (demarcated by the epigastric fat pad). 
The microsurgery scissors are then applied across the gastric cardia (1-2mm from the 
gastroesophageal junction) toward the angle of His to create a small gastric pouch of 
approximately 0.0625mL (proportionally equivalent to the 15mL pouch in human 
Roux-En-Y Gastric Bypass Surgery). The incised edge of the larger stomach pouch is 
over-sewn with 5-0 polypropylene sutures in two layers to ensure adequate closure 
and haemostasis. The edges on both sides of the transected stomach are examined to 
ensure that they are intact and not bleeding. The Roux-limb is then advanced toward 
the gastric pouch in preparation for an omega-loop end-side gastrojejunal 
anastomosis. 
 
Creation of the gastrojejunostomy 
The antimesenteric border of the Roux-limb is approximated to the posterior wall of 
the gastric pouch with running 7-0 polypropylene sutures. A gastrotomy and then an 
enterotomy are made by means of microsurgery scissors. A single layer interrupted 
concentric anastomosis is performed with 7-0 polypropylene sutures using 
Castroviejo Micro Needle Holders. The gastric pouch is then covered with an omental 
patch (equivalent to the “shower cap” in human surgery) to protect against leakage. 
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Jejuno-jejunostomy 
An end-side jejuno-jejunostomy is performed by approximating the Roux-limb to the 
biliopancreatic limb (28cm proximal to the caecum) at the antimesenteric borders 
with 7-0 polypropylene. This is used as a stay suture during creation of the 
anastomosis. By means of microsurgery scissors enterotomies are made at the 
biliopancreatic corner and antimesenteric border of the Roux-limb. A single layer 
interrupted concentric jejuno-jejunostomy anastomosis is performed with 7-0 
polypropylene sutures using Castroviejo Micro Needle Holders. Care is taken to 
ensure that the lumen on the Roux limb side is not compromised. An anti-obstruction 
stitch (Brolin stitch) is applied to approximate the Roux-limb to the biliopancreatic 
limb proximal to the anastomosis. This is intended to prevent the afferent limb from 
folding back on itself and causing an obstruction. The jejuno-jejunostomy is 
completed by closing the mesenteric defect with a running 5-0 polypropylene suture. 
An internal hernia resulting in a bowel obstruction may develop if the defect is left 
unclosed. 
 
Closure and Recovery 
After ensuring adequate anastomotic integrity and haemostasis, the midline 
laparotomy is closed with interrupted vertical mattress suture formation using 2-0 
polypropylene sutures. Local anaesthesia is inserted into the site of laparotomy 
incision and general analgesia is also administered. Anaesthesia is reversed and 
subjects are allowed to recover in a cage with: (1) a heating mat; (2) provision of in-
cage drinking water (it would be painful for subjects to exert and stretch their 
abdominal incisions to reach cage water dispensers after abdominal surgery); (3) 
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cages filled with soft shredded paper (for subject comfort) and (4) soft water-soaked 
chow placed in the cage for subject spontaneous feeding. Subjects are monitored 
regularly in the post-operative period to ensure adequate recovery and analgesia. 
Figure 2-3 – Anatomical configuration diagram of the author’s rodent model of Roux-En-Y Gastric 
Bypass 
 
2.2.2	  Developed	  rodent	  model	  of	  Sham	  Procedure	  for	  the	  Roux-­‐En-­‐Y	  Gastric	  Bypass	  
 
Overview of the Developed Sham Procedure for the Roux-En-Y Gastric Bypass  
The procedure involves the creation of a laparotomy and two enterotomies to offer 
equivalence to the incisions made in my model of the Roux-En-Y Gastric Bypass. 
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Both operations involve a midline laparotomy. The two enterotomies in the sham 
operation represent the incisions for the gastrojejunostomy and jejuno-jejunostomy. 
 
Set-up and Positioning 
All procedures are performed under the Animals (Scientific Procedures) Act of 
Parliament (United Kingdom) in 1986. Furthermore Universal/Standard surgical 
precautions are applied throughout the procedure. The surgeon prepares for the 
operation by employing surgical loupes or surgical microscope. 
 
After the induction of general anesthesia and the administration of prophylactic 
antibiotics and analgesia, the subject is placed supine on a microscopic operating table 
and is strapped in above and below the waist. Drapes are placed to cover the torso and 
limbs, excluding the abdominal skin. Animal monitoring (visual and 
electrophysiological) is commenced to ensure subject safety at all times. 
 
The abdomen is shaved and prepped with anti-septic solution. 
A midline laparotomy is performed with McIndoe Scissors. 
 
Jenunostomy and closure 
With the patient in the supine position, the omentum is advanced toward the upper 
abdomen to expose the ligament of Treitz. The jejunum is measured 10cm distal to 
the pylorus.  
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Microsurgery scissors are applied perpendicular to the jejunum and parallel to the 
mesenteric vascular arcade to create a jejunostomy. This is closed with 7-0 
polypropylene sutures using Castroviejo Micro Needle Holders. 
 
Creation of the Gastrotomy 
The omentum is divided with microsurgical scissors from the transverse mesocolon to 
its inferior edge (as in the Roux-En-Y Gastric Bypass Procedure).  The upper stomach 
is exposed by manually retracting the liver anteriorly. A window is created in the 
“bare area” of the gastrohepatic ligament immediately anterior to the caudate lobe of 
the liver. Microsurgery scissors are used to divide the lesser omentum 2-3 mm distal 
to the gastroesophageal junction (demarcated by the epigastric fat pad). Dividing the 
lesser omentum does transect the rodent nerve of Latarjet (to minimize the potential 
effects of pyloric dysfunction). The microsurgery scissors are then applied to the 
gastric cardia (1-2mm from the gastro-oesophageal junction) toward the angle of His 
to create a gastrotomy. This is over-sewn with 5-0 polypropylene sutures in two 
layers to ensure adequate closure and haemostasis. The edges on both sides of the 
incised stomach are examined to ensure that they are intact and not bleeding.  
 
Closure and Recovery 
After ensuring adequate anastomotic integrity and haemostasis, the midline 
laparotomy is closed with interrupted vertical mattress suture formation using 2-0 
polypropylene sutures. Local anaesthesia is inserted into the site of laparotomy 
incision and general analgesia is also administered. 
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Anaesthesia is reversed and subjects are allowed to recover in a cage with: (1) a 
heating mat; (2) provision of in-cage drinking water (it would be painful for subjects 
to exert and stretch their abdominal incisions to reach cage water dispensers after 
abdominal surgery); (3) cages filled with soft shredded paper (for subject comfort) 
and (4) soft water-soaked chow placed in the cage for subject spontaneous feeding. 
Subjects are monitored regularly in the post-operative period to ensure adequate 
recovery and analgesia. 
 
2.2.3	  Rodent	  Model	  Validation	  –	  Food	  Preference	  
 
RYGB operations were initially proposed to include stomach size restriction and 
malabsorption of food. Smaller stomach sizes after surgery lead to an early satiety 
following a meal, although there is no clear evidence to support a role for ‘caloric 
malabsorption’. Anecdotal evidence from post-RYGB patients led to our hypothesis 
that these operations modify food preference – the so-called “I don’t like burgers 
anymore” status. Here patients who enjoy high-fat, high-caloric diets before surgery 
change their feeding preferences to low-fat low-caloric diets based on food 
preference.[73]  
 
I undertook a randomized controlled trial (Figure 2-4) where 26 male obese Wistar 
rats were assigned to either RYGB or sham control procedure. Subjects were exposed 
to equal quantities of 3 types of food: (1) standard high fat, (2) flavoured high-fat and 
(3) flavoured low-fat chow. Food types 2 and 3 carried the same flavour to control for 
taste. Consumption of each food type was measured over 48-hours pre-operatively 
and then over 48-hours at day 10 post-operatively. 
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Figure 2-4 – Randomised Controlled Trial of Taste modulation to validate RYGB model  
 
Animals 
Wistar rats, aged 8–12 wk and weighing 350–450 g, to be purchased from Harlan, 
UK. Animals were allowed free access to water and were fed normal diets. 
 
Pre-Surgery 
Two days prior to surgery animals were placed in individual cages and fed three diets: 
• High Fat Chow 
• High Fat Chow sprayed with flavoured salt and meat liquid (Bisto, Premier 
Foods, UK) 
• Low Fat Chow sprayed with flavoured salt and meat liquid (Bisto, Premier 
Foods, UK) 
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These were made available to the rats in their standard food cages and separated by 
metallic sheets. The amount of each type of chow consumed by rats was measured 
each day by weighing each category of chow in the cage. 
 
Surgery 
All procedures are approved by the Institutional and Home Office Ethical Approval. 
Rats were anaesthetized using 2.5% isoflurane. They underwent one of two 
procedures under aseptic precautions: 
1. Sham Surgery (N = 12) - (Laparotomy, Gastrotomy and Enterotomy) 
2. Roux-En-Y Gastric Bypass Surgery (N = 12) 
 
Post-Surgery 
All rats received standard post-operative analgesia with diclofenac sodium. 
They will all had exposure to normal chow that has been made wet with water for the 
first 8 days post surgery. 
 
Day 9 and 10, the rats were offered the same three pre-operative food types. 
 
Food consumption was measured by daily weight measurements and all rats were 
weighed daily. 
 
The taste experiment was completed by 10 days post-operatively. All subjects were 
monitored until 200 days to assess for weight loss. 
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Statistical Analysis 
 
Statistical analysis were performed on data reported by mean ± SE with GraphPad 
Prism (version 6.00; GraphPad Software) applying unpaired Student's t tests, one-way 
ANOVA or two-way ANOVA, depending on data structures. P values <0.05 are 
considered statistically significant. 
 
2.3	  Results	  
2.3.1	  Weight	  Loss	  
The body mass of rats in the bariatric surgical model revealed a successful and 
consistent weight loss (Figure 2-5). Roux-En-Y Gastric Bypass (RYGB) subjects lost 
a mean of 72g from 483g by the 25th post-operative day, and this weight remained 
stable for the duration of the experiment. Rats undergoing sham (control) surgery 
gained a mean of 37g weight from 491g by the 25th post-operative day. The weight of 
sham subjects continued to rise throughout the experiment. From the 25th day onward 
the sham subjects demonstrated significantly higher body masses when compared to 
RYGB subjects. This continued throughout the remained of the experiment. 
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Figure 2-5 – Body mass of rats in a bariatric surgical model of Roux-en-Y gastric bypass compared to 
the sham operation up to 200 days post-operatively 
 
2.3.2	  Post-­‐operative	  Food	  Preference	  Change	  and	  Caloric	  Consumption	  
Both pre-operative groups (Figure 2-6) demonstrated significant preferences for 
flavored and standard high fat chow compared to low fat chow (p<0.005). Post-
operatively (Figure 2-7), sham operated rats also demonstrated a similar preference 
for high-fat over low fat chow with no significant alteration to their pre-operative 
food status. When compared to pre-operative feeding status and post-sham subjects, 
post-RYGB rats had a significant decrease in their preference for high fat chow 
(p<0.005) and an increase in preference for low fat chow (p<0.01). 
 
Pre-operatively both groups consumed comparable calorific loads (Figure 2-8), sham 
(291±4 kcal), RYGB (293±5 kcal). Post-operatively (Figure 2-9) the sham group 
continued with a consistent caloric intake (297±2 kcal), whereas the RYGB 
demonstrated a significant decrease in caloric intake (182±3 kcal) (p<0.005).    
 50 
 
PreOp
Pr
eO
pS
HA
M-
HF
Bi
sto
Pr
eO
pS
HA
M-
HF
St
an
da
rd
Pr
eO
pS
HA
M-
LF
Bi
sto
Pr
eO
pB
yp
as
s-H
FB
ist
o
Pr
eO
pB
yp
as
s-H
FS
tan
da
rd
Pr
eO
pB
yp
as
s-L
FB
ist
o
0
10
20
30
48
h 
Fo
od
 C
on
su
m
pt
io
n 
(g
)
	  
Figure 2-6 – Pre-operative food preferences in 3 study groups 
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Figure 2-7 – Post-operative food preferences in 3 study groups 
 
 51 
 
 
Figure 2-8 – Pre-operative caloric intake in 3 study groups 
 
 
 
 
Figure 2-9 – Post-operative caloric intake in 3 study groups 
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2.4	  Discussion	  
 
The results from this experimental model of bariatric surgery reveal an anatomically 
equivalent operation to human Roux-En-Y Gastric Bypass Surgery (RYGB) that also 
offers consistent and long-term weight loss. As in humans, the experimental model 
subjects do not lose weight through starvation and malnutrition, but demonstrate an 
initial weight loss that is succeeded by a physiological plateau in weight.  
 
Limitations of the rat model of gastric bypass 
(1) Lifespan: Rat vs. Human 
The results observed in my animal model appear somewhat similar to human bariatric 
surgery, where there is an initial sharp weight loss followed by a subsequent plateau 
over time.[87, 145] However, despite this similarity, it is not possible to directly 
compare these findings to those of human studies for a number of reasons. Firstly, 
there are fundamental differences in the physiology of rodents and humans such that 
the timescale of effects and animal lifespan varies between the two groups. Humans 
reach puberty and can thus reproduce at approximately 11.5 years of age, whereas 
Wistar rats are sexually mature at 42 days.[146] Similarly, the overall lifespan of a 
Wistar rat is approximately 2.5 to 3 years, compared to that of a  human at 
approximately 80 years.[146] Furthermore, the birth weight of the rat is 
approximately 1% of its adult weight, whereas humans are approximately 3% of their 
adult weight at birth. Consequently, the rat does not reach 3% of adult weight until 
approximately 12 days of age. This, along with other differences in sexual 
development,[147] leads to variation in the equivalence between rat days and human 
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days throughout their lifespan, meaning that like-for-like comparison of changes in rat 
body weight to human body weight changes after bariatric surgery is not possible.   
 
(2) Gut anatomy and physiology: Rat vs. Human 
Rodents and humans share a similar gastrointestinal anatomical sequence of mouth, 
oesophagus, stomach, small bowel (duodenum, jejunum and ileum) and large bowel 
(caecum, colon, rectum and anal canal). Furthermore, the small bowel accounts for 
approximately 80% of the length gastrointestinal tract in both species. However, 
despite these similarities a number of differences must be considered[148, 149]. 
These are summarised in Table 2-3. 
 
Anatomical Differences 
The rodent oesophagus enters the stomach in a central location 
The rodent duodenum commences in a cranial direction 
The caecum of rats is much proportionally much larger in rats when compared to 
humans 
Rodents do not have a vermiform appendix 
The typical length for the gastrointestinal length in a Human is 835cm and that for a 
rat is 150cm. Physiologically however, the relative absorptive surface area of human 
small bowel is over four times that of rat small bowel 
Rat bowel length per kilogram is approximately 45 times that of humans  
Physiological Differences 
Rat stomach pH ranges from 2.3-5.1 whereas in humans this ranges from 1.5-7.0 
In the ileum rats demonstrate a pH of 7.1-8.0 and Humans 5.7-5.9 
The bile flow rate in rats ranges between 48-92 ml/day/Kg and humans 2.2-22 
ml/day/Kg 
Transit times in the rat stomach range between 0.7-2.1hrs and humans 0.8-1.8hrs 
In the small bowel rat transit times range between 2.6-3.3hrs and those for humans 
2.0-4.2hrs 
 
Table 2-3: Anatomical and physiological differences between the rodent and human 
gastrointestinal tract 
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(3) Vagus nerve anatomy: Rat vs. Human 
In humans the gastrointestinal branches of the Vagus nerve[150, 151] consist of those 
to oesophagus, the Anterior vagal trunk (primarily from the Left Vagus dividing into 
Hepatic, Coeliac and Anterior Gastric Branches with some contribution to the 
oesophageal plexus) and the Posterior vagal trunk (primarily from the Right Vagus) 
contributing to the oesophageal plexus, the nerve of Grassi that supplies the gastric 
fundus and also the nerve of Latarjet which innervates the gastric pylorus. This differs 
in rodents where there are 5 major gastrointestinal branches of the Vagus. These 
include the four classic branches (hepatic, anterior gastric, coeliac, and posterior 
gastric) and an accessory coeliac branch.[152, 153] As in humans, rats demonstrate a 
Latarjet nerve in the rat comes off the anterior vagal branch.[154] However, the 
branches of the Vagus in rodents consist of two or more separate bundles whereas in 
humans these primarily consist of single fibre bundles.[152]  
 
Despite the aforementioned limitations, this operative method reveals a technique that 
is feasible, reproducible and shows some analogy to human bariatric methods. Many 
previous models offered either weight loss or metabolic change in the absence of any 
comparison to modern human bariatric surgery. For example many animal models 
relied on a modified jejuno-ileal bypass as an experimental model in rodents to 
represent RYGB. The jejuno-ileal bypass procedure is now over 60 years old and is 
no longer performed routinely in human subjects and therefore its application in 
rodents and other experimental models is limited. The benefits of the model presented 
here directly reflect the very small stomach pouch in RYGB surgery, whilst also 
providing the Y configuration required for bypass surgery.  
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These results also suggest that the weight loss induced by RYGB includes an 
alteration of food preference independent to taste in this rodent model and offers new 
potential mechanisms through which these operations offer weight loss through eating 
behaviour. Future work includes a translational experiment of food preference and 
taste sensitivity in humans following RYGB, and further research into post-operative 
neuro-gustatory modulation. 
 
The application of this animal model to the study of bariatric surgical mechanisms 
therefore offers several advantages. Human bariatric surgical studies are limited by 
recruitment difficulties and poor follow-up. Patient adherence to diets and post-
operative lifestyle strategies are variable, and accurate and regular assessment in the 
schedules of young patients (the typical modern bariatric cohort) is challenging. 
Human patients undergoing these procedures may consume a highly varied diet based 
on their social networks, cultures and customs. Furthermore, individual healthcare 
systems offer patients a vast array of differing medications and treatments ranging 
from antibiotic use to daily post-operative multi-vitamin advice. The application of 
the developed experimental model offers real benefits in terms of minimizing these 
variables to offer a consistent and quantifiable set of variables with which to assess 
the mechanisms of bariatric surgical benefits. Subjects can undergo almost identical 
procedures in the same environment with regular follow-up of physiological 
characteristics and direct assessment of physiological and biological outcomes. As a 
result, this experimental model reflecting human bariatric surgery can now be applied 
in an experimental setting to assess the bio-systems modulation and the translational 
metabolic physiology of bariatric procedures. This can ultimately lead to novel 
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therapies for obesity, diabetes and metabolic syndrome, but can also help enhance 
current bariatric surgical procedures.  
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Chapter	  3	  –	  Systemic	  Metabolic	  Profile	  of	  Bariatric	  Surgery	  in	  
validating	  the	  term	  ‘Metabolic	  Surgery’	  
 
3.1	  Introduction	  
3.1.1	  Metabonomics	  and	  Metagenomics	  	  
The technique of studying patients and their diseases at a systems biology level has 
recently been enhanced through metabonomics. ‘Metabonomics’ can be defined as 
measurement of the ‘whole system, dynamic metabolic response of an organism to 
biological stimuli or genetic manipulation’.[155] Techniques including nuclear 
magnetic resonance (NMR) spectroscopy, mass spectrometry (MS) and multivariate 
chemometrics are used to characterize the small molecular make-up of biological 
samples in order to generate a ‘metabolic profile’. This “top-down” approach may be 
termed ‘systems biology’ (as opposed to the bottom-up approach of studying single-
gene effects, proteins and metabolites in individual cell types). This new paradigm 
can be used to identify disease mechanisms and novel therapeutic targets, whilst also 
providing personalized healthcare through the characterization of an individual’s 
metabolic status.[155, 156]  
 
In the context of bariatric surgery, this metabonomic approach may be augmented by 
metagenomic assessment of the gut flora [157, 158]. Metagenomics can be defined as 
the ‘functional characterization or sequence based analysis of individual microbial 
genomes contained within an environmental sample’.[159] In bariatric surgical 
patients, this is the genomic composition of gut microbiota as obtained from faecal 
sampling.  
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Results from previous metabonomic analysis have shown that Roux-en-Y gastric 
bypass surgery can alter the metabolic profile of subjects by modulating metabolites 
such as asparagine, lysophosphatidylcholine (C18:2), nervonic (C24:1) acid, p-Cresol 
sulfate, lactate, lycopene, glucose, and mannose. Furthermore, changes in nervonic 
acid have been significantly and negatively correlated with the HOMA-IR estimation 
of insulin resistance [160]. 
 
Similarly, it has been demonstrated that there is a clear differentiation between the gut 
microbiota of lean and obese individuals, with a shift towards a higher firmicute to 
bacteroidetes ratio that can be modulated by dietary intervention [161]. By examining 
sequences of microbial 16S rRNA genes, it has also been observed that gastric bypass 
surgery can modify the relative magnitude of bacterial colonies in the intestinal 
community to increase Gammaproteobacteria proportions[162]. These bacterial shifts 
have been hypothesized to contribute to changes in food ingestion and digestion.[162]  
 
3.1.2	  Assessing	  Surgical	  Metabolic	  Mechanisms	  through	  Systems	  Biology 
 
The traditional method of studying disease resolution methods through a bottom-up 
scientific paradigm of hypothesis - gene - gene knockout - protein and 
pharmacotherapeutic protein target has not yet yielded any definite clues as to the 
direct mechanism of the weight-independent effects of bariatric operations. However, 
the aforementioned holistic top-down ‘systems biology’ method now provides an 
alternate approach to assessing effects such as post bariatric surgery improvement in 
type 2 diabetes or even its complete resolution (defined as a reduction in 2 hour 
plasma glucose levels from ≥11.1 mmol/l to <7.8mmol/l in accordance with WHO 
 59 
diagnostic criteria).[163-166] Furthermore, by applying these techniques, we may not 
only be able to characterize patients more likely to achieve successful bariatric 
surgical outcomes [167], but also elucidate biochemical mechanisms with the 
potential to give rise to new druggable antidiabetic and obesity targets. 
 
3.1.3	  Aims	  	  	  
The aim of this study was to elucidate the mammalian metabolic changes after 
bariatric surgery. As such, I applied a metabolic profiling strategy based on 1H NMR 
spectroscopy to explore the impact of Roux-en-Y gastric bypass on the interactions 
between the fecal and urinary metabolic phenotype and fecal bile acids in Wistar rats   
(Figure 3-1).  
 
3.2	  Methods	  
 
Figure 3-1 – Study methodology 
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Animal model sampling 
 
Male Wistar rats were individually housed under a 12 hour/12 hour light-dark cycle at 
a room temperature of 21±2 °C. Animals were 4 weeks old, with mean starting weight 
of 366g and were monitored for 2 months. Water and standard chow were available 
ad libitum, unless otherwise stated.  All experiments were performed under a license 
issued by the Home Office UK (PL 70-6669). Animals were acclimatized for 1 week 
and were randomized to gastric bypass or sham operation. Urine and Stool was 
collected for 24 hours at 2 weeks, 4 weeks, 6 weeks and 8 weeks post-operatively and 
stored at −80° C. 
 
Surgical Technique 
Preoperatively rats were food deprived overnight for 12 hours with water available ad 
libitum. Rats were weighed, and then anesthetized with isofluorane (4% for induction, 
3% for maintenance). Preoperative antibacterial prophylaxis was administered intra-
peritoneally (1 ml of an Amoxicillin/Flucloxacillin solution, both at 12.5 mg/ml). 
Surgery was performed according to my above described technique [105] on a heating 
pad to avoid decrease of body temperature during the procedure. The abdomen was 
shaved and disinfected with surgical scrub and a midline laparotomy was performed.  
 
The sham procedure consisted of a 7 mm gastrotomy on the anterior wall of the 
stomach with subsequent closure (interrupted prolene 5-0 sutures) and a 7 mm 
jejunotomy with subsequent closure (running prolene 6-0 suture). No surgical 
vagotomy was performed in the sham group. In the gastric bypass procedure, the 
proximal jejunum was divided 15 cm distal to the pylorus to create a biliopancreatic 
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limb. After identification of the cecum, the ileum was followed proximally to create a 
common channel of 25 cm. Here, a 7 mm side-to-side Jejuno-Jejunostomy (running 
prolene 7-0 suture) between the biliopancreatic limb and the common channel was 
performed. The gastric pouch and alimentary limb were anastomosed end-to-side 
using a running prolene 7-0 suture. The anatomy can be clearly visualized in Figure 
2-3. The gastric remnant was closed with interrupted 5-0 prolene sutures. The 
complete bypass procedure lasted approximately 60 minutes and the abdominal wall 
was closed in layers using 4-0 and 5-0 prolene sutures. Approximately 20 minutes 
before the anticipated end of general anesthesia, all rats were injected with 0.1 ml of 
0.3% buprenorphine subcutaneously to minimize postoperative discomfort. Other 
than the gastrointestinal anatomical anastomoses and lack of vagotomy in sham 
animals, the sham and gastric bypass operation were carried out in exactly the same 
manner. The total bowel handling time was kept consistent between sham and 
operated animals to minimize differences in post-operative ileus. Immediately after 
abdominal closure, all rats were injected subcutaneously with 5 ml of normal saline to 
compensate for intra-operative fluid loss. After 24 hours of wet diet (normal chow 
soaked in tap water), regular chow was offered on postoperative day 2. 
 
Nuclear Magnetic Resonance Spectroscopy 
Urine samples were thawed and vortexed for 15 s prior to mixing an aliquot of 400 µl 
with 250 µl of 0.2 M phosphate buffer (pH=7.4) containing 20% deuterium oxide 
(D2O) for the magnetic field lock, 0.01% 3-(trimethylsilyl)-[2,2,3,3-2H4]-propionic 
acid sodium salt (TSP) for the spectral calibration and 3 mM sodium azide (Na3N) for 
avoiding bacterial contamination. The resulting mixture was centrifuged at 10392 g 
for 10 min and 600 µl of supernatants was transferred into a NMR tube with an out 
 62 
diameter of 5 mm pending 1H NMR spectral acquizition. A single fecal pellet from 
each sample was placed into a 2 ml Eppendorf™ containing 1.4 ml of phosphate 
buffer. The sample was homogenised, vortexed for 15 s, sonicated for 30 min at a 
temperature of 298 K and centrifuged at 10392 g for 20 min. A total of 700 µl 
supernatant was taken into a 1.5 ml Eppendorf™ tube and centrifuged again under the 
same condition. The supernatant (600 µl) was taken into a NMR tube pending 1H 
NMR spectral acquisition. 
 
1H NMR spectra of urine and fecal extract samples were obtained using a Bruker 600 
MHz spectrometer (Bruker; Rheinstetten, Germany) at the operating 1H frequency of 
600.13 MHz with a temperature of 300 K. A standard 1 dimensional solvent 
suppression NMR pulse sequence (recycle delay [RD]-90o-t1-90o-tm-90o-acquisition) 
was applied to acquire 1-dimensional (1-D) 1H NMR spectral data, where t1 was set to 
3 µs and tm (mixing time) was set to 100 ms. The water peak suppression was 
achieved using selective irradiation during RD of 2 s and tm. A 90-degree pulse was 
adjusted to 10 µs. A total of 128 scans were collected into 64 k data points with a 
spectral width of 20 ppm. A series of 2-D NMR spectra including 1H-1H correlation 
spectroscopy (COSY), 1H-1H total correlation spectroscopy (TOCSY), J-resolved 
spectroscopy, 1H-13C heteronuclear single quantum coherence (HSQC), 1H-13C 
heteronuclear multiple bond coherence (HMBC) were acquired on the selected urine 
and fecal extract samples for the purpose of metabolite annotations. 
 
Multivariate data analysis 
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Multivariate data analyses were performed based on the pre-possessed NMR dataset. 
1H NMR spectra obtained from urine and fecal extracts were automatically phased, 
referenced and baseline-corrected using a MATLAB script developed by Dr. T. 
Ebbels at Imperial College. The resulting NMR spectra (δ0-10) were imported to 
MATLAB software and digitized into 20 k data points with the resolution of 0.0005 
ppm using script developed in house (Dr. O. Cloarec). The water peak region δ 4.62-
5.05 and in urine spectra and δ 4.7-4.9 in fecal water spectra were removed in order to 
minimize the effect of the disordered baseline. Additionally, regions between δ 0-
0.10, δ 5.47-6.24 and δ 9.90-10.00 in urinary spectra, and regions between δ 0-0.30 
and δ 9.4-10.00 in fecal water spectra containing only noise were removed, followed 
by normalization to the remaining spectral areas of NMR data in order to perform 
further analyses. Principal component analysis (PCA), O-PLS and O-PLS-DA were 
carried out based on the resulting NMR spectral datasets using SIMCA (P+11.5) and 
MATLAB (2009a) software. 
 
3.3	  Results	  
 
The metabolic shifts of Roux-En-Y Gastric Bypass were demonstrable in my animal 
model (Figure 3-2). Cross validation plots and O-PLS-DA coefficient plots of urinary 
(A, B (R2X =32%; Q2Y =0.86)) and fecal (C, D, (R2X =33.5%; Q2Y =0.84)) NMR 
spectral data obtained from sham control (blue) and Roux-en-Y Gastric Bypass-
operated rats (red) at week 8, reflected the metabolic discrimination between these 
two groups. 
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Figure 3-2 - Urinary NMR spectral data from RYGB and Sham controls at 8 weeks. AP: 2-oxoadipate; 
Asp: aspartate; AV: 5-aminovalerate; Cre: creatine; Crn: creatinine; DE: diaminoethane; ET: ethanol; 
FA: formate; FM: fumarate; GABA: γ-animo N-butyrate; Gly: glycine; GT: 2-oxoglutarate; HA: p-
hydroxyphenylacetate; HP: hippurate; IS: indoxyl sulfate; Lac: lactate; MA: methylamine; OS: 
oligosaccharides; PAG: phenylacetylglycine; PG: p-cresyl glucuronide; PS: p-cresyl sulfate; PT: 
putrescine; Suc: succinate; TMA: trimethylamine; TMAO: trimethylamine N-oxide; Ura: uracil. 
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PLS-DA scores plot (A, Q2Y=0.83) derived from UPLC-MS(-) data demonstrated a 
separation between sham (blue) and RYGB (red)-operated rats at week 8. The 
corresponding loadings plot (B) indicates higher levels of cholic acid in sham rats. 
Relative concentrations of observed unconjugated (C) and taurine-conjugated (D) bile 
acids demonstrated a significant difference between sham and RYGB-operated rats at 
weeks 6 and 8 (Figure 3-3). 
 
 
Figure 3-3 - PLS-DA plot demonstrating the metabolic shift between sham (blue) and RYGB (red). 
 
 
Urinary and Faecal NMR spectra from sham and RYGB subjects were assessed 
(typical spectra in Figures 3-4 & 3-5). Overall metabolic shifts after surgery are 
outlined in Table 3-1.  
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Figure 3-4 - Typical 600 MHz 1H NMR spectra of urine obtained from a sham control rat (A) and a 
Roux-en-Y Gastric Bypass (RYGB)-operated rat (B) 8-week post operation. The spectra in the 
aromatic region (δ1H 6.4-9.3) and the region δ1H 0.6-2.28 were magnified twice compared to the 
region δ1H 2.28-4.7. Keys: Ace: acetate; Ala: alanine; AP: 2-oxoadipate; AV: 5-aminovalerate; BT: 
butyrate; Cit: citrate; Cre: creatine; Crn: creatinine; DMA: dimethylamine; FA: formate; FM: fumarate; 
GT: 2-oxoglutarate; HA: p-hydroxyphenylacetate; HP: hippurate; IS: indoxyl sulfate; Lac: lactate; MA: 
methylamine; MNA: 1-methylnicotinamide; PAG: phenylacetylglycine; PG: p-cresyl glucuronide; PS: 
p-cresyl sulfate; Suc: succinate; Tau: taurine; TMAO: trimethylamine N-oxide. 
 
 
 
 
 
 
	  
Figure 3-5- Typical 600 MHz 1H NMR spectra of fecal extracts obtained from a sham control rat (A) 
and a Roux-en-Y Gastric Bypass (RYGB)-operated rat (B) 8-week post operation. The spectra in the 
aromatic region (δ1H 5.75-8.5) were magnified 4 times compared to the region δ1H 0.5-4.7. Keys: 
Ace: acetate; Ala: alanine; AP: 2-oxoadipate; Asp: aspartate; AV: 5-aminovalerate; BT: butyrate; DE: 
diaminoethane; ET: ethanol; FA: formate; FM: fumarate; GABA: γ-animo-N-butyrate; Glu: glutamate; 
Gly: glycine; Ileu: isoleucine; Lac: lactate; Leu: leucine; MA: methylamine; MT: methanol; OS: 
oligosaccharides; Phe: phenylalanine; PP: propionate; PT: putrescine; Suc: succinate; TMA: 
trimethylamine; Tyr: tyrosine; Ura: uracil; Val: valine. 
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Table 3-1 - Summary of metabolic changes in urinary (u) and fecal (f) NMR profiles.  
“+” indicates a higher level of metabolites in RYGB-operated rats; “-” indicates a lower level of 
metabolites in RYGB-operated rats. “*” –labelled metabolites are found to be changed in sham control 
rats in comparison to pre-operation, where “+”/“-“ indicates higher/lower levels of metabolites post-
sham. ** Putative assignment. 	  	  	  	  
Class Metabolites 
O-PLS-DA models of RYGB-operated and sham control rats 
2-week post-op 4-week post-op 6-week post-op 8-week post-op 
TCA cycle succinate -0.6977(u) 
-0.6591(u); 
+0.5879(f) -0.8562(u) 
-0.7674(u); 
+0.6286(f) 
 2-oxoglutarate -0.6509(u) 
-0.6333(u); 
*+0.6170(u) -0.8084(u) -0.8153(u) 
 citrate -0.6090(u) -0.4856(u) -0.6150(u) -0.5045(u) 
 fumarate -0.6518(u) -0.6374(u);  -0.8703(u) -0.7200(u) 
Amines trimethylamine N-oxide 
+0.5183(u); 
*+0.7718(u) 
+0.5755(u); 
*+0.6994(u) 
+0.6311(u); 
*+0.6241(u) 
+0.6937(u); 
*+0.7320(u) 
 trimethylamine +0.6016(f) +0.8156(f)  +0.6865(f) 
 methylamine +0.5196(f) +0.7819(f) +0.6933(f) +0.7167(f) 
 putrescine +0.6133(f) +0.6601(f) +0.7048(f) +0.7328(f) 
 diaminoethane  +0.5170(f) +0.6573(f) +0.7230(f) 
Microbial activity oligosaccharides   -0.6144(f) -0.6461(f) 
 acetate +0.5415(f)  +0.5413(f)  
 propionate  +0.5916(f) +0.5186(f)  
 p-cresol glucuronide +0.7785(u) +0.6304(u) +0.7116(u) 
+0.7225(u); 
*+0.6367(u) 
 p-cresol sulfate +0.7980(u) +0.6911(u) +0.6501(u) +0.7303(u) 
 5-aminovalerate +0.6977(u) +0.5518(u) +0.6297(u) +0.6921(u) 
 phenylacetylglycine 
+0.9192(u); 
*+0.5416(u) +0.7038(u) 
+0.8432(u); 
*+0.5497(u) +0.7533(u) 
 p-hydroxyphenylacetate +0.7129(u) +0.5207(u) +0.6546(u) +0.6176(u) 
 hippurate   -0.8768(u) -0.6692(u) 
 methanol   +0.5561(f) +0.5167(f) 
 formate   +0.6820(f) +0.5907(f) 
 tyrosine -0.6139(f) -0.6726(f) 
-0.6543(f); 
*+0.5820(f) -0.6065(f) 
Peripheral neuroactive 
intermediate g-amino-N-butyrate +0.7036(f) +0.7373(f) +0.7038(f) +0.6806(f) 
 glutamate   +0.5514(f) +0.5914(f) 
Urea cycle aspartate -0.6653(f) -0.7314(f) -0.6881(f) -0.6999(f) 
Muscle metabolism creatine +0.6619 (u) +0.4473(u) +0.7781(u) +0.7294(u) 
 creatinine   *+0.6337(u) 
-0.7473(u); 
*+0.6424(u) 
 lactate +0.5871(f)    
Renal metabolism indoxyl sulfate +0.8598(u) +0.7271(u) 
+0.6550(u); 
*+0.7770(u) +0.6542(u) 
Amino acids valine   +0.5822(f)  
 phenylalanine   
+0.5849(f); 
*+0.5719(f)  
 alanine   *+0.5636(f)  
 glycine +0.6577(f) +0.6317(f) 
+0.5698(f); 
*+0.6521(f) +0.5377(f) 
others 
N-acetyl glycoproteins 
2.06(s)**   -0.7523(f) 
-0.6160(f); *-
0.5648(f) 
 ethanol   +0.6365(f) +0.6904(f) 
 phenylalanine   
+0.5849(f); 
*+0.5719(f)  
 2-oxoadipate -0.8260(u) -0.6238(u) -0.9030(u) -0.9045(u) 
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3.4	  Discussion	  
 
Effect of RYGB surgery on weight loss 
The multimodal effects of RYGB on the systemic metabolic and microbiotic 
phenotype can be described in terms of the BRAVE effects ((i) bile flow alteration, 
(ii) reduction of gastric size, (iii) anatomical gut rearrangement and altered flow of 
nutrients, (iv) vagal manipulation and (v) enteric gut hormone modulation [105]). 
These metabolic changes result in altered gastric and intestinal conditions including a 
reduction of acid production with a resultant increase in pH [105, 168] and a 
suggested alteration in gut oxygen bioavailability [162]. They also exert a substantial 
impact not only on the host metabolism but also on gastrointestinal ecology, mainly 
manifesting in a reduction in Firmicutes (includes the Clostridial family) and 
Bacteroidetes with a corresponding increase in Proteobacteria (g-proteobacteria 
family).  These changes are consistent with findings in a previous study of 3 human 
surgical subjects and 6 controls [162]. The surgically altered anatomy and flow of 
nutrients was associated with a global change in the urinary and fecal profiles 
reflecting: (a) an increased activity of oligosaccharide fermentation in the gut; (b) 
biogenesis of p-cresol and related compounds; and (c) the generation of amines which 
may mechanistically contribute to body weight loss and metabolic enhancements. We 
summarize the effects of RYGB surgery in male Wistar rats (n=14) over an 8-week 
period post surgery in comparison with a sham operated control group (n=15) 
according to the BRAVE framework and define microbial-metabolic interactions 
which contribute to the current understanding of the mechanism by which RYGB 
surgery operates to reduce obesity and type 2 diabetes.  
 
 69 
 
Bile flow changes 
The gastric bypass procedure modifies the anatomical location at which bile enters the 
upper gastrointestinal tract via the biliopancreatic limb of the Roux-en-Y construction 
and increases primary and secondary serum bile acid levels [169], including 
taurochenodeoxycholic, taurodeoxycholic, glycocholic, glychochenodeoxycholic and 
glycodeoxycholic acid.[170] A targeted ultra-performance liquid-chromatography 
(UPLC)-MS method [171] was used to profile the fecal bile acids. We detected 
decreased fecal bile acids post RYGB (>6 weeks), which were mainly unconjugated  
(Figure 3-5). The relative concentration of taurine-conjugated and several 
unconjugated fecal bile acids in sham operated rats was significantly greater than in 
the RYGB operated animals at week 8 (taurine-conjugated: 15.6x p=0.049, 
unconjugated: 3.6x, p=0.026). It is possible that this modulation of bile acids may in 
part explain the earlier satiety and improved glucose regulation seen in RYGB treated 
animals.[172] Changes to the composition of nutrients or chyme within the 
gastrointestinal tract or modified lipid metabolism after weight loss may trigger the 
gut-brain-liver axis thus mediating these effects; however, the exact mechanism for 
this remains unknown.  
 
Evidence for the putative role of bile acid receptors in mediating the beneficial effects 
of bariatric surgery has also recently been demonstrated in a rodent model of sleeve 
gastrectomy (VSG).[173] Based on earlier evidence revealing an increase in total bile 
acids in the enterohepatic circulation after bariatric surgery, bile-modulating 
mechanisms after bariatric surgery were assessed through unbiased pathway analysis. 
Here mRNA from post-operative terminal ileum revealed the differential regulation of 
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the Nr1h4 gene that encodes the FXR (farnesoid X receptor) bile acid receptor, which 
is a known contributor to lipid, glucose and energy metabolism.  
 
Comparison of the results of VSG performed in wild type and FXR knockout mice 
identified approximately 30% weight loss in wild type mice in the first week after 
surgery. Furthermore, following this initial rapid weight loss, post-VSG wild type 
animals gained weight at a similar rate to sham surgical controls, although there was 
no compensation for their initial weight loss. VSG surgery also offered a persistent 
improvement in wild type mouse glycaemic control when compared to sham controls. 
FXR-knockout mice similarly demonstrated a rapid weight loss after VSG surgery, 
however they compensated for this by revealing higher rates of food intake at 3-5 
weeks. At 11 weeks, wild type post-VSG mice had lost 50% of their body fat, 
whereas post-VSG FXR-knockouts and sham knockouts had equivalent body fat 
compositions. At 8 weeks after VSG surgery the FXR-knockout mice did not 
demonstrate improved glycaemic control.  
 
These data highlight the importance of bile acids and their receptors in maintaining 
weight loss and glycaemic control after bariatric surgery. Further studies are now 
required to examine in more detail the effects of bariatric surgery on bile metabolism 
and how bile acid modulation may regulate satiety and glycaemic control.   
 
Restriction of gastric size 
As previously described, the anatomical re-arrangement in RYGB surgery involves 
bypassing the main body of the stomach and duodenum so that nutrients are exposed 
to the small intestine (jejunum) immediately after transit through the esophagus and a 
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subtracted small gastric remnant (Figure 2-3). In rats that underwent RYGB surgery 
(n=14, mean pre-operative weight of 383g), I measured an average weight loss of 
91.3 g +/- 45.3 g over an 8 week post surgical period in contrast to a matched control 
group of sham operated rats (n=15, mean pre-operative weight of 353g) that gained 
59.0 g +/- 35.8 g with a corresponding food consumption of 14 g/day for the RYGB 
group compared with 20.5 g/day consumed by the sham group. These effects provide 
a degree of caloric restriction that is associated with a specific metabolic profile. We 
have previously demonstrated [174] that caloric restriction in rats result in a decrease 
of 2-oxoglutarate and an increase in creatine. The urinary metabolites (including 
succinate, 2-oxoglutarate, citrate and fumarate) of the RYGB operated rats, as 
measured by 1H nuclear magnetic resonance (NMR) spectroscopy at 2, 4, 6 and 8 
weeks were decreased over all observation time points (Table 3-1), which indicates a 
modulation of cellular energy metabolism through increased utilization of 
tricarboxylic acid (TCA) cycle intermediates. These findings agree with the findings 
of caloric restriction where substrates are up regulated as a result of an acidotic effect. 
These changes could therefore indicate renal tubular acidosis which associates with an 
increased flux of tricarboxylic acid cycle intermediates in the mitochondrion [175] 
and may contribute as a post-operative mechanism of weight loss and metabolic 
enhancement. Further studies of cellular energy metabolism after gastric bypass 
surgery demonstrate the down regulation of mitochondrial complex I-IV post-RYGB 
in diet-induced obese Sprague-Dawley rats and post-operative human subjects [105, 
122, 176]. Rhabdomyolysis (muscle lysis and metabolism; RML) is a recognized 
complication of gastric bypass surgery and is also observed in extreme caloric 
restriction. The criteria for a RML diagnosis is >5 fold increase of normal creatine 
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kinase levels in plasma. The higher urinary level of creatine in this study may 
therefore reflect the increased muscle protein catabolism following surgery.  
 
Altered gastrointestinal anatomy 
The RYGB procedure results in a large stomach remnant (up to 1000 ml in humans 
and 5 ml in rats) with an associated segment of small bowel being bypassed lower 
down the upper gastrointestinal tract (Figure 2-3). As a result, ingested nutrients only 
have exposure to a small stomach pouch (approximately 15-30 ml in man and 0.25 ml 
in rats) before entering the small intestine earlier than the standard gastrointestinal 
configuration (figure 2-2). Consequently the distal small intestine receives a higher 
load of nutrients that have not been exposed to the standard volume of stomach 
mucosa.  
 
A further consequence of the RYGB surgery is to modulate gastric emptying and 
intestinal mobility, which have been demonstrated to decrease post-operatively such 
that approximately 40% of human patients demonstrate very slow or no emptying on 
upper gastrointestinal contrast studies at one year post-operatively [177, 178] and 
rodents demonstrate an approximate 40% decrease in 30-minute-intestinal transit time 
after RYGB compared to controls. This is associated with the effects of proximal 
surgical vagotomy [179] and the action of gut peptides such as ghrelin, Glucagon-like 
peptide-1 (GLP-1) and Peptide YY (PYY) on gastric and intestinal motility [119]. 
Reduced upper-gastrointestinal motility can lengthen intestinal exposure times to 
promote the conditions for protein putrefaction. Consequently, incompletely digested 
proteins reaching the colon due to the surgical bypass of the foregut are likely to 
result in a high bioavailability of proteins in the hindgut. As a result, several 
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polyamines such as putrescine, diaminoethane (aliphatic biogenic amine) are derived 
from microbial catabolic processes [180]. The neuroactive peptide g-aminobutyric 
acid (GABA) is also increased in post-RYGB fecal samples and has also been 
demonstrated to derive from the microbial processing of putrescine [181]. Increased 
expression of fecal GABA is consistent with the well-defined increase of GLP-1 
following RYGB [73]. GABA can stimulate GLP-1 release from intestinal cells [182] 
and raised GLP-1 levels in turn promote GABA formation by pancreatic b-cells to 
provide autocrine and paracrine effects including a-cell regulation to inhibit glucagon 
release, acinar cells activity to amplify cholecystokinin release and also 
immunomodulatory actions on infiltrating T cells to suppress autoimmune damage 
(35). Increased brain GABA levels can also reflect the hypothalamic GABA-mediated 
control of food intake [183, 184]. 
 
Vagal nerve effects and enterohumoural (gut hormone) activity 
Vagal nerve innervation and neurohormonal processes play a key role in the short-
term regulation of food intake and the release of key gastrointestinal hormones 
including gastrin and secretin [73]. Furthermore, vagal nerve stimulation has been 
demonstrated to attenuate weight gain [185]. Gastric bypass surgery typically results 
in a surgical vagotomy, and the effect of this may modulate post-operative weight loss 
through altered signaling within the gut-brain-liver axis. However, the exact 
mechanistic effects of vagus nerve neural transmission following bariatric surgical 
vagotomy are currently not well understood. Further studies clarifying the 
electrophysiological and downstream molecular effects of vagotomy can contribute to 
a deeper understanding of the role of the vagus nerve on the beneficial effects of 
Roux-en-Y gastric bypass. Of particular note, RYGB animals in this rodent model 
 74 
underwent vagotomy to replicate the operative technique of the human RYGB 
procedure, however sham animals did not undergo surgical vagotomy. This may act 
as a confounder, and thus limitation, when generalizing these results to consider the 
effect of purely the anatomical rearrangement in RYGB. Furthermore, differences in 
the vagal anatomy between humans and rodents also serve as a limitation to these 
results and are discussed in detail in Chapter 2.  
 
In summary, a number of changes are observed in the urinary and fecal spectra of 
RYGB compared to sham operated rodents. Changes in gut microbial ecology 
occurring after these procedures may account for some of these findings given the 
results of previously published studies, which show a reduction in Firmicutes and 
Bacteroidetes with corresponding increase in Proteobacteria[162]. However, despite 
the positive correlations observed in this study, these inferences currently remain 
speculation and further research is required to quantify the gut microbial shifts 
occurring in this rodent model. To address this question, I will now go on to combine 
these studies with metagenomic profiling of the gut microbiota, with the aim to 
improve our mechanistic understanding of the interaction between the fecal and 
urinary metabolic phenotype, fecal bile acids and gut microbial modulation in my 
rodent model of roux-en-Y gastric bypass. 
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Chapter	  4	  –	  Gastrointestinal	  Gut	  Microbial	  Shifts	  of	  Metabolic	  
Surgery	  
 
4.1	  Introduction	  -­‐	  Initial	  concepts	  in	  the	  Metabolic	  Activity	  of	  Bariatric	  
Surgery	  
4.1.1	  The	  role	  of	  Gut	  Microbes	  in	  Health	  and	  Disease	  
The symbiosis between the human host and gut microbiota can trigger specific 
biological responses both locally and systemically.  Of the 55 bacterial divisions only 
two are prominent in mammalian gut microbiota (Bacteroidetes and Firmicutes) and 
it is therefore likely that host eukaryotic organisms have co-evolved with gut 
microbiota in the context of this symbiosis to achieve a physiological homeostasis 
[186]. Individual bacterial species present unique pathological effects and similarly 
shifts in gut bacterial colonies can also prompt specific disease-inducing activity 
(dysbiosis) or disease-protective activity (probiosis). This balance between the 
bacterial host defence reinforcement and pro-inflammatory pathology was first 
proposed by the 1908 Nobel laureate Elie (Ilya Ilyich) Metchnikoff who noted the 
therapeutic benefits of acid-producing lactic bacilli [187]. The beneficial effects of 
gut microbiota include: (i) immune-cell development and homeostasis (Th1 vs. Th2 
and Th17), (ii) food digestion, (iii) supporting fat metabolism, (iv) epithelial 
homeostasis, (v) enteric nerve regulation and (vi) promoting angiogenesis.  
Conversely, maladapted microbial ecology can impair many of these homeostatic and 
physiological signals so that they result in a number of disease states that include 
allergy, inflammatory bowel disease (IBD), obesity, cancer and diabetes.  
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Metabolic profiling studies, mainly adopting mass spectrometric (MS) and nuclear 
magnetic resonance (NMR) spectroscopic platforms to measure the metabolic 
composition of biological samples, have been instrumental in characterizing a wide 
variety of diseases and have been used for biomarker screening, elucidating 
mechanistic information relating to disease aetiology and in monitoring response to 
therapeutic interventions [167, 188]. Subtle changes in metabolic profiles in response 
to physiological perturbations or environmental stimuli have also been described 
[189, 190]. In many such studies, the panel of ‘diagnostic’ biomarkers has included 
several metabolites of gut microbial or microbial-mammalian co-metabolic origin. In 
order to probe the exact nature of the metabolic handshake between the mammalian 
host and the resident gut microbiota, several animal models of simplified microbiota 
have been developed including germ-free animals, antibiotic treated rodent models 
(resulting in a temporary knockout effect of selected bacterial groups) and animals 
with transplanted microbiota such as the Schaedler microbiota (consisting of eight 
bacteria including Escherichia coli var. mutabilis, Streptococcus faecalis, 
Lactobacillus acidophilus, Lactobacillus salivarius, group N Streptococcus, 
Bacteroides distasonis, a Clostridium sp., and an extremely oxygen-sensitive fusiform 
bacterium) [191]or human infant microbiota.  
 
Diabetes  
The notion that gut microbiota are key players in the onset and development of 
diabetes is becoming more widely accepted as the evidence base grows. Experimental 
evidence has shown that the non-obese diabetic (NOD) mouse lacking the innate 
microbial-recognition immune system receptor MyD88 is resistant to type 1 diabetes 
[192]. If the MyD88 knockout mice were depleted of normal intestinal flora, type 1 
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diabetes would ensue, whereas if the NOD mice were colonized with the altered 
Schaedler flora (ASF) the diabetes would be attenuated [192]. This alluded to the role 
of gut microbiota and the innate immune receptor MyD88 in priming the immune 
system in the context of type 1 diabetes autoimmunity. As type 2 diabetes is strongly 
associated with obesity, these two conditions could be linked by an underlying 
physiological process including the disordered regulation of gut bacterial profiles.  
 
From the metabolic profiling literature, several studies have reported modulated 
choline degradation products and bile acids as characteristic of insulin resistance and 
diabetes in animal models. Studies involving high fat diet-induced initiation of insulin 
resistance found alterations in the plasma lipids and in the concentrations of urinary 
metabolites such as phenylacetate, hydroxyphenylacetylglycine and 
hydroxyindoleacetic acid, although host species and strain influenced the exact 
metabolic composition of the biofluids in these animal models [193-196]. Low 
urinary concentrations of hippurate, and higher concentrations of dimethylamine have 
been found in Zucker obese and Goto-kakizaki (GK) rats in comparison with the 
respective control strains [194, 197]. A streptozotocin-induced rat model of diabetes 
reported acetate, ethanol and lactate amongst the key discriminatory metabolites in 
addition to a modulated plasma lipid profile [195]. NMR spectroscopy was applied to 
characterize the plasma profiles of congenic strains of rats derived from a crossing a 
diabetic and control animal. Quantitative trait loci were used to generate a correlation 
matrix with the plasma metabolite profiles and linkage to benzoate was found to be a 
consequence of deletion of a uridine diphosphate glucuronosyltransferase [198]. The 
ability of the microbiota to influence the expression of diabetes in animal models and 
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the clear impact upon the choline degradation pathway in diabetic animals and man 
emphasizes their potential in contributing to the etiology of this disease. 
 
Obesity  
Obesity has traditionally been considered to be a disorder of energetic and nutritional 
surplus, which in some cases is associated with a genetic predisposition. Recently 
however the evidence for the role of the gut microbiome has offered new aspects to 
our understanding of obesity pathogenesis. These include the association of gut 
microbiota with the following: intestinal permeability, systemic quantity of adipose 
tissue and body weight. 
 
The initial association between gut bacterial species and weight gain was derived 
from studies where decreasing dietary fibre resulted in excess body weight and 
diabetes, and was hypothesized to result from a change in gut microbiota as a 
consequence of altered nutrient supply and digestion. Subsequently it has been 
demonstrated that consumption of a high fat diet results in a decrease of total gut 
bacterial levels and an increase in Gram-negative bacteria. Four bacterial mechanisms 
have been identified to result in excess bodily energy gain: (i) The microbiota 
increases energy bioavailability by transforming increased proportions of non-
digestible food into biochemically absorbable nutrients; (ii) the influence of intrinsic 
bacterial metabolism to generate and raise systemic levels of short-chain fatty acids to 
activate triglyceride synthesis; (iii) high fat diets can result in a responsive bacterial 
metabolism resulting in pathology (such as the microbial conversion of choline to 
methylamines leading to a choline deficient state, which induces liver disease); and 
(iv) the ability of the microbiome in regulating gut gene expression to favour an obese 
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state. This could occur through the reduction of lipoprotein lipase activity through the 
inhibition of angiopoietin-like 4 (Angptl4) and fasting-induced adipocyte factor 
(FIAF) to increase free fatty acids and adipose levels [199, 200]. 
 
Experimental evidence has revealed that germ-free mice are less obese than normal 
controls but gain weight and have decreased Angptl4 expression following 
colonization by conventional gut bacteria [186]. The ob/ob leptin-deficient obese 
mouse has a microbiome with a 50% reduction in Bacteriodetes and a concurrent 
increase in Firmicutes which might be associated with increased food consumption in 
these animals. Obese humans also demonstrate an alteration of the Firmicutes to 
Bacteroidetes ratio that can be altered by weight loss [161, 201]. Furthermore, 
bacterial modulation of obesity is also suggested by the transmission of obesogenic 
bacterial profiles in ex-germ-free mice [202]. The fact that consistent differences have 
been noted in the metabolic profiles of animals and humans following caloric 
restriction also concurs with the notion that body weight and weight change is 
associated with alteration in microbial composition. Amongst these microbial 
signature changes include increased urinary excretion of hippurate, 4-
hydroxyphenylacetic acid, phenylacetylglycine and decreased acetate and lactate 
[174, 203]. 
 
Bariatric surgery offers the most consistent method of weight loss in morbidly obese 
patients, and also achieves the resolution of metabolic dysfunction including T2DM. 
Bariatric surgery procedures modify the gut microbiome to achieve a low 
inflammatory and weight loss profile that might reverse the effects of the metabolic 
syndrome [204]. The microbial effects of successful weight loss and anti-diabetic 
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operations could lead to novel mechanisms and therapies for obesity and T2DM. In a 
recent study by Mutch et al., where weight loss was achieved in obese subjects 
following Roux-en-Y gastric bypass surgery, marked alterations in the plasma profile 
were found with many classes of metabolites changing post surgery. In addition to 
lipids, indoles, lipids, fatty acids and amino acids, 4-cresyl sulfate was characteristic 
of the obese profiles [160] and might indicate an altered clostridial profile. To date, 
investigating microbial functions in obesity have been approached via both weight 
gain (obese patients/murine models) and weight loss (bariatric surgery in human and 
murine) with good consensus that body weight influences or is influenced by the host 
microbiota. The exact nature of this host-microbial interplay requires further 
mechanistic investigation.   
 
Cardiovascular dyslipidaemia and metabolic endotoxaemia  
Dyslipidaemia is a disorder of lipoprotein metabolism, which results in a systemic 
increase of disease-inducing blood lipids such as cholesterol, triglycerides and LDL 
particles whilst decreasing the levels of protective lipids such as high-density 
lipoprotein (HDL) particles.  A sustained high fat diet can induce dyslipidaemia that 
results in a pro-inflammatory response including an increase of Gram-negative 
bacterial outer membrane LPS (lipopolysaccharide) levels to result in a ‘metabolic 
endotoxaemia’ demonstrable in both rodents [205] and humans [206]. An infusion of 
LPS into rodents caused clinical features of metabolic syndrome such as weight gain, 
insulin resistance and hepatic lipid overload. Fat has been demonstrated to be a highly 
efficient transporter of LPS from the gut lumen to the bloodstream and its effects can 
be delayed in mice lacking the LPS-CD14 receptor [207]. Non-fatty diets are 
associated with decreased levels of LPS and lipoprotein particles can buffer its pro-
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inflammatory effects. High-fat diets demonstrate a shift in gut bacterial ecology by 
increasing the Gram-negative:Gram-positive ratio whereas an increased fibre intake 
has been demonstrated to reverse these changes [205] and heralds a possible avenue 
to promote dietary therapy for the prevention of metabolic endotoxaemia and 
atherogenic dislipidaemia.  
 
Disease Animal model Experimental design Mechanism Refs 
Obesity Mice Conventionally reared 
vs. germ-free 
Increased food consumption [208] 
Obesity Mice Conventionally reared 
vs. germ-free 
Increased gut monosaccharide 
absorption and induction of hepatic 
lipogenesis 
[208] 
Obesity Mice FIAF (fasting-induced 
adipocyte factor) 
genetic knockouts 
Fat storage (increased lipoprotein 
lipase activity) 
[208] 
Obesity Mice (genetic 
obese leptin-
deficient ob/ob) 
Obese ob/ob vs. lean 
ob/+ and ob+/+ 
Genes encoding enzymes that 
breakdown otherwise indigestible 
polysaccharides 
[209] 
Obesity Mice (genetic 
obese leptin-
deficient ob/ob) 
Obese ob/ob vs. lean 
ob/+ and ob+/+ 
Increased fermentation [209] 
Obesity Mice Obese ob/ob vs. lean 
ob/+, ob+/+ and ob/+ 
mothers  
Decreased Bacteroidetes, increased 
Firmicutes 
  
Obesity Mice Colonization of germ-
free mice 
Increased energy extraction by 
bacterial interactions 
[210] 
Obesity and 
diabetes 
Mice Non-mutant vs. CD14 
mutant mice 
Bacterial lipopolysaccharide from 
Gram-negative bacteria triggers 
inflammation in response to a high 
fat diet which results in metabolic 
syndrome 
[207] 
Diabetes Mice NOD (non-obese 
diabetic) MyD88 
knockout mice vs. non-
mutant mice 
A dysfunction in the microbial 
responsive immune system can lead 
to autoimmunity and diabetes  
[192] 
Diabetes Rats BB-DR (Biobreeding 
diabetes resistant) vs. 
BB-DP (Biobreeding 
diabetes prone) 
The administration of Lactobacillus 
johnsonii isolated from BB-DR 
delays the onset of type 1 diabetes 
in BB-DP 
[211] 
Cardiovascular 
dyslipidaemia 
Mice Normal chow-fed mice 
vs. HF (high fat)-fed 
mice vs. HF-OFS 
(oligofructose)-fed 
mice 
Endotoxaemia significantly and 
negatively correlates with 
Bifidobacterium spp. 
[205] 
 
Cardiovascular 
dyslipidaemia 
Hamsters GSL (grain sorghum 
lipid extract)-fed 
hamsters 
Bifidobacteria increased in GSL-
fed hamsters and positively 
associated with HDL plasma 
cholesterol 
[212] 
 
Table 4-1 – Animal models of disease with Gut micrbiome derangement 
 82 
4.1.2	  Aims	  -­‐	  Microbial	  Metabolism	  After	  Bariatric	  Surgery	  
The aim of this study was to assess the effects of bariatric surgery on the gut 
microbiome through my established animal model. Since both gut microbial and 
mammalian metabolism exhibit an interdependence with respect to controlling energy 
balance, I applied a metagenomic profiling strategy based on 454 Pyrosequencing 
technology in parallel with my previous metabolic profiling technique using 1H NMR 
spectroscopy to explore the impact of Roux-en-Y gastric bypass surgery on the 
interactions between the fecal and urinary metabolic phenotype, fecal bile acids and 
gut microbial modulation in Wistar rats. 
	  
4.2	  Methods	  
 
 
Figure 4-1 – Study methodology 
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Animal model sampling, Surgical Technique, Nuclear Magnetic Resonance 
Spectroscopy and Multivariate Data Analysis. These were performed in 
accordance with Chapter 3.2, and samples were derived from the same animal 
subjects. 
 
Analysis of the gut microbiota by pyrosequencing. DNA was extracted from fecal 
pellets (250mg) using a modified protocol based on the Qiagen Stool Kit (Qiagen, 
Crawly, UK) with an additional bead beating step to homogenise and lyse bacteria in 
the samples (0.1 g 0.1mm sterile glass beads, 3 × 4500 rpm for 30 secs with 5 mins on 
ice in between cycles).  DNA obtained from this extraction was quantified using the 
Invitrogen Qubit platform and diluted to a working concentration of 10 ng µl-1.  The 
PCR was used to amplify the V1-V3 regions of the 16S rRNA gene from each DNA 
sample using the primers shown in Table 4-2.  The PCR was performed in triplicate 
on all DNA extracts using a MJ Research PTC-200P Thermal Cycler (MJ Research, 
USA).  PCR mixtures (25 µl) contained 1 X Buffer (20 mM Tris pH 8.4, 50 mM 
KCl), 1.5 mM MgCl2, 200 µM of each dNTP, 1.25 U of Taq polymerase (NEB, UK), 
5 pmol of each primer and 10 ng of DNA. The PCR conditions were: 95 °ºC for 5 min 
initial denaturation, followed by 25 cycles of amplification at 95 °ºC denaturation for 
30 s, annealing at 55 °C for 40 s and extension of 72 °ºC for 1 min, with a final 
extension of 72ºC for 5 min.  PCR products were pooled for each sample, purified 
using a Qiagen PCR purification kit, quantified and equimolar amounts pooled prior 
to running on a ¼ of a PTP (Pico titre plate) using titanium chemistry (AGOWA, 
Berlin, Germany).  The sequences were binned according to their sample source and 
processed via the RDP’s pyropipeline to remove any reads that were less than 250 bp 
and which contained any ambiguities. The filtered sequences were classified using the 
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RDP classifier and the relative proportions of phyla and families determined.  
Community analysis of the data was undertaken using MOTHUR.  All sequences are 
deposited at EMBL’s ERA under number ERPnnnnnn. 
 
Sample Forward primer and barcode in bold 
S1 CCATCTCATCCCTGCGTGTCTCCGACTCAG GATCT GCCTAACACATGCAAGTC 
S2 CCATCTCATCCCTGCGTGTCTCCGACTCAG ATCAG GCCTAACACATGCAAGTC 
S3 CCATCTCATCCCTGCGTGTCTCCGACTCAG ACACT GCCTAACACATGCAAGTC 
S4 CCATCTCATCCCTGCGTGTCTCCGACTCAG AGCTA GCCTAACACATGCAAGTC 
S5 CCATCTCATCCCTGCGTGTCTCCGACTCAG CACAC GCCTAACACATGCAAGTC 
S6 CCATCTCATCCCTGCGTGTCTCCGACTCAG ACAGA GCCTAACACATGCAAGTC 
S7 CCATCTCATCCCTGCGTGTCTCCGACTCAG AGATG GCCTAACACATGCAAGTC 
S8 CCATCTCATCCCTGCGTGTCTCCGACTCAG CACTG GCCTAACACATGCAAGTC 
S9 CCATCTCATCCCTGCGTGTCTCCGACTCAG CAGAG GCCTAACACATGCAAGTC 
S10 CCATCTCATCCCTGCGTGTCTCCGACTCAG CGCAG GCCTAACACATGCAAGTC 
S11 CCATCTCATCCCTGCGTGTCTCCGACTCAG CTGTG GCCTAACACATGCAAGTC 
S12 CCATCTCATCCCTGCGTGTCTCCGACTCAG GTGAG GCCTAACACATGCAAGTC 
B1 CCATCTCATCCCTGCGTGTCTCCGACTCAG TCATG GCCTAACACATGCAAGTC 
B2 CCATCTCATCCCTGCGTGTCTCCGACTCAG AGCAT GCCTAACACATGCAAGTC 
B3 CCATCTCATCCCTGCGTGTCTCCGACTCAG CAGCT GCCTAACACATGCAAGTC 
B4 CCATCTCATCCCTGCGTGTCTCCGACTCAG CATGT GCCTAACACATGCAAGTC 
B5 CCATCTCATCCCTGCGTGTCTCCGACTCAG CTGAT GCCTAACACATGCAAGTC 
B6 CCATCTCATCCCTGCGTGTCTCCGACTCAG CTGCA GCCTAACACATGCAAGTC 
B7 CCATCTCATCCCTGCGTGTCTCCGACTCAG GATGA GCCTAACACATGCAAGTC 
B8 CCATCTCATCCCTGCGTGTCTCCGACTCAG TACGC GCCTAACACATGCAAGTC 
B9 CCATCTCATCCCTGCGTGTCTCCGACTCAG ACTGC GCCTAACACATGCAAGTC 
B10 CCATCTCATCCCTGCGTGTCTCCGACTCAG GTCAC GCCTAACACATGCAAGTC 
B11 CCATCTCATCCCTGCGTGTCTCCGACTCAG CGTAC GCCTAACACATGCAAGTC 
B12 CCATCTCATCCCTGCGTGTCTCCGACTCAG TGCGT GCCTAACACATGCAAGTC 
  
Reverse primer CCTATCCCCTGTGTGCCTTGGCAGTCTCAG ATTACCGCGGCTGCTGG 
 
 
Table 4-2 - 454 primers use to amplify the V1-V3 regions of the 16S rRNA gene, the portion in bold is 
the unique barcode (5mer) that distinguished each sample and allows for multiplexing of the sample on 
the 454.  To the right of the barcode is the target primer which anneals to the 16S rRNA gene 
 
	  
4.3	  Results	  
The bacterial class profile of RYGB and sham operated individuals revealed clear 
differences between these groups. A heatmap (Figure 4-2) shows pairwise similarities 
between gut communities generated using MOTHUR and a cutoff of 0.10. Microbial 
composition of individual rat from sham control and RYGB-operated groups at week 
2 and 8 (B). The pie chart (C) shows the mean of each bacterial class level within the 
control (N=6) and RYGB (N=6) groups at week 2 and 8. *Of note was the anomalous 
 85 
behaviour of one of the sham rats (S06) which exhibited a high level of Proteobacteria 
at week 2, more consistent with the response of the RYGB-operated animals. This 
animal was unwell immediately following the sham surgical intervention, but 
subsequently recovered by week 8 post surgery, at which stage the microbial profile 
of this animal was similar to that of the other sham operated animals. Amongst these, 
the main taxonomic group of Enterobacter hormaechei was identified as the most 
modulated bacterium after bariatric surgery (Figure 4-3 & 4-5). 
 
 
Figure 4-2 – (A) Heatmap showing pairwise similarities between gut communities. (B) Microbial 
composition of individual rat from sham control and RYGB-operated groups at week 2 and 8. (C) Pie 
chart showing the mean of each bacterial class level within the control (N=6) and RYGB (N=6) groups 
at week 2 and 8.  
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Figure 4-3 – Phylogenetic tree (neighbour-joining from a jukes-cantor matrix) of the main taxonomic 
groups which varied between the two test groups, only the higher taxonomic groups from which they 
were clustered is shown.  The bar chart to the right of the tree shows the reads associated with a 
representative from its taxonomic group. * Enterobacter hormaechei. 
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There was an association between the combination of urinary and fecal NMR spectral 
data and γ-proteobacteria (Q2Y=0.58; R2X=18.0%) and Clostridia Q2Y=0.45; 
R2X=18.7%) levels based on O-PLS regression (Figure 4-5). 
 
 
Figure 4-4 – O-PLS regression loadings plot shows the correlation between the combination of urinary 
and faecal NMR spectral data and g-proteobacteria (Q2Y=0.58; R2X=18.0%) and Clostridia Q2Y=0.45; 
R2X=18.7%) levels.  
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Figure 4-5 - O-PLS regression loadings plot shows the correlation between the combination of urinary 
and fecal NMR spectral data and Enterobacter hormaechei (Q2Y=0.7; R2X=28%) level. 
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Figure 4-6 - (A) O-PLS regression coefficient plot derived from 1H NMR urinary (Q2Y=0.58; 
R2X=31.4%) and fecal (Q2Y=0.61; R2X=28%) spectral data against body weight. (B) Scatter plots of 
bacterial family levels and body weight of rats (red: RYGB-operated; blue: sham control) at week 2 
(circles) and 8 (stars). 
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Figure 4-7 - Cross correlation plots between selected urinary and faecal metabolites and the abundance 
levels of 37 bacterial families across matched samples (correlations significant at p < 0.01) Key: PS, p-
cresyl sulfate; PG, p-cresyl glucuronide; PAG, phenylacetylglycine. 	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4.4	  Discussion	  	  
RYGB profoundly disrupts the gut microbial ecology as evidenced in the 454 
sequencing data of 6 randomly selected animals from each group at 2 and 8 weeks 
post-surgery. I show a dramatic increase (52-fold) in the relative proportion of 
phylum Proteobacteria (mainly the order Enterobacteriaceae) with a corresponding 
but less dramatic fall in the level of phylum Firmicutes (4.5-fold reduction - mainly 
the family Peptostreptococcaceae) in RYGB-operated individuals (Figure 4-2 (b)). 
The most striking alteration in microbial ecology following RYGB surgery was the 
growth of the class g-proteobacteria, particularly the species Enterobacter 
hormaechei (Figure 4-2 (c) and 4-3) which has not been reported previously. This is 
a Gram-negative bacterium with extended-spectrum beta-lactamase activity that has 
previously been described as a nosocomial pathogen, although its role in contributing 
to gut and systemic metabolism require furthers investigation [213]. The selection for 
this bacterium is likely to derive from the effects of surgically altered gastrointestinal 
anatomy and inherent bacterial beta-lactamase activity. The RYGB operation 
provides an anatomical path where carbohydrates directly enter the ileum without 
prior exposure to the main body of stomach.  This favors the growth of enterobacterial 
species as they display a high level of flexibility in fermenting carbohydrates [214]. 
The fecal profile also showed evidence of altered energy metabolism with the spectral 
region containing oligosaccharides and other sugars deceasing in relative percentage 
in the RYGB group. This is consistent with an altered microbial ecology favouring 
oligosaccharide use in the post-operative gut [215]. Furthermore, the increased 
concentrations of various amines (methylamine, trimethylamine) in fecal extracts 
(Table 3-1) reflects the fundamental role for the intestinal microflora after RYGB 
 92 
surgery in the provision of methylamine and trimethylamine from the catabolism of 
precursors such as choline [216]. 
 
Cross talk between mammalian metabolism and the intestinal microbiome and 
its impact on weight loss following RYGB operation.  
The most striking metabolic feature of RYGB operated rats is an increase in the 
diversity and complexity of signals in the aromatic region of the 1H NMR urinary 
spectra (Figure 3-2), corresponding to increased concentrations of p-cresyl 
glucuronide, p-cresyl sulfate, 5-aminovalerate, phenylacetylglycine, p-
hydroxyphenylacetate and indoxyl sulfate (Figure 3-3 A and B, Table 3-1). The 
aromatic region of the 1H NMR spectrum provides a convenient spectral window on 
gut microbial activity [217] and many of the metabolites with signals in the range 
δ6.5-8.0 derive from mammalian-microbial co-metabolism [217]. 
 
Fermentation is one of the many functions provided by gut microbes, where those of 
the proximal colon are mainly responsible for enhanced calorific recovery from 
otherwise indigestible polysaccharides [218]. The lower concentrations of 
oligosaccharides and higher concentrations of short chain fatty acids (Table 3-1), 
which are major products of fermentation, suggest increased microbial fermentation 
activity. There was a positive trend between fermentation-generated compounds and 
lower body weight although this was not significant, but may suggest a role in 
metabolic modulation and metabolic syndrome resolution after surgery [62, 219]. The 
efficiency of microbially-mediated energy recovery is determined by the composition 
of the microbiome.  
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In order to probe the deeper association between the changes in the metagenome and 
metabolic phenotype, key discriminatory bacterial classes and selected species were 
correlated directly with the metabolic profiles. A significant proportional increase in 
the g-proteobacteria in RYGB-operated rats was positively correlated with urinary p-
hydroxyphenylacetate, p-cresyl glucuronide, p-cresyl sulfate, creatine, 
phenylacetylglycine (PAG) and indoxyl sulfate and with fecal succinate, putrescine, 
diaminoethane, uracil, glycine, methylamine and formate (Figure 4-4). Clostridia 
demonstrated an association with decreased urinary p-cresyl glucuronide, PAG and 
creatine, and with decreased fecal succinate, glycine, uracil and formate and increased 
fecal oligosaccharides (Figure 4-4). The main contributor to the increase in g-
proteobacteria was Enterobacter hormaechei which manifested a 200 and 42.8 fold 
increase at weeks 2 and 8 post RYGB surgery respectively. In the case of E. 
hormaechei strong direct covariation with p-cresyl derivatives, p-cresyl glucuronide 
and p-cresyl sulfate, PAG and creatine were detected (Figure 4-5). Thus, although 
earlier studies have indicated that some species of Clostridia produce phenol and p-
cresol together with ammonia and hydrogen via the anaerobic degradation of aromatic 
amino acid such as tyrosine [220], our findings suggest that g-proteobacteria 
(predominantly in this case E. hormaechei), may also contribute to the pool of cresol 
metabolites in the urine. This finding is consistent with previous studies reporting that 
changes in gut Enterobacter are associated with corresponding alterations in p-cresol 
metabolite levels [221]. 
 
Urinary concentrations of PAG, p-cresyl glucuronide, 5-aminovalerate, p-cresyl 
sulfate, creatine and p-hydroxyphenylacetate, and fecal concentrations of uracil, 
putrescine and methylamine increased as body weight reduced (Figure 4-6 A). High 
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intensities of Enterobacteriaceae and Pasteurellaceae are associated with weight loss, 
whereas Lachinospiraceae, Incertae Sedis XIII and Prevotellaceae increased with 
weight gain (Figure 4-6 B). The Enterobacteriaceae levels exhibit a strong correlation 
with surgical weight loss and urinary PAG, putrescine, uracil, p-cresyl glucuronide, 
creatine and methylamine levels whereas the urinary excretion of p-cresyl sulfate 
correlates with Bifidobacteriaceae and Micrococcaceae (Figure 4-7). 
 
Does bariatric surgery have a short-term gain and a long-term weight loss 
through changes in microbial ecology?  
Bariatric surgery-induced microbial and metabolic alterations can contribute to 
surgical weight loss, beneficial metabolic outcomes and decreased mortality. 
However a shift towards the g-proteobacteria as a major component of the microbiota 
and elevation in p-cresol derivatives and another uremic toxin, indoxyl sulfate could 
have long-term impacts on host health with unpredictable outcomes.  
 
Recent evidence also identifies the bacterium E. Hormaechei as an apoptosis-inducing 
agent in human epithelial cells [222]. A deeper understanding of the disease-
modifying mechanisms of bariatric surgery is therefore essential. Studying such 
metabolic interactions through a top-down systems biology approach can thus 
improve our current understanding of surgery to provide improved outcomes and 
novel treatments for obesity and metabolic disorders.  
 
At 8 weeks post-RYGB operation, urinary creatinine levels were lower and may 
reflect improved creatinine clearance post-operatively or surgically induced kidney or 
muscle injury as the uremic toxin, indoxyl sulfate was also found to increase in the 
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RYGB group. The role of these metabolic changes on kidney function require further 
investigation as clinical studies demonstrate the beneficial effects of RYGB [223] and 
GLP-1 [132] on renal function. 
 
The current work represents a systematic and dynamic investigation of the metabolic 
and microbial effects of the RYGB procedure in Wistar rats using metagenomic and 
NMR-based metabonomic approaches. Both longitudinal (time-effect) and horizontal 
(surgery-effect) results are prominent in metabolic and microbial signatures where I 
also provide triangular (body weight loss, metabolite profiles and bacterial 
compositions) correlations. I have uncovered mechanistic insights into the role of the 
Roux-en-Y gastric bypass to achieve weight loss and metabolic enhancement. This 
includes the surgically effect of modulating the biochemical crosstalk between the gut 
microbiome and systemic host metabolism. For the first time, I identify E. 
hormaechei as a long-term key contributor to post-operative gut ecology. This 
organism is an excellent beta-lactamase producer [213] and therefore may be resistant 
to pre-operative antibiotics (Amoxycillin and Flucloxacillin, both beta-lactams), thus 
allowing it to persist peri-operatively and colonise in the early post-operative period. 
Interestingly however, bacterial levels remained high in the RYGB population, 
whereas this was not the case in sham animals. These changes are associated with my 
findings of increased protein putrefaction after surgery.  
 
When considering the translational impact of this finding, it should be remembered 
that although the weight loss and metabolic shifts seen in this animal model relate to 
the findings of human studies, patients exhibit large variances in their pre-surgical, 
intra- and post-operative antibiotic exposure. This represents a limitation in 
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translating these rodent results to human subjects as the gut ecology of bariatric 
surgical patients will differ from that observed in my controlled rodent model. 
Consequently, this methodology must now be applied to human patients to better 
examine the translational impact of this animal model in a human surgical population.  
 
Despite these limitations, my results offer additional evidence to support the 
contribution of integrated host and microbial metabolism to the sophisticated 
mechanisms behind the metabolic benefits of bariatric surgery. 
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Chapter	  5	  –Systemic	  Metabolic	  Profile	  of	  Human	  Subjects	  
undergoing	  Bariatric	  Surgery	  as	  translational	  validation	  of	  the	  
Experimental	  Surgical	  Model	  	  	  	  
5.1	  Introduction	  	  
The global shift in metabolism following bariatric surgery demonstrated through 
systems biological profiling in my rodent model demonstrates the profound metabolic 
effects of these procedures. Furthermore, the dominant effects noted on metabolic 
changes resulting from gut microflora metabolism revealed a novel mechanism 
through which these operations may offer beneficial disease resolution. This data 
offers an increased understanding of the initial findings that bariatric surgery carries 
powerful metabolic enhancing effects in human subjects and validates the randomised 
controlled trials and longitudinal studies demonstrating metabolic weight-independent 
disease resolution through some bariatric operations. As a result, the information 
derived from my animal model helps overcomes some of the obstacles of identifying 
the causation that bariatric surgery enhances systemic metabolism through six of the 
nine the elements of the Bradford Hill Causation criteria (consistency, specificity, 
temporality, plausibility, coherence and experiment).  
 
Although the results from rodent bariatric surgery offer translational biological 
insights [224] regarding human bariatric surgery, the necessary inference when 
studying this data carries some complexities. These include: 
 
(i) Species differences in obesity and fat deposition 
(ii) Species differences in gastrointestinal anatomy and biology 
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(iii) Species differences in response to surgery and anaesthesia 
(iv) The relationship between mass, volume and metabolic rate (scaling law) 
 
As the underlying objective of my experimental rodent model was for the assessment 
of human bariatric surgery, my aim was to carry out directly equivalent translational 
experiments on human subjects undergoing these procedures to assess the robustness 
of my experimental data on a human surgical cohort. A central question to assist the 
study of this translation would be whether the metabolic changes in my rodent animal 
model reflect similar shifts in human bariatric surgery (figure 5-1).  
 
 
 
Figure 5-1: Interspecies translation of the systems biology pyramid 
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The increasing wealth of knowledge concerning gut microbial ecology in human 
health and disease carries a plausible translational direction through which human 
bariatric surgery may offer its beneficial effects, however this observation requires the 
validation of equivalency in human subjects. This would consequently allow the 
application of my animal model in future experiments not only clarifying the 
mechanism of bariatric metabolic modulation, but also offering a platform on which 
to boost further characterisation of the beneficial metabolic elements directly from 
human bariatric surgical candidates. 
 
My aim was to perform a translational experiment in human subjects undergoing 
bariatric procedures to: (i) identify the systemic metabolic modulation of subjects 
following surgery and (ii) clarify if these metabolic changes reflect the metabolic 
effects resulting from bariatric surgery in my rodent model.  
	  
5.2	  Materials	  and	  Methods	  
Participants 
A total of 48 participants were included in the current study and were recruited from a 
single institution bariatric centre of excellence, Imperial College Healthcare NHS 
Trust, London, United Kingdom. Inclusion criteria were age between 21 to 65 years 
and BMI of ≥35 kg/m2 for in patients selected for bariatric surgery according to the 
United Kingdom’s National Institute for Health and Care Excellence guidelines.[225] 
 
These included subjects: 
 100 
• With a BMI of 40 kg/m2 or more, or between 35 kg/m2 and 40 kg/m2 and other 
significant disease (for example, type 2 diabetes or high blood pressure) that 
could be improved if they lost weight 
• All appropriate non-surgical measures have been tried but have failed to 
achieve or maintain adequate, clinically beneficial weight loss for at least 6 
months 
• The person has been receiving or will receive intensive management in a 
specialist obesity service 
• The person is generally fit for anaesthesia and surgery 
• The person commits to the need for long-term follow-up. 
• First-line option for adults with a BMI of more than 50 kg/m2 in whom 
surgical intervention is considered appropriate. 
 
The exclusion criteria were: Previous bariatric surgery, previous surgery for gastric or 
duodenal ulcer, gastric ulcer during the past six months, on-going malignancy, active 
malignancy during the past five years, myocardial infarction during the past six 
months, bulimic eating pattern, psychiatric or cooperative problems contraindicating 
bariatric surgery, regular use of cortisone or non-steroidal anti-inflammatory 
treatment; excess of alcohol intake and alcohol or drug abuse, and other severe 
illnesses. 
 
All patients underwent either Roux-en-Y gastric bypass surgery or adjustable gastric 
banding surgery. Within this sample, only two bariatric surgery patients underwent 
adjustable gastric banding. Thus, no comparisons for surgery type were made. 
 
 101 
Interventions and Clinical Follow-Up 
The study and all procedures were approved by the National Research Ethics Service 
and all participants provided written informed consent prior to participation. Subjects 
completed self-report measures of demographic and medical history and were 
assessed clinically by a bariatric multidisciplinary team at Imperial College 
Healthcare NHS Trust, London, United Kingdom. Medical records were reviewed by 
research staff to corroborate patient report of medical conditions and to supplement 
participant self-report. The bariatric multidisciplinary team consisted of specialist 
trained (consultant) surgeons, specialist trained (consultant) physicians, dieticians, 
nurses, psychologists and psychiatrists and exercise/physical activity professionals in 
accordance with the United Kingdom’s Action on Obesity.[226] 
 
Patients were reviewed in the obesity clinic by all members of the multidisciplinary 
team and once selected for surgery by unanimous decision had pre-operative surgical 
review. Subjects received standard surgical intra-operative and immediate post-
operative care. They were followed up at 4 weeks, 8 weeks, 6 months, 12 months, 
18months and 24 months after surgery as an institutional standard. More frequent 
reviews were performed based on clinical need.  
 
Biosampling 
Baseline biosamples (Urine and Stool) were collected within 4 hours preceding 
bariatric surgery. Furthermore within 4 weeks before surgery anthropometric, clinical 
and biochemical parameters were measured. Post-intervention biosamples were 
collected at 2, 6 and 12 months following surgery. 
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Midstream urine specimen was carefully collected at the time of presentation into 
sterile universal bottles for each patient and were immediately transferred and kept in 
a freezer at -80°C. Faecal specimens were also collected at the time of presentation 
into sterile universal bottles for each patient and were immediately transferred and 
kept in a freezer at -80°C. 
 
Surgical Technique 
A laparoscopic Roux-en-Y Gastric Bypass (RYGB) procedure was performed by 
creating a 15-30mL gastric pouch isolated from the distal stomach by applications of 
a linear stapler. The jejunum is divided 50 to 100 cm distal to the ligament of Treitz, 
and the distal limb is connected to the gastric pouch, creating an alimentary Roux 
limb. The proximal bowel segment or biliopancreatic limb is connected to the 
alimentary limb through a jejunojejunostomy 100-150 cm distal to the 
gastrojejunostomy. Laparoscopic Adjustable Gastric Banding (AGB), was performed 
by placing a restrictive band across the gastric pars flaccida (to reduce band slippage). 
The band is kept in place by the belt bevels on the device and is further stabilised by 
polyglactin 910 stay sutures. The band contains an inflatable balloon that can be 
inflated through an attachment to plastic tubing attached to a port placed on or in the 
rectus muscle or fixed in an accessible subcutaneous space. The tubing may be 
shortened to tailor the position of the port to the patient. The Access Port is then 
sutured in place utilizing the suture holes in the port base. During the surgical 
procedure, the inflatable band is flushed with sterile saline. The device was typically 
adjusted from 6 to 8 weeks after surgery according to the clinical assessment and in 
every visit thereafter, along with the usual care. Data for gastric band patients was 
assessed from the time of first balloon filling. 
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Nuclear Magnetic Resonance Spectroscopy 
Urine samples were thawed and vortexed for 15 seconds prior to mixing an aliquot of 
400 µl with 250 µl of 0.2 M phosphate buffer (pH=7.4) containing 20% deuterium 
oxide (D2O) for the magnetic field lock, 0.01% 3-(trimethylsilyl)-[2,2,3,3-2H4]-
propionic acid sodium salt (TSP) for the spectral calibration and 3 mM sodium azide 
(Na3N) for avoiding bacterial contamination. The resulting mixture was centrifuged at 
10392 g for 10 min and 600 µl of supernatants was transferred into a NMR tube with 
an out diameter of 5 mm pending 1H NMR spectral acquizition. A single fecal pellet 
from each sample was placed into a 2 ml Eppendorf™ containing 1.4 ml of phosphate 
buffer. The sample was homogenised, vortexed for 15 s, sonicated for 30 min at the 
temperature of 298 K and centrifuged at 10392 g for 20 min. A total of 700 µl 
supernatant was taken into a 1.5 ml Eppendorf™ tube and centrifuged again under the 
same condition. The supernatant (600 µl) was taken into a NMR tube pending 1H 
NMR spectral acquisition. 
 
1H NMR spectra of urine and fecal extract samples were obtained using a Bruker 600 
MHz spectrometer (Bruker; Rheinstetten, Germany) at the operating 1H frequency of 
600.13 MHz with a temperature of 300 K. A standard 1 dimensional solvent 
suppression NMR pulse sequence (recycle delay [RD]-90o-t1-90o-tm-90o-acquisition) 
was applied to acquire 1-dimensional (1-D) 1H NMR spectral data, where t1 was set to 
3 µs and tm (mixing time) was set to 100 ms. The water peak suppression was 
achieved using selective irradiation during RD of 2 s and tm. A 90-degree pulse was 
adjusted to 10 µs. A total of 128 scans were collected into 64 k data points with a 
spectral width of 20 ppm. A series of 2-D NMR spectra including 1H-1H correlation 
spectroscopy (COSY), 1H-1H total correlation spectroscopy (TOCSY), J-resolved 
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spectroscopy, 1H-13C heteronuclear single quantum coherence (HSQC), 1H-13C 
heteronuclear multiple bond coherence (HMBC) were acquired on the selected urine 
and fecal extract samples for the purpose of metabolite annotations. 
 
Multivariate data analysis 
Multivariate data analyses were performed based on the pre-possessed NMR dataset. 
1H NMR spectra obtained from urine and fecal extracts were automatically phased, 
referenced and baseline-corrected using a MATLAB script developed by Dr. T. 
Ebbels at Imperial College. The resulting NMR spectra (δ0-10) were imported to 
MATLAB software and digitized into 20 k data points with the resolution of 0.0005 
ppm using script developed in house (Dr. O. Cloarec). The water peak region δ 4.62-
5.05 and in urine spectra and δ 4.7-4.9 in fecal water spectra were removed in order to 
minimize the effect of the disordered baseline. Additionally, regions between δ 0-
0.10, δ 5.47-6.24 and δ 9.90-10.00 in urinary spectra, and regions δ 0-0.30 and δ 9.4-
10.00 in fecal water spectra containing only noise were removed, followed by 
normalization to the remaining spectral areas of NMR data in order to perform further 
analyses. Principal component analysis (PCA), O-PLS and O-PLS-DA were carried 
out based on the resulting NMR spectral datasets in SIMCA (P+11.5) and MATLAB 
(2009a) software. 
 
5.3	  Results	  	  
The metabolic shifts of Roux-En-Y Gastric Bypass were demonstrable in human 
subjects undergoing bariatric surgery (Figure 5-2). Cross validation plots and PLS-
DA coefficient plots of urinary NMR spectral data obtained from patients at 2 months 
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and 1 year after surgery reflected the metabolic discrimination between these two 
groups. 
 
PLS-DA scores plot (Q2Y=0.37) derived from UPLC-MS(-) data demonstrated a 
clear separation between pre surgery (green), 2 months post surgery (purple) and 1 
year post surgery (Figure 5-3).  
 
 
 
 
Figure 5-2 - Urinary NMR spectral data from patients at 2 months and 1 year after surgery. Higher 
levels of phenylacetylglutamine (PAG) and trimethylamine N-oxide (TMAO) were observed in 2-
month post surgery patients compared with pre surgery. Higher PAG was observed in 1-year post 
surgery patients compared with pre surgery. Hippurate was found to be higher in 1-year post surgery 
samples compared with 2 months post operation. 
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Figure 5-3 – (a) Principal Component Analysis (PCA) of urine samples at 3 time points. (b) Partial 
Least Square-Discriminant Analysis (PLS-DA) of urine samples demonstrating a metabolic shift 
between 3 time points (green= pre-surgery, Purple=2 months post surgery, Orange=1 year post 
surgery) 
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However, faecal PLS-DA scores plot (Q2Y=0.37) derived from UPLC-MS(-) data 
demonstrated no significant separation observed between pre surgery (green), 2 
months post surgery (purple) and 1 year post surgery (Figure 5-4). 
 
 
 
Figure 5-4 – (a) PCA scores plot of faecal aqueous extracts at 3 time points (green= pre-surgery, 
Purple=2 months post surgery, Orange=1 year post surgery); (b) Corresponding PLS-DA scores plot of 
faecal aqueous extracts pre-surgery and at 2 months and 1 year post surgery. 
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5.4	  Discussion	  	  
The results from this translational metabolic profile of human subjects undergoing 
bariatric surgery revealed the multimodal effects of these operations on systemic 
metabolism. These metabolic effects confirm the translational validity of the 
previously developed experimental rodent model of gastric bypass surgery in terms of 
metabolic outcomes.  
 
These results identify that bariatric surgical subjects can be differentiated based on 
their metabolic profile according to their time after surgery. As a result, there are 
demonstrable sequential metabolic changes identifiable at 2 months post-operatively 
compared to pre-operative subjects. Furthermore, there are increased changes at 12 
months after surgery. Specifically, urinary spectral data revealed higher levels of 
phenylacetylglutamine (PAG) and trimethylamine N-oxide (TMAO) in 2-month post 
surgery patients compared with subjects before surgery. Higher PAG was observed in 
1-year post surgery patients compared with pre surgery. Hippurate was found to be 
higher in 1-year post surgery samples compared with 2 months post operation. 
 
The significant changes and sequential shifts in urinary spectra comparing pre-
operative samples to post-operative samples at 2 and 12 months reinforces the 
concept of systemic ‘metabolic’ transformation in bariatric surgical subjects. These 
changes may help explain the consistent and longstanding metabolic benefits in these 
patients. As post-operative weight loss requires up to 6 months to be accomplished, 
the profound 2-month changes noted in these results therefore also offer further 
evidence to support a weight-independent metabolic effect offered by bariatric 
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procedures. The finding that some of the initial metabolic modulations persist for up 
to 12 months also reinforces the longstanding nature of these metabolic changes and 
may help explain the long-term reduction in cardiovascular disease, type II diabetes 
mellitus and even cancer.  
 
As previously identified, increases in PAG and TMAO reflect a profound shift in 
microbial ecology as they are typical microbial metabolites. The increase in urinary 
hippurate at 1 year is consistent with previous studies identifying decreased hippurate 
levels in obesity,[197] such that the rise in hiuppurate seen in these bariatric subjects 
may be a reflection of their weight loss. This metabolite was not raised at 2 months 
where subjects have not yet undergone majority weight loss, so that its increased 
levels at one year might reflect hippurate as a putative marker for weight loss that 
warrants further investigation. 
 
These changes in microbial and mammalian metabolites do however require further 
clarification in terms of clinical outcomes and patient phenotypes. Furthermore, 
identification of microbial ecological shifts is warranted as this may reveal novel 
mechanistic information and possible future targets for the management of metabolic 
dysfunction and obesity. This data was inconsistent with the findings from my animal 
model of bariatric surgery in terms of faecal metabonomic profiles. Whilst this could 
reflect interspecies variation in resting and post-operative metabolism, the effects 
noted in the urinary spectral data do not support this. One explanation for the lack of 
significance in faecal data and the milder changes noted in urinary data in humans 
may be due to smaller subject number and type 2 statistical error. However, it may 
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also have resulted from several experimental barriers and complexities in deriving 
data from human subjects. These include: 
 
(i) Inconsistency of follow-up between different patients and clinicians 
(ii) Variable social networks 
(iii) Variable cultural influences on lifestyle and diet 
(iv) Variability in genetic background 
(v) Variability in demographics, psychographics and social background 
(vi) Variability in medical and pharmacological history 
(vii) Variability in age 
(viii) Variability in primary healthcare 
(ix) Variability due to treatment preferences 
(x) Lack of behavioural transparency (such as ‘cheating’ the gastric band by 
consuming high caloric foods in liquid form in private) 	  
The globally common trends observable between the post-operative metabolic profile 
of my experimental animal model and that of human subjects however offers 
preliminary translational validation for the experimental surgical model. As such, this 
data can act as a future platform to derive further mechanistic understanding of 
bariatric operations, and identify novel metabolic enhancing strategies.  	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Chapter	  6	  -­‐	  Cardiac-­‐specific	  Metabolic	  Activity	  of	  Bariatric	  
Surgery	  
 
6.1	  Introduction	  
 
Obesity and Heart Failure  
A strong association between obesity, increased BMI and heart failure was described 
by the Framingham Heart Study, which reported that obese patients have double risk 
of developing heart failure when compared to subjects with a normal BMI and 
identified weight as the third most important predictor of heart disease after age and 
dyslipidemia.[227] In this study, approximately 11% of male and 14% of female 
cases of heart failure were directly correlated to obesity, and each incremental BMI 
rise of 1kg/m2 increased the risk of heart failure by 5% for males and by 7% for 
females. Further evidence from the National Health and Nutrition Examination 
Survey (NHANES I) revealed that obese patients are 30% more likely to develop 
heart failure when compared to non-obese patients,[228] and analysis of the 15,402 
individuals of the Renfrew-Paisley study demonstrated that the obesity-associated 
adjusted risk of heart failure was 2.09.[229] 
 
Patients who suffer from heart failure either exclusively or predominantly as a result 
of their obesity are considered to have ‘obesity cardiomyopathy’. This has been 
under-recognized as a separate disease entity, and is now considered as any 
myocardial disease or dysfunction in obese individuals inexplicable by other 
etiologies of heart failure, such as diabetes mellitus, hypertension and coronary artery 
disease.[230]  
 112 
 
The literature associating obesity and heart disease is however not wholly clear-cut, as 
there exists a phenomenon known as the ‘obesity-paradox’ where it has been 
demonstrated that obese patients with established cardiovascular disease have a better 
prognosis and cardiovascular outcomes than “ideal-weighted” or underweight 
patients.[231] This phenomenon is not fully understood, and must be weighed against 
a number of studies associating improved metabolic profiles and decreased 
cardiovascular events following successful weight reduction therapy in obese 
individuals. It is also becoming increasingly clear that the obese population are not 
necessarily one single entity but can be classified into a heterogeneous group of 
individuals with complicated and uncomplicated obesity subtypes.[232] The latter 
group is obese subjects who do not demonstrate any obesity-related metabolic 
comorbidities, whereas the former group are those who may benefit from medical and 
surgical management. 
 
 
Epicardial Fat and Bariatric Surgery 
Post-mortem analyses demonstrate that there is strong evidence of ventricular 
dysfunction in obese patients.[233] ‘Excessive’ epicardial fat occurs in 95% of 
subjects, and approximately 40% demonstrate ventricular fatty infiltration. This 
excessive cardiac fat has been described as resulting from metaplasia of connective 
tissue,[234] which subsequently develops into a fatty infiltration in approximately 3% 
of morbidly obese individuals.[235] 
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The fat that surrounds and infiltrates the myocardium shares the same coronary blood 
supply, and is not anatomically separated by any discernible fasica that is visible in 
other tissues such as in skeletal muscle.[236] This adipose tissue around the heart is 
now recognized as a metabolically active organ that can modulate both cardiac 
morphology and function.[237] It has also been suggested that these adipocyte cells 
can also mediate direct cardiotoxicity as a result of myocardial steatosis[238] that can 
result in obesity cardiomyopathy. 
 
Measuring maximal epicardial fat thickness at the point of the free wall of the right 
ventricle by echocardiography, Iacobellis et al.[239] reported that an increase in mass 
during cardiac hypertrophy is associated with a consensual and proportional increase 
in epicardial adipose mass. Furthermore, although there does not seem to be a strong 
relationship between epicardial mass and overall adiposity,[240] it closely relates to 
visceral fat quantity.[241] As visceral adiposity also has a strong association with the 
metabolic syndrome, the concurrent association with epicardial fat on 
echocardiography has led Iacobellis et al. to describe threshold values of epicardial fat 
dimensions for white high-risk metabolic syndrome patients to be 9.5mm for men and 
7.5mm for women.  
 
Bariatric surgery is an effective treatment for obesity cardiomyopathy,[242] and has 
been reported to improve cardiac function in two individuals with end-stage heart 
failure  previously under consideration for cardiac transplantation.[243] Surgery can 
decrease the obesity ‘cardiotoxic load’, and demonstrates significant decreases in 
epicardial fat thickness on postoperative echocardiograms from 5.3 ± 2.4 to 4.0 ± 1.6 
mm in 23 patients at 8-11 months after surgery.[244] 
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Obesity, Maladaptive Ventricular Remodeling and Cardiomyopathy 
Heart weight and body weight exhibit a linear relationship,[233, 245] and 
pathological studies reveal that long-term obesity results in systemic hypertension, 
left ventricular hypertrophy and dilatation, and ensuing cardiac failure[246] (Figure 
7-1). These morphological changes result in a deterioration of ventricular contractile 
function and distortion of cavity and shape consistent with maladaptive left 
ventricular remodeling which can progress to non-ischemic dilated 
cardiomyopathy.[227] Similar structural changes also occur to the right ventricle, but 
generally to a lesser degree, with the hypertrophy on both sides demonstrating 
distinctive concentric to eccentric changes.[247] In patients suffering from heart 
failure, the ventricular hypertrophy has a stronger association to obese individuals 
when compared to lean subjects.[246] Both animal and human studies of obesity 
associated heart failure reveal an increase in the prevalence of myocardial 
fibrosis,[248] which is proportional to the extent of obesity,[249] and is typically 
accompanied by tissue degeneration and inflammation.[250] These morphological 
findings allude to obesity as an independent factor contributing to heart failure and 
therefore reinforce the concept of a specific obesity cardiomyopathy. This has also 
been confirmed in-vivo by echocardiography of obese patients, where the severity of 
obesity positively correlates to the degree of left ventricular dimensions and 
hypertrophy. In obese patients, the incidence of left ventricular dilation is reported as 
being between 8-40% and the left ventricular wall mass is raised in up to 87% of 
individuals.[251] 
 
A number of studies have examined the relationship between bariatric surgery and 
cardiac morphology on two-dimensional echocardiography, and have demonstrated 
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some beneficial reductions in pathological cardiac variables (Table 6-1). These 
cardiac parameters include left ventricular mass indices, diastolic function and 
systolic function, which are surrogate markers for ventricular remodeling. As they are 
beneficially modulated by bariatric surgery, these procedures can therefore be 
considered as mediators of ‘reverse remodeling’ 
 
 
 
 
 
 
Figure 6-1 – Beneficial Cardiovascular Effects of Bariatric Surgery   
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Author N FU (months) 
ESD 
(cm) 
EDD 
(cm) 
E 
(cm/s) 
A 
(cm/s) 
E/A 
Ratio 
Deceleration 
Time (cm/s) 
 
Isovolumic 
Relaxation 
Time (ms) 
Left 
Ventricular 
Mass Index 
Di Bello et al. 
[252] 2008 13 6-24 NS -0.53 -4.8 -10.6* 
+0.12
* -5.5* -8.4* 
LVM/ht 
(g/m) 
-14.4* 
Ippisch et al. 
[253] 2008 
(Adolescents 
only) 
38 7-13 NS +0.13 +1 -8* +0.3* NS NS 
LVM/ht2.7 
g/m2.7 
-12* 
Nault et al. 
[254] 2007 10 6-12 +1 -3* NS NS +0.13 NS 0 
LVM 
(g) 
-16 
Ikonomidis et 
al. [255] 2007 60 36 +0.13 -0.2* NS NS +0.13 -19* -9* 
LVM/ht 
(g/m) 
-12* 
Leichman et 
al. [256] 2006 22 3 NS NS -3 -1 -0.04 -17 NS 
LVM/ht2.7 
g/m2.7 
-3.9* 
Cunha et al. 
[257] 2005 23 36 NS 
-
0.39* -4 -9* 
+0.31
* NS -25 
LVM/ht2 
g/m2 
-7.1* 
Willens et al. 
[258] 2005 17 3-15 NS -0.2 -7* -13* +0.3* -13 NS 
LVM/ht 
(g/m) 
-15 
Kanoupakis 
et al.[259] 
2001 
16 6 -0.08 -0.06 +2 -3.7 +0.14* NS -24* 
LVM 
(g) 
-35.4 
Karason et al. 
[260, 261] 
1997 & 1998 
41 12 NS NS +3 -4* +0.15* NS -9* 
LVM 
(g) 
-28* 
Alpert et al. 
[262] 1997 14 4-5 NS -0.8 +11 -9 +0.25 -40 NS 
LVM/ht 
(g/m) 
-31 
Alpert et al. 
[262] 1997 39 4-5 NS -0.5 +8 -6 +0.22 -29 NS 
LVM/ht 
(g/m) 
-46 
Alpert et al. 
[263] 1995 25 4-5 NS NS +8* -6* 
+0.22
* -28* NS 
LVM/ht 
(g/m) 
-44 
Alpert et al. 
[264] 1994 39 NS NS -0.5* NS NS NS NS NS 
LVM/ht 
(g/m) 
-46 
Alaud-din et 
al. [265] 1990 12 9-17 -0.08 -0.09 NS NS NS NS NS 
LVM 
(g) 
-41 	  
Table 6-1 - Effects of bariatric surgery on the mean changes in two-dimensional echocardiographic 
parameters. (N = patient number, FU = Follow-up time, *= Significant = P <0.05, ESD = End-Systolic 
Dimension, EDD = End-Diastolic Dimension, E = E wave, A = A wave, NS = Not Specified). 
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Bariatric Surgery and Ventricular Mass Indices 
Bariatric surgery has been demonstrated as successful modality to beneficially 
decrease ventricular mass indices in a number of studies (Table 6-1). Alpert et al. 
revealed that a longer duration of preoperative morbid obesity resulted in an even 
more sizeable regression of left ventricular mass after surgery,[251] although the 
beneficial effects were only observed in those who had an increased preoperative 
ventricular mass.[264] These positive findings on cardiac geometry following 
bariatric surgery have been reproduced by later studies with a follow-up of up to 3 
years.[255] The SOS study demonstrated significant reductions in wall thickness, 
relative wall thickness, and left ventricular mass at one year after surgery compared to 
a set of matched controls.[260] Subsequent multivariate regression analysis revealed 
that these changes in relative wall thickness and left ventricular structure were 
predicted by baseline relative wall thickness and baseline left ventricular mass 
respectively, as well as by changes in body weight.[260] 
 
 
Bariatric Surgery and Diastolic Cardiac Function 
Obesity is associated with an increased left ventricular end-diastolic pressure,[266] 
whilst BMI is an independent predictor of both end-diastolic volumes[267] and LV 
strain.[249] These studies are in accordance with the previous work on obesity 
associated ventricular morphology and convey that the “cardiomyopathy of obesity” 
is manifested by LV diastolic dysfunction and LV remodelling in obese patients.[266] 
Obese patients with diastolic dysfunction typically present with an unfavorable E/A 
ratio (early to late or atrial-A diastolic filling velocity) and worse iso-volumetric 
relaxation times (IVRT) as was shown by two-dimensional echocardiography and 
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also by reduced mitral annular velocity and myocardial early diastolic velocity (EM) 
on tissue Doppler. 
 
Bariatric surgery beneficially modulates these echocardiographic markers of diastolic 
dysfunction (Table 6-1), with trends across a number of studies confirming a 
significant increase of the post-operative E/A ratio, reduction of the A wave and 
shortening of the isovolumic relation time. Furthermore many of these beneficial 
changes occur alongside a beneficial regression of end-diastolic diameter and left 
ventricular mass indices.  Data on the changes on end systolic diameter and the E 
wave are more heterogeneous, but it has been shown that the greatest 
echocardiographic improvements in diastolic function are most noticeable in those 
patients who have been obese for a longer duration of time.[251] Tissue doppler 
evaluation also reveals that these operations increase both tricuspid and mitral annular 
early diastolic velocities.[258]    
 
 
Bariatric Surgery and Systolic Function 
Morbid obesity has long been established as impairing left ventricular systolic 
function,[268] although this finding is not universal[267] (maybe as a result of the 
‘obesity paradox’) and has not been confirmed for the right ventricle.[269] Cases of 
moderate obesity however can show mild to moderate left systolic dysfunction, 
typically demonstrated by a decreased ejection fraction (EF), and increased left 
ventricular dimensions and volumes. Improved echocardiography suggests that all 
obese patients harbor a degree of systolic dysfunction, albeit subclinically in milder 
 119 
forms,[249] such that only subtle markers of systolic dysfunction might be 
demonstrable (such as basal septal strain and increased reflectivity). 
 
Although a number of bariatric studies report on improved systolic function as 
discerned by end diastolic diameters after surgery (Table 6-1), the results on ejection 
fraction are not universally improved, particularly if the preoperative value is 
moderate or good (Table 6-2). Alpert et al. were able to demonstrate that 
improvements in systolic function only occur in those obese individuals whose 
systolic function was significantly depressed preoperatively,[270] and that the best 
improvement of systolic parameters following surgery occurs in those who have been 
morbidly obese for longer periods of time.[251] One case does describe an 
improvement in ejection fraction by 35% at eight year follow-up,[271] and these 
operations have also been shown to be beneficial for the systolic function of morbidly 
obese patients who have developed severe cardiomyopathy.[242, 243] One 
retrospective study demonstrated a significant improvement in mean left ventricular 
ejection fraction from 23±2% to 32%±4% at six months after surgery.[242] 
 
Author N FU (months) PreOp (%) PostOp (%) 
Di Bello et al.[252] 2008 13 6-24 72.5 ± 9.9 70.6 ± 8.8 
Nault et al.[254] 2007 10 6-12 64.7 ± 3.6 65.6 ± 8.3 
McCloskey et al.[242] 2007 14 6 23 ± 2 32 ± 4* 
Leichman et al.[256] 2006 22 3 61 ± 2.4 57 ± 4.0 
Karason et al.[261] 1998 41 12 62 ± 8 64 ± 8 
Alaud-din et al.[265] 1990 12 9-17 48.8 ± 2.9 54.7 ± 2.8 
 
Table 6-2 - Studies on the effects of bariatric surgery on Ejection Fraction. 
(N = patient number, FU = Follow-up time, *= Significant = P <0.05, PreOp = Preoperative Ejection 
Fraction, PostOp = Postoperative Ejection Fraction). 
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Bariatric Surgery and the Symptoms of Heart Failure 
 
In addition to the positive changes on cardiac function noted on imaging following 
bariatric surgery, both functional and clinical symptoms have also been shown to 
improve (Table 6-3), such that at five years after surgery, the risk of pulmonary 
edema remains significantly decreased.[79] McCloskey et al.[242] reported on the 
successful improvement of New York Heart Association (NYHA) status following 
surgery in morbidly obese patients with severe cardiomyopathy; two of whom went 
on to receive successful cardiac transplants.  
 
Author N FU (months) 
Improved Cardiopulmonary Status 
Assessed by: 
de Castro Cesar et al.[272] 2008 21 3 
Oxygen Uptake 
Carbon Dioxide Output 
Non-protein respiratory quotient 
McCloskey et al.[242] 2007 
 14 6 New York Heart Association Score 
Maniscalco et al.[273] 2007 
 12 12 6-min Walking Test 
Maniscalco et al.[274] 2007 
 24 12 Exhaled Nitric Oxide Test 
Sere´s et al.[275] 2006 
 31 12 Cardiopulmonary Exercise Stress Test 
Kanoupakis et al.[259] 2001 16 6 Mean O2 consumption at Peak Exercise Mean Anaerobic Threshold 
Karason et al.[276] 2000 1210 24 
Decreased Dyspnea 
Decreased Chest Pain 
Increased Physical Activity 
Alpert et al.[262] 1997 
 53 4-5 New York Heart Association Score 
 
Table 6-3 - Studies on the beneficial effects of bariatric surgery on functional status and 
cardiopulmonary symptoms. (N = patient number, FU = Follow-up time). 
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Bariatric Surgery and the Cardiac biomarker B-type Natriuretic Peptide 
Natriuretic peptides have been introduced as objective biochemical markers of cardiac 
function and heart failure. Serum levels of B-type natriuretic peptide (BNP) are lower 
in patients with obesity or those with an elevated BMI, although it remains to be a 
reliable marker for heart failure in this patient group.[277] The role of bariatric 
surgery in modulating the levels of BNP in patients with detailed heart failure has not 
been formally studied to-date, although it has been shown that levels of N-terminal 
proBNP drop significantly after gastric banding.[278] This decrease in levels of N-
terminal proBNP were presumed to be associated with a decrease in postoperative 
cardiac dysfunction, although conversely a cross-sectional study of patients without 
heart failure attending an obesity clinic revealed that BNP and N-terminal proBNP 
were higher in patients with a history of gastric bypass.[279] The association between 
bariatric surgery, heart failure and natriuretic peptides is complex and requires further 
clarification within the context of a formal research study. 
 
Bariatric Surgery, Sleep Apnea and Cardiac disease 
Obstructive sleep apnea (OSA) and obesity-hypoventilation syndrome (OHS) are both 
co-morbidities that frequently associate with obesity but also contribute to cardiac 
pathology, likely through the mechanical effects of excess weight suppressing 
adequate breathing and ventilation. In addition to a clear association of OSA to 
systemic hypertension, there is also an increasing body of evidence alluding that OSA 
results in right ventricular dysfunction and subsequent pulmonary hypertension.[280] 
Furthermore atrial fibrillation (AF) also has a greater prevalence in patients with heart 
failure suffering from OSA.[281]  
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Bariatric surgery has been demonstrated to resolve OSA and OHS in 85.7% of 
patients.[74] Cardiorespiratory complications such as hypoxemia, pulmonary 
hypertension, hypercapnea and even OSA associated atrial fibrillation may also be 
concurrently improved.[74, 282, 283]  
 
Bariatric Surgery and the Cardiac Electroconduction 
The cardiac electroconduction system can be affected by obesity, both due to direct 
infiltration, and by autonomic disturbances. As early as 1931 Samuel Herschel Proger 
demonstrated electrographic changes associated with obesity, reporting a lower QRS 
voltage, and a leftward shift in the P, QRS and T wave axes in obese subjects. Further 
studies implicate obesity associated changes in nearly every section of the 
electrocardiogram, with resting bradycardia being reported in up to 19% of 
patients.[284] Bariatric surgery improves the electrocardiogram of obese patients in a 
small number of studies (Table 6-4), where it beneficially modulates heart rate 
variability and QT intervals. 
Author N FU (months) Electrocardiographic effects 
de Castro Cesar et al.[272] 
2008 21 3 Decreased Resting Heart Rate 
Nault et al.[254] 2007 10 6-12 Improved Heart Rate Variability 
Russo et al.[285] 2007 100 12 Reduction of Spatial Dispersion (QTc-d, JTc-d) Reduction of Transmural Dispersion of Repolarization 
Bezante et al.[286] 2007 
 85 6 Reduction in QT Interval and Dispersion 
Perego et al.[287] 2005 31 12 Reduction of ECG criteria of Left ventricular Mass 
Papaioannou et al.[288] 2003 17 8-10 Shortening of the QTc interval 
Alpert et al.[289] 2001 
 60 4-5 
Reduced  frequencies of low QRS voltage 
Romhilt-Estes point score > or = 5 
 
Karason et al.[290] 1999 28 12 Improved Heart Rate Variability 
 
Table 6-4 - Studies on the beneficial effects of bariatric surgery on Electrocardiophysiology. 
(N = patient number, FU = Follow-up time) 
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Bariatric Surgery and Beneficial Cardiac Reverse Remodeling 
Obesity results in increased numbers of adipocytes leading to an expanded circulating 
volume thereby raising metabolic demands.[291] The subsequent increase of left 
ventricular stroke volume induces a persistent rise in cardiac output, which in turn 
results in systemic hypertension. In obese individuals, it was therefore proposed that 
the left ventricular stroke workload is higher due to an increased preload and stroke 
volume so that left ventricular dilatation occurs, causing a rise in wall stress and 
increasing myocardial mass to compensate. Eccentric hypertrophy follows (Figure 6-
2) with subsequent left ventricular systolic and diastolic dysfunction (the latter being 
more significantly affected).[251] 
 
The problems with this traditional haemodynamic hypothesis are: (i) the sequence of 
change in myocardial pathology which does not correlate to the extent of obesity, (ii) 
the use of 2-dminesional echocardiographic imaging complicated by excessive fat 
limiting acoustic windows, (iii) not taking into account the metabolic changes (both 
local and systemic) associated with heart failure, (iv) the volumetric changes in the 
circulation and cardiac adaption were not fully demonstrable, (v) the differentiation 
between eccentric, concentric and ventricular dilation geometries which were not 
fully accounted for and (vi) the model does not accommodate the Obesity Paradox 
where increased body mass index may provide prognostic benefits in the elderly. 
 
Local and Systemic Metabolic Effects of Obesity on Cardiac Remodeling 
There is now an increased awareness of the local and systemic metabolic 
consequences of obesity on cardiac remodeling. At a local level, both epicardial fat 
and ventricular fatty infiltration are present in approximately 3% of morbidly obese 
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individuals (BMI>40 kg/m2)[235] and this can be associated with ventricular 
dysfunction. The excess in ventricular apidocytes may result in myocardial steatosis 
acting as direct cardiotoxins[238]. Epicardial fat also contributes to cardiac 
dysfunction, because unlike skeletal muscle, the myocardium has no fascial 
compartments to separate muscular and fatty layers which share the same local blood 
supply. Therefore epicardial fat can contribute to the metabolic dialogue between fat 
and muscle. The biochemical characteristics of epicardial fat reflect a tendency 
toward increased lipolysis and low mitochondrial oxidative capacity reinforced by the 
pro-atherogenic modulation of adipokines (decreased adiponectin and increased 
resistin) and inflammatory factors which can contribute to adverse ventricular 
remodeling.[292] 
 
The systemic metabolic profile of obesity is associated with impaired glucose 
metabolism or even frank diabetes and hypertension, leading to the status of 
‘complicated obesity’ which is associated with disordered cardiac structure which 
may lead to cardiomyopathy. [227],[293] Identifying the relative contribution of 
obesity, diabetes, impaired glucose metabolism and hypertension on cardiac geometry 
and remodeling can thus be difficult as these pathologies usually co-exist within the 
same individuals. As a result, many patients with complicated obesity present with 
concentric hypertrophy (Figure 6-2). 
 
Recently one group[294] have addressed the many of the limitations of previous 
studies on obesity and cardiac geometry. They applied their extensive expertise in 
cardiovascular magnetic resonance (CMR), to achieve clear and consistent measures 
of ventricular mass and volumes in eighty-eight non-diabetic normotensive female 
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subjects over a range of body mass indices from normal weight to overweight, obese 
and morbidly obese.  
 
They demonstrated that a subtle increase in body mass index from normal to 
overweight results in eccentric cardiac hypertrophy without the expected volume-
dependent change to myocardial dilatation (Figure 6-2). This geometry is consistent 
even in mild obesity and only tends toward dilatation in morbidly obesity. The 
authors suggest the early hypertrophic changes of the heart are secondary to obesity-
associated hyperleptinaemia and that the subsequent cardiac dilation seen in morbid 
obesity is likely volume-induced. The multifaceted metabolic role of increased leptin 
levels in obesity has been increasingly recognised, and the data from this study are 
consistent with in-vitro studies suggesting leptin as a successful agent in stimulating 
cardiac hypertrophy.[295] This hypothesis lends itself to further testing as the 20-30% 
weight loss achieved with metabolic surgery decreases leptin significantly.[62] 
Moreover metabolic surgery demonstrated improved glycaemic control, reduced 
epicardial fat thickness as well as beneficial reverse modeling through reduction in 
wall thickness and ventricle mass.[62]   
 
This study[294] therefore contributes to our understanding as the majority of previous 
studies only used two-dimensional echocardiography to quantify cardiac geometry. 
The role of male gender on ventricular remodeling and subsequent heart failure still 
needs to be addressed.[227] Future studies can benefit by correlating these geometric 
findings with cardiac function to derive further mechanistic insights. These can clarify 
whether the initial effects of obesity are associated with diastolic dysfunction in the 
context of disordered metabolism and whether subsequent volume overload 
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eventually progresses to systolic dysfunction. Furthermore, the issue of the Obesity 
Paradox remains an unanswered entity in these obese patients, as the prevalence of 
cardiac geometric abnormalities in these individuals is associated with a lower 
mortality than normal weight patients.[296] Elucidating this geometry-mortality 
paradox in obese patients therefore remains a crucial question to be answered. 
Identifying the precise mechanisms of obesity induced cardiac remodeling can help 
predict patients most at risk of cardiac failure and can also provide novel treatments in 
the management of pathological cardiac geometries and obesity-associated cardiac 
failure. 
 
 
 
Figure 6-2 – Traditional and Metabolic explanation of pathological remodeling in obesity and 
subsequent beneficial reverse remodeling by Bariatric Surgery. BRAVE effects= (1) Bile Flow 
alteration, (2) Reduction of gastric size, (3) Anatomical gut rearrangement and altered flow of 
nutrients, (4) Vagal manipulation and (5) Enteric gut hormone modulation. 
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Atherosclerotic Load and Bariatric Surgery 
As bariatric procedures improve the metabolic profile, it could be predicted that there 
would be concomitant improvements on atherosclerotic load in obese subjects after 
surgery compared to controls. There are however few studies that have examined the 
role of bariatric surgery on imaged atherosclerosis, although one does confirm the 
benefits on disease status.[297] In this controlled 4-year interventional study carried 
out on a subgroup of the SOS study patients, intima-media thickness (IMT) and 
lumen diameter (LD) of the carotid artery were used as markers of atherosclerosis. It 
was demonstrated that the progression rate of carotid bulb IMT increased significantly 
by almost 29% for both mean and maximum values in nine obese controls compared 
to 11% mean and 6% maximum IMT progression in fourteen surgical patients. 
 
Inflammatory Prevention and Bariatric Surgery 
Metabolic syndrome seems to increase cardiovascular risk through the development 
of atherosclerosis.[298] The molecular mechanisms that lead to atheroma formation 
and subsequent cardiovascular events involves inflammatory steps, oxidative stress 
and endothelial dysfunction.[299]  
 
Bariatric operations beneficially modulate a number of the molecular culprits that lead 
to atheroma formation (Figure 6-3). Surgery results in an attenuation of oxidative 
stress and decreased levels of systemic inflammatory markers such as C-reactive 
protein (CRP), sialic acid, plasminogen activator inhibitor-1, malondialdehyde and 
von Willebrand factor.[300, 301] At the endothelium, there is an associated decrease 
in circulating levels of activating adhesion molecules such as E-selectin, P-selectin 
and ICAM-1,[300, 302, 303] and although nitric oxide and endothelin-1 levels are 
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paradoxically reduced and increased respectively after surgery,[302, 304] there is 
nonetheless an improved endothelium-dependent vasodilatory response.[300, 305] 
 
Compared to medical therapy, bariatric operations are associated with a greater 
weight loss and a more pronounced improvement in endothelium-dependent 
vasodilatation. The effects of surgery cannot however be explained by weight loss 
alone, and may include other mechanisms such as surgically induced improvements 
of glucose tolerance, lipid profiles and hypertension.[306] 
 
Epidemiological studies report that the relative risk of suffering from a cardiovascular 
event associated with CRP maybe independent to other risk factors such as 
cholesterol and LDL.[307] Both in vitro and in vivo research reveal CRP to play a 
role in cellular inflammation, atherosclerosis[308], subsequent risk of peripheral 
artery disease, myocardial infarction and sudden death.[309] Furthermore raised 
plasma levels of adhesion molecules such as ICAM-1 which mediate leukocyte 
trafficking, are associated with carotid intimal thickness[310] and subsequent 
cardiovascular events in some but not all studies.[311] Surgical reduction of these 
inflammatory biomarkers may therefore be one mechanism through which 
cardiovascular risk can be beneficially modulated to decrease ischemic event rates 
and mortality. 
 
Of further interest is the finding that to-date bariatric surgery is the only weight loss 
modality that can improve both the serum biochemistry and hepatic histological 
inflammation[312] of patients with non-alcoholic fatty liver disease, a condition that 
can result from increased oxidative stress, is considered as part of the metabolic 
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syndrome, but which has also been independently associated with coronary artery 
disease.[313]    
 
Adipokines and Bariatric Surgery 
Increased obesity results from an increase in the size and number of adipocytes, 
which are no longer considered simply to be energy-storage cells, but rather key 
physiological players in immunity and inflammation, and thus implicated in 
atherosclerosis (Figure 6-3).  They are known to release cellular mediators known as 
‘adipokines’ such as leptin, adiponectin, and resistin.[314-316] These participate in 
molecular pathways that produce downstream effects on the insulin axis, and also 
display effects on the heart via an ‘adipocardiac axis’. They have also been shown to 
be modulated by bariatric procedures, which may therefore mediate some of their 
cardioprotective effects through their effects on these adipocyte hormones. 
 
Leptin is mainly produced by white adipose tissue, and exhibits effects in nearly 
every body system. Cardiac myocytes express several isoforms of the its receptor, and 
hyperleptinemia has been shown to protect the heart from lipotoxicity[317], whilst 
also displaying antihypertrophic effects. Peripheral administration of leptin results in 
a beneficial nitric oxide mediated endothelial vasorelaxation,[318] although 
conversely chronic hyperleptinemia demonstrates increased heart rate, hypertrophy, 
intimal hyperplasia and also chronic heart failure.[319] 
 
Most bariatric procedures have been associated with a significant decrease in leptin 
levels which persist for up to two years after surgery.[320] Although changes in leptin 
concentrations are correlated with changes in subcutaneous, visceral, and total 
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adipose tissues, surgical modulation of this adipokine can be through both weight loss 
dependent and independent mechanisms. The latter can be multifactorial, but may 
involve a postoperative association of leptin with insulin levels.[321] Leptin 
modulation through bariatric procedures may result in a favorable effect on 
atherosclerosis, as decreased serum levels are associated with a reduction in intimal 
hyperplasia, while raised levels are related to increased intima-media thickness, 
atheroma formation and myocardial infarction.[314] Furthermore, circulating leptin 
levels correlate well with left ventricular mass in morbid obesity both before and after 
bariatric surgery.[287] 
 
Adiponectin is amongst the highest produced adipokines, possessing both anti-
inflammatory and anti-diabetic properties, although levels are paradoxically decreased 
in obesity and insulin-resistance states. Early epidemiological data suggests that that 
lower plasma concentrations of adiponectin are associated with the risk of coronary 
artery disease when adjusted for age and BMI,[316] whilst raised levels reveal a 
lower risk of myocardial infarction.[322] Although these associations have not been 
universally demonstrated,[323] in vitro studies reveal that adiponectin can mediate 
nitric oxide production, inhibit apoptosis in human endothelial cells and inhibit 
arterial smooth muscle cell proliferation.[324] These effects may be augmented by 
bariatric surgery, as these procedures maintain raised levels of adiponectin at up to 
one year postoperatively in some but not all studies.[303] Conversely, high 
adiponectin levels have been reported as a predictor of mortality in patients with 
chronic heart failure.[325]  
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Resistin is a recently discovered adipokine that has also been shown to play a role in 
atherogenesis, as it activates endothelial cells, and raised levels are associated with 
increased coronary artery calcification.[315] Bariatric operations can significantly 
reduce levels of resistin at over a year postoperatively,[326] which may contribute to 
the post-surgical decrease in atherosclerotic events. 
 
 
 
Figure 6-3 – Beneficial Anti-Atherosclerotic Effects of Bariatric Surgery 
 
Bariatric modified Gut Hormones and Cardiac Function - The “Enterocardiac 
Axis” 
The effects of gut hormones on the myocardium have been noted ever since a number 
of surgical studies demonstrated that the removal of gut hormone secreting tumors 
can result in a poorly understood heart failure.[327] Since the late 1970s, hormones 
such as Secretin (duodenum), Glucagon (pancreas) and Vasoactive Intestinal Peptide 
(gut, pancreas and brain) were used to treat heart failure, as they were shown to act as 
inotropes by activating cardiac membrane adenylate cyclase.[328] More recently, 
some of the gut hormones modulated by bariatric surgery have also been shown to 
 132 
demonstrate beneficial effects on cardiac function, and may account for some of the 
cardiac effects of these operations via the proposed concept of an ‘enterocardiac axis’ 
(Figure 6-1). 
 
Glucagon-like peptide-1 (GLP-1) is a molecule that raises satiety, improves insulin 
secretion and is increased following bariatric surgery.[59, 329] Its cardiac effects 
include the enhancement of myocardial glucose uptake and improvement in both left 
ventricular and systemic hemodynamics in a canine model of dilated cardiomyopathy 
(DCM) and humans with LV systolic dysfunction after acute myocardial 
infarction.[330] Infusion results in improved functional status in patients with chronic 
heart failure,[331] and also demonstrates direct beneficial effects on endothelium-
dependent vasodilatation.[332] 
 
Ghrelin is a known appetite stimulant, increased by both dietary weight loss and 
bariatric surgery,[333] although this is not universally found.[334] It acts on the 
growth hormone secretagogue receptor, and can also regulate sympathetic nerve 
activity, wherein central injection can decrease blood pressure in rats by acting on the 
brainstem.[335]   
 
The role of ghrelin on the heart and cardiovascular system has been shown to be quite 
important. This hormone can induce vasodilatation in isolated human endothelium-
denuded arteries, and recent genetic evidence has alluded to the role of specific 
haplotypes of ghrelin ligand and its receptor in effecting susceptibility and tolerance 
to coronary artery disease.[336] When infused in subjects with congestive heart 
failure, cardiac index, stroke volume index and ejection fraction are all significantly 
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improved and left ventricular wall stress is reduced.[337] Circulating ghrelin levels 
are elevated in cachexia associated with chronic heart failure,[338] whilst infusion to 
rats with heart failure can attenuate the development of cardiac cachexia.[339] Further 
insights into the role of this hormone can be discerned from patients with Prader-Willi 
Syndrome who demonstrate hyperghrelinemia and can also develop cardiac failure, 
which may occur as a result of an underlying ‘ghrelin resistance’.[340] One case has 
been reported where gastric bypass resulted in maintaining an improvement in heart 
failure following medical therapy in a patient with Prader-Willi Syndrome.[341]  
 
Current status of bariatric surgery in cardiac disease 
Results from non-randomized trials looking at the direct cardiac effects of bariatric 
surgery, seem to confirm this suggested trend of improvement in cardiac function and 
a reversal of the detrimental effects of obesity cardiomyopathy. Improvements in both 
markers of cardiac function, ventricular remodeling and atherosclerotic load have 
alluded to the benefits of this type of surgery in preventing cardiac failure and 
coronary atherosclerosis. These operations have been applied to patients with 
established cardiac disease with no cardiac mortality,[242, 243, 342] although some 
of these patients did require revascularization and stenting. Furthermore their 
beneficial effects need to be weighed against the possibility of an increased operative 
risk in patients with obesity cardiomyopathy or pulmonary hypertension despite the 
favourble long-term outcomes on cardiovascular parameters. Unfortunately, there are 
currently no comprehensive randomized studies assessing the role of these procedures 
on rigorously defined endpoints on heart failure and atherosclerotic status. A number 
of mechanisms through which bariatric surgery improves cardiovascular physiology 
may include direct mechanical weight loss effects, decreased inflammation, 
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modification of adipokines and gut hormone release, and potentially other as of yet 
‘unknown factors’.  
 
The future therefore lies with more in-depth research accurately defining the 
beneficial cardiac effects and mechanisms of bariatric surgery on obesity associated 
heart disease, and comparing these results to other weight loss therapies. If bariatric 
surgery is found to confer substantial cardiovascular benefit through metabolic and 
obesity modulation, its indications may potentially be expanded to treat patients with 
lower obese severity who suffer from metabolic syndrome or concurrent cardiac 
dysfunction, and by doing so may prove to be of increasing use in the prevention of 
ischemic coronary disease and cardiac failure. 
 
Study aims 
My study aim is therefore to characterize the cardiac specific metabolic shifts after 
bariatric surgery using a systems biology approach in order to better understand the 
beneficial cardioprotective activity of these operations. 
  
6.2	  Methods	  
 
Animal model and sampling 
A total of 27 Male Wistar rats were individually housed under a 12 hour /12 hour 
light-dark cycle at a room temperature of 21±2 ºC. Water and standard chow were 
available ad libitum, unless otherwise stated.  All experiments were performed under 
a license issued by the Home Office UK (PL 70-6669). Subjects were acclimatized 
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for 1 week and were randomized to gastric bypass (N=13) or sham (N=14) operation 
according to our previously described technique[343]. 
 
Preoperatively rats were food deprived overnight for 12 hours with water available ad 
libitum. Subjects were weighed, and then anesthetized with isofluorane (4% for 
induction, 3% for maintenance). Preoperative antibacterial prophylaxis was 
administered intra-peritoneally (1 ml of an Amoxicillin/Flucoxacillin solution, both at 
12.5 mg/ml). Surgery was performed on a heating pad to avoid decrease of body 
temperature during the procedure. The abdomen was shaved and disinfected with 
surgical scrub and a midline laparotomy was performed. 
 
The sham procedure consisted of a 7 mm gastrotomy on the anterior wall of the 
stomach with subsequent closure (interrupted prolene 5-0 sutures) and a 7 mm 
jejunotomy with subsequent closure (running prolene 6-0 suture). In the gastric 
bypass procedure, the proximal jejunum was divided 15 cm distal to the pylorus to 
create a biliopancreatic limb. After identification of the cecum, the ileum was then 
followed proximally to create a common channel of 25 cm. Here, a 7 mm side-to-side 
Jejuno-Jejunostomy (running prolene 7-0 suture) between the biliopancreatic limb and 
the common channel was performed. The gastric pouch and alimentary limb were 
anastomosed end-to side using a running prolene 7-0 suture. The gastric remnant was 
closed with interrupted prolene 5-0 sutures. The complete bypass procedure lasted 
approximately 60 minutes and the abdominal wall was closed in layers using 4-0 and 
5-0 prolene sutures. Approximately 20 minutes before the anticipated end of general 
anesthesia, all rats were injected with 0.1 ml of 0.3% buprenorphine subcutaneously 
to minimize postoperative discomfort.  Immediately after abdominal closure, all rats 
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were injected subcutaneously with 5 ml of normal saline to compensate for intra-
operative fluid loss. After 24 hours of wet diet (normal chow soaked in tap water), 
regular chow was offered on postoperative day 2. 
 
At 8 weeks post operation, a total of 27 plasma samples and 16 (8 RYGB; 8 Sham) 
heart samples were collected from animals and all samples were subsequently snap-
frozen and stored at −80° C.  
 
Heart sample extraction 
A total of 16 left heart samples (≈400 mg) were put into a 2 ml Eppendorf tube 
containing a metal ball, 0.5 ml of prechilled chloroform:methanol mixture (v:v, 2:1) 
and 0.5 ml of prechilled water. The Eppendorfs were placed in a Tissue Lyser and 
shaken for 8 min at 25 Hz, and then centrifuged at 4 °C for 10 min at 10,000 g. The 
top aqueous lay was transferred in to a 7 ml container and lower lipid phase was 
transferred into a 5 ml glass vial. The above procedure was repeated 3 times and the 
aqueous and chloroform phases from the same sample were combined with previous 
phases. The aqueous phase was divided into 2 equal portions, speed vacuumed 
overnight, and the organic phase left in the fume hood to evaporate over night.  
 
Sample preparation for NMR spectroscopic analyses  
Plasma samples were thoroughly defrosted and vortexed for 15 s prior to mixing an 
aliquot of 300 µl with 250 µl of saline containing 20% deuterium oxide (D2O) for the 
magnetic field lock. The resulting mixture was centrifuged at 10,000 g for 10 min and 
540 µl of supernatants was transferred into a NMR tube with an outer diameter of 5 
mm pending for 1H NMR spectral acquisition.  
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Prior to 1H NMR analysis, the powder obtained from the aqueous phase was 
resuspended in 600 µl 0.2 M sodium phosphate buffer (D2O:H2O=1:4, v:v, 0.01% of 
sodium 3-(trimethylsilyl) propionate-2,2,3,3-d4 [TSP], pH=7.4), centrifuged for 10 
min at 10,000 and 580 µl of supernatant was transferred into a NMR tube with an 
outer diameter of 5 mm pending for 1H NMR spectral acquisition. 
 
Nuclear magnetic resonance spectroscopy 
1H NMR spectra of plasma and heart extract samples were obtained using a Bruker 
600 MHz spectrometer (Bruker; Rheinstetten, Germany) at the operating 1H 
frequency of 600.13 MHz with a temperature of 300 K. A standard NMR pulse 
sequence (recycle delay [RD]-90o-t1-90o-tm-90o-acquisition) was applied to acquire 1-
dimensional (1-D) 1H NMR spectral data, where t1 was set to 3 µs and tm (mixing 
time) was set to 100 ms. The water peak suppression was achieved using selective 
irradiation during RD of 2 s and tm. A 90 degree pulse was adjusted to approximately 
10 µs. A total of 128 scans for heart aqueous extracts and 256 scans for plasma 
samples were collected into 64 k data points with a spectral width of 20 ppm. A Carr-
Purcell-Meiboom-Gill (CPMG) pulse sequence [RD-90°-(τ-180°-τ)n-acquire FID] 
was applied additionally to plasma samples to better visualize the signals of the low 
molecular weight metabolites. For the CPMG experiment, a spin relaxation delay 
(2nτ) of 64 ms was used. 
 
A series of 2-D NMR spectra including 1H-1H correlation spectroscopy (COSY) and 
1H-1H total correlation spectroscopy (TOCSY) were acquired on the selected urine 
and faecal extract samples for the purpose of metabolite annotations. The standard 
parameters for these spectral acquisitions were previously reported[344]. 
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NMR spectral data processing 
1H NMR spectra of plasma and heart aqueous extracts were manually phased, 
referenced and baseline-corrected in TopSpin 3.0 (Bruker, Germany). The resulting 
NMR spectral data (δ 0-10) were imported to MATLAB software and bucketed into 
20 k data points with the resolution of 0.0005 using a script developed in house (Dr. 
O. Cloarec). The water peak region (δ 4.62-5.05) was removed in order to minimise 
the effect of the disordered baseline. Total normalisation was performed on the 
remaining plasma spectral data, whereas the peak alignment and subsequent 
probabilistic normalisation were carried out on the spectral data of heart aqueous 
extracts. Principal component analysis (PCA) and O-PLS-DA were carried out based 
on the resulting NMR spectral datasets in SIMCA (P+11.5) and MATLAB (2010a) 
software. The selected peak integral of metabolites that are highly correlated with 
classification (r > 0.52) were further evaluated using a two-tailed student t test. 
 
Sample preparation for UPLC-MS experiment  
A total of 50 µl plasma sample was mixed with 150 µl of prechilled methanol, placed 
in -20 °C freezer for 20 min and centrifuged at 10,000 g for 10 mins after thawing. A 
total of 160 µl of supernatant was transferred into a new Eppendorf tube and speed 
vacuumed for 2.5 hours at 45 °C. The dry mass was resuspended in 120 µl of HPLC-
grade water, vortexed, sonicated for 10 min at 25 °C and centrifuged for 2 min at 
10,000 g. A total of 90 µl of supernatant was transferred into a 96-well plate and 
another 20 µl of supernatant from each sample was mixed to form a sample for 
quality control. 
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The other portion of aqueous phase was resuspended into 1 ml of HPLC-grade water, 
vortexed and spun at 10,000 g for 10 min. 200 µl of supernatant was transferred into a 
96-well plate and another 50 µl supernatant from each sample were taken to form a 
sample for quality control. The organic phase was resuspended in 3 ml of 
water:methanol mixture (v:v, 1:5), sonicated for 10 min and vortexed. Similar to the 
aqueous phase, 200 µl of supernatant was transferred into a 96-well plate and another 
50 µl supernatant from each sample were taken to form a sample for quality control. 
 
UPLC-MS analysis of plasma and heart tissue extracts 
UPLC-MS analyses were performed for both aqueous and organic extracts using an 
Acquity UPLC system coupled with a LCT Premier time-of-flight mass spectrometer 
(Waters, Manchester, UK), operating in both positive (ESI+) and negative (ESI-) 
electrospray ionization modes. The reversed-phase chromatography was performed 
with a HSS T3 Acquity column (2.1 × 100 mm, 1.7 µm, Waters Corp., Milford, MA) 
for all samples. The injection volume was 5 µl. For plasma samples, chromatography 
was carried out at 40 °C with a flow rate of 0.5 ml/min. Mobile phase A was water 
with 0.1% formic acid and B was methanol with 0.1% formic acid. For both ESI+ and 
ESI-, the initial gradient was 99.9% water for 2 min, linearly changed to 50% water at 
12 min and stayed for 1 min, then linearly changed to 0.1% at 17 min and held on for 
4 min, and altered back to initial gradient at 23 min and followed by a 3-min re-
equilibration phase.  
 
For heart aqueous extracts, chromatography was carried out at 50 °C with a flow rate 
of 0.4 ml/min. The mobile phases were the same as for plasma samples. The initial 
gradient was 99.9% water for 2 min, linearly changed to 75% water at 6 min (ESI+/-), 
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subsequently changed to 20% water at 10 min (ESI+) or 8 min (ESI-), reduced to 10% 
at 12 min (ESI+) or to 7% at 14 min and 3% at 15 min (ESI-), and 0.1% at 21 min or 
19 min (ESI-) and held for 2 min (ESI+/-), followed by a 3-min re-equilibration phase 
(ESI+/-). 
 
ESI conditions were as follows: source temperature 120 °C, desolvation temperature 
350 °C, cone gas flow 25 L/h, desolvation gas flow 900 L/h, capillary voltage for 
ESI+ 3200 V and ESI- 2400 V, sample cone voltage 35 V, m/z range 50-1000 with 
scan time of 0.2 s and an interscan delay of 0.01s. Data were collected in centroid 
mode. Leucine enkephalin (MW =555.62 Da) (200 pg/µL in acetonitrile/water 50:50) 
was used as a lock mass with an analyte-to-reference scan ratio of 24:1. A quality 
control (QC) sample was injected 6 times prior to running test samples and injected 
once every 10 injection to monitor the instrumental performance stability. 
 
UPLC-MS data processing 
A total of six datasets were derived from plasma, aqueous and organic extracts of 
hearts with both positive and negative ionization modes. Each dataset was pre-
processed and analysed separately using XCMS software in R environment via six 
steps: (1) filtration and peak identification; (2) Matching peaks across samples; (3) 
Retention time correction; (4) Peak re-grouping; (5) filling missing peaks; (6) median 
fold change normalisation. The resulting datasets are 2 dimensional containing peak 
intensities with sample IDs as observations and combination of retention time and m/z 
ratio as variables. The data then were imported into SIMCA 12.0.1 for further PCA 
and PLS-DA analysis using pareto scaling method. The intensities of metabolites that 
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are highly correlated with classification (r > 0.52) were further evaluated using a two-
tail student t test and the coefficient of variation (CV) of each ion was calculated. 
 
Network Correlation Analysis 
Metabolites that are found to be significantly altered in plasma and heart tissue are 
included into network correlation analysis. Spearman correlation is performed in R 
2.12.2 and a cut-off value of 0.55 and 0.75 were applied to plasma and heart 
metabolites, separately. The correlation values were subsequently imported into 
Cytoscape 2.8.3 to obtain network analysis plots in a degree sorted circle layout. 
	  
6.3	  Results	  
RYGB operation alters plasma metabolic profiles 
Plasma samples obtained from Wistar rats at 8 weeks post operation were analysed 
using both 1H NMR spectroscopy and UPLC-MS-based metabolic profiling 
approaches in order to extensively characterize the global metabolite perturbation 
induced by RYGB operation. The resulting three datasets including NMR spectra, MS 
ESI+ and ESI- exhibit clear separation between SHAM and RYGB rats along the PLS 
component (Figures 6-4A, 6-4B and 6-5) attributed to changes of bile acids, 
phosphocholines, amino acids, energy-related metabolites, nucleosides and amine 
metabolites, which are summarised in Table 6-5. The CVs of metabolites detected by 
UPLC-MS are under 10% with an exception of 1-stearoylglycerophosphocholine in 
negative mode (CV=26.6). 
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Figure 6-4 – Metabolic changes observed in UPLC-MS datasets of plasma from RYGB and SHAM 
rats. A, a PLS-DA scores plot of plasma MS (ESI+) data (Q2Y=0.77). B, a PLS-DA scores plot of 
plasma MS (ESI-) data (Q2Y=0.82). C, box plots of relative ion intensities of metabolites including 
cholic acid, glycocholic acid, indoxyl sulphate and 2-deoxycytidine detected in RYGB and SHAM 
animals. The central red mark of each box is the median; the edges of the box are the 25th- 75th% of 
the datapoints; outliers are plotted individually.* p<0.05; *** p<0.001. 
 
 
 
 
 
 
 
 
Figure 6-5 – Metabolic changes observed in 1H NMR CPMG spectral datasets of plasma from RYGB 
and SHAM rats. Cross-validation plots on the left and O-PLS-DA coefficient loadings plots 
(R2X=30.8%; Q2Y=0.69) indicate the discriminatory metabolites between RYGB and SHAM-
operated rats. 
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Table 6-5 – Altered plasma metabolites (red, higher in RYBG rats; blue, higher in SHAM rats). 
*putative assignment; d: doublet; dd: double of doublets; t: triplets; s: singlet; bs: broad singlet; m: 
multiplets; q: quartets. 
 
 
 
 
Energy related metabolism was perturbed, evidenced by increased circulation levels 
of TCA cycle intermediates (citrate), glycolysis end product (pyruvate), and short 
chain fatty acid (acetate) and decreased lipolysis product (glycerol). I also observed 
that higher concentrations of acetate, alanine, trimethylamine N-oxide (TMAO), 
formate, lysine and glycocholic acid are present after RYGB operation compared with 
sham-operated animals, together with lower levels of glycerol, 2-deoxycytidine, 
phenylalanine and N/O acetyl compounds in plasma. 
 
Effects of RYGB on cardiac metabolism 
Clinical data have shown that bariatric surgery play beneficial role in improving 
cardiac functions and blood lipid profiles. I therefore explored the heart metabolic 
signatures after RYGB, which demonstrated substantial alterations in both aqueous 
and organic extracts of heart tissue (Figure 6-6). PLS-DA models constructed based 
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on aqueous extracts showed higher predictive ability, indicated by Q2Y, in contrast to 
organic extracts.  
 
Figure 6-6 – PLS-DA scores plots of heart aqueous extracts from UPLS-MS datasets of ESI+ (A, 
Q2Y=0.85) and ESI- (B, Q2Y=0.88). PLS-DA scores plots of heart organic extracts from UPLC-MS 
datasets of ESI+ (C, Q2Y=0.76) and ESI- (D, Q2Y=0.74). Red dots represent RYGB-operated rats, 
whereas blue ones are SHAM rats. 
 
 
Selected metabolites including adenosine 5 monophosphate (AMP), beta nicotinamide 
adenine dinucleotide (NAD+), carnitine, malate, pantothenic acid, phenylalanine, 
pyridoxal 5 phosphate and creatine were shown in Figure 6-7 in a box plot fashion 
and additional discriminant metabolites are summarised in Table 6-6. Glycogen, 
formate and lysine levels significantly increased post RYGB surgery, whereas the 
majority of metabolites such as AMP, NAD, carnitine, creatinine glutamine, 
pantothenic acid, malate, tryptophan, taurine, hypotaurine are higher in sham rats. 
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Figure 6-7 – Metabolic changes observed in UPLC-MS datasets of heart aqueous extracts of RYGB 
and SHAM rats. Box plots of relative ion intensities of metabolites including Adenosine 5 
monophosphate (AMP),  beta nicotinamide adenine dinucleotide (NAD+), carnitine, malate, 
pantothenic acid, phenylalanine, pyridoxal 5 phosphate and creatine detected in RYGB and SHAM 
animals. The central red mark of each box is the median; the edges of the box are the 25th- 75th% of the 
data points; outliers are plotted individually.* p<0.05; ** p<0.01; *** p<0.001. 
 
 
Table 6-6 - Altered metabolites observed in heart aqueous extracts (red, higher in RYBG rats; blue, 
higher in SHAM rats). *putative assignment; d: doublet; dd: double of doublets; t: triplets; s: singlet; 
bs: broad singlet; m: multiplets; q: quartets.     
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Network Analysis of plasma and cardiac metabolites 
Several strongest positive correlations were observed (Figure 6-8) in cardiac 
nucleotides (e.g. AMP vs. NAD, r=0.93), plasma bile acids (e.g. glycodeoxylcholic 
acid vs. glycocholic acid, r=0.89), cardiac amino acids (e.g. tryptophan vs. 
phenylalanine, r=0.91), and cardiac TCA cycle intermediates (e.g. malate vs. 
succinate, r=0.87).  Formate and alanine in plasma, and lysine in heart are highly and 
positively correlated with each other (r=0.86-0.87).  
Cardiac glycogen exhibited strongly inverse correlations with malate (r=-0.87), 
phenylalanine (r=-0.81) and xanthine (r=-0.80). Interestingly, cardiac hypotaurine is 
inversely correlated with plasma TMAO (r=-0.83) and formate (r=-0.80). 
 
 
 
Figure 6-8 – Network analysis of plasma and cardio metabolites using Spearman correlation. A. Inter-
metabolite correlation based on significantly altered plasma metabolites, cut off value of r>0.55, 
p<0.01; B. Inter-metabolite correlation based on significantly altered cardio metabolites, cut off value 
of r>0.75, p<0.01; C.  Inter-metabolite correlation based on metabolites observed in both plasma (red) 
and heart tissues (black), cut off value of r>0.55, p<0.01. Red lines represent positive correlation and 
blue ones represent negative correlation. The stroke of line (0.5 - 4 pt) represents correlation strength 
(0.55 < │r│<0.93). Keys: AMP, adenosine 5 monophosphate; GCA, glycocholic acid; GDCA, 
glycodeoxylcholic acid; NAD, beta-nicotinamide adenine dinucleotide; PA, Pantothenic acid; PP, 
Pyridoxal 5 phosphate; SGP, 1-stearoylglycerophosphocholine; TMAO, trimethylamine N-oxide. 
	  
6.4	  Discussion	  	  
Bariatric operations modulate metabolic activity through a number of different 
mechanisms, including enteric gut hormone modulation and bile flow alteration.[105, 
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345-348] RYGB anatomy alters the bile flow, delaying contact with ingested nutrients 
and resulting in substantial disturbance in bile metabolism. Plasma bile acids, in 
particular, glycocholic acid and putatively assigned glycodeoxycholic acid, were 
observed to be increased 8 weeks post RYGB in contrast to sham animals, a finding 
consistent with the results of Mutch and colleagues observed in human patients[160]. 
The higher plasma bile acid levels demonstrated in this study and lower faecal bile 
acid excretion reported in Chapter 4 (based on the same animal subjects), suggest that 
the shortened journey for bile acid reaching the ileum may up-regulate bile acid re-
absorption. Post RYGB bile acid regulation is currently incompletely understood due 
to the multifactorial metabolic effects of the RYGB procedure, however, bile acid 
recycling after ileal interposition surgery has been previously reported.[349, 350] Ileal 
interposition is a bariatric procedure, involving interposition of distal ileum into the 
proximal jejunum that has been implemented to manage the severity of metabolic 
syndrome. This procedure is proposed to act through the “hindgut” mechanism, where 
processed nutrients reach the hindgut with less exposure to the foregut subsequently 
stimulating anti-diabetic activity. The interposed ileal segment has adapted jejunal 
villi length, mucosal surface area, epithelial jejunal specific gene GATA4 expression, 
and diminished epithelial ileal specific gene ILBP. However, it also remains able to 
re-absorb bile acids via increased levels of apical sodium-dependent bile acid 
transporter (ASBT) that are both comparable with sham ileum and demonstrate a 
significantly increased number of GLP-1-producing enteroendocrine cells in the villi 
[349].  
 
The major role of bile acids/salts is to facilitate lipid absorption from the intestine, 
however they may also stimulate GLP-1 secretion through the bile acid receptor 
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GPBA (TGR5: the cell surface G protein-coupled receptor) in intestinal L-cells[351, 
352]. Interestingly however, in male Long-Evans rats, sleeve gastrectomy has also 
been reported to reduce hepatic CYP7A1 expression, a rate-limiting step in hepatic 
bile acid synthesis. Furthermore, this operation also decreased postprandial plasma 
triglyceride levels by reducing intestinal triglyceride secretion[353], and reduced the 
rate of appearance of plasma triglycerides after an oil gavage compared with pair-fed 
sham group. This helps identify potential mechanisms of improved cardiovascular 
function after bariatric surgery as higher plasma levels of postprandial lipids are 
associated with atherosclerosis[354]. Moreover, it suggests that the modulation of 
cardiac-regulating intermediaries such as bile acids may have direct and systemic 
activity on the cardiovascular system through an entero-cardiac axis[62]. 
 
Decreased urinary TCA cycle intermediates have also previously been found in 
RYGB-operated animals compared with sham controls, implying an up-regulation of 
the TCA cycle and an alteration in mitochondrial metabolism[343]. Increased 
pyruvate levels may reflect altered glycolysis and TCA cycle metabolism as pyruvate 
is a major product of glycolysis that can subsequently be utilised in the TCA cycle as 
both acetyl CoA and oxaloacetate (via decarboxylation by pyruvate dehydrogenase 
and carboxylation by pyruvate carboxlase respectively). Increased pyruvate could also 
lead to higher levels of alanine through the transfer of an amine group from glutamate 
to pyruvate. Furthermore, the depleted glycerol level seen in here may indicate 
concomitant up-regulation of gluconeogenesis and glycogen storage. This is 
supported by the finding of increased glycogen in heart extracts and increased glucose 
and glycogen found in the liver samples of these animals (unpublished data). 
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RYGB-operated rats also exhibit reduced concentrations of various phosphocholine, 
lysophosphatidylcholines and N-acetyl glycoproteins in plasma, which are in 
agreement with plasma metabolic profiles of dietary-restricted male C57BL/6 
mice[355]. Observations of elevated concentrations of citrate and TMAO in RYGB 
rats could be also associated with caloric restriction as reported previously[355]. 
TMAO has been found to be strongly associated with coronary artery atherosclerotic 
burden and cardiac risk in humans, thought to be regulated through choline/dietary 
phosphocholine metabolism.[356] This occurs through the choline-TMA-TMAO 
pathway, which comprises two key steps: the conversion of choline products into 
TMA by functional gut microbiota, and the metabolism of TMA into TMAO in the 
liver by FMO3 and other FMOs. 
 
Indoxyl sulphate was also found to be higher in RYGB rats. This is consistent with 
results reported in Chapter 4, where I demonstrated a higher urinary concentration of 
this metabolite in rats undergoing RYBG surgery. Indoxyl sulphate is derived from 
the bacterial metabolite indole via hepatic transformation, and is a uremic toxin 
associated with arteriosclerosis[357]. This metabolic modulation may reveal the 
concurrent effect of bariatric surgery on both the heart and the kidneys to act on the 
cardiorenal syndrome. Aerobic gut microbes such as Escherichia coli are heavily 
responsible for the indole pool, which arises from dietary tryptophan metabolism. 
Plasma extracts of conventional mice were found to contain significantly higher levels 
of indoxyl sulphate, hippurate, phenylacetylglycine, phenylpropionylglycine and 
indole-3-propionate compared with germ-free mice, indicating that the presence of 
these metabolites in host plasma is largely attributable to enteric gut microbial 
activities[358]. In hemodialysis patients, the gut microbial composition exhibits high 
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aerobacteria and low anaerobacteria. A 5-week administration of Bifidobacteria, a 
group of anaerobic microbiota, can effectively decrease plasma indoxyl sulphate 
levels in these patients[359].  
 
A principal nucleoside of DNA, 2-deoxycytidine, presents lower levels in RYGB 
animals in comparison with sham. This could result from the metabolism of 2-
deoxycytidine to deoxyuridine, which is subsequently metabolised to uracil before 
being further processed and excreted as urea.  
 
The results of this study also suggest that bariatric surgery specifically modulates key 
TCA cycle metabolic intermediaries in a manner that would offer a post-operative 
shift toward energy efficiency. Firstly, I demonstrate a significant reduction in 
myocardial succinate and its downstream energetic effector pantothenic acid (vitamin 
B5). Decreased levels of succinate can represent its increased flux through the 
mitochondrial electron transport chain or increased enzymatic activity within the 
Kreb’s cycle (Succinate dehydrogenase-SDH). Succinate oxidation also offers the 
lowest energy yield in the citric acid cycle, and raised levels can reduce Kreb’s cycle 
efficiency resulting in harmful increases in Reactive Oxygen Species (ROS) such as 
superoxide.[360] Decreased myocardial levels of succinate can therefore represent 
increased energy efficiency utilising other Kreb’s intermediaries that offer protection 
from myocardial hypoxia.[361, 362] These mitochondrial effects offer increased 
cellular energy production and may therefore not only augment surgical weight loss, 
but also reduce ROS, protecting against the systemic inflammation of obesity co-
morbidities. These protective effects may be further supported by the observed fall in 
pantothenic acid, which in normal circumstances may be consumed during the 
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synthesis coenzyme A (CoA) and the acylation and acetylation of key citric acid 
enzymes. The myocardial reduction of this water-soluble vitamin may therefore 
represent increased consumption though the Kreb’s cycle, leading to increased energy 
expenditure and weight loss whilst also offering protection from cardiac 
ischaemia.[363] A reduction of panthothenic acid has however also been 
demonstrated to deplete systemic glycogen stores whilst contributing to weight 
loss[364] and it is therefore possible that this finding may reflect a dietary deficiency 
after surgery. My results however contradict this hypothesis, as I have demonstrated 
an increase in cardiac glycogen stores, thus reflecting a myocardial energy rich state 
where there is an abundant source of rapid glucose metabolism for myocardial tissue 
homeostasis.[365] Furthermore, excessive myocardial tissue glycogen can lead to 
harmful effects[366] including electrophysiological dysfunction and hypertrophy, 
which was not observed in this cohort.  
 
It is pertinent to also consider that the results of this study suggest that RYGB in rats 
may also be associated with some harmful metabolic shifts including a raised level of 
cardiac and plasma formate. Increases in formate can represent a source for both local 
and systemic acidosis that can lead to detrimental tissue toxicity. Conversely 
however, formate is an important constituent of healthy diets[367] and its deficiency 
can also be harmful. Notably however, the formate results seen in this rodent model 
do not readily translate to human clinical outcomes in view of the trans-species 
variability in its kinetics. As such, these changes must be further evaluated in human 
patients in order for the effects of bariatric surgery on formate metabolism to be 
accurately evaluated.  
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I have previously highlighted the putative cardio-protective role of bariatric surgery 
through an “entero-cardiac axis”.[62, 346] Further metabolic corroboration of a 
cardio-protective metabolic profile after bariatric surgery in this model includes a 
reduction in cardiac phenylalanine representing a decrease in muscle protein over-
degradation[368]. These results also reveal dramatic shifts in mediators of cellular 
homeostasis, osmoregulation and membrane stabilisation. Of these the central 
pathway transforming cysteine to isethionic acid in cardiomyocytes utilises the two 
chief intermediaries of taurine and hypotaurine. I demonstrate a significant decrease 
in the cardiac levels of these intermediaries following Roux-en-Y gastric bypass 
surgery. Taurine is amongst the few naturally occurring organic sulphonic acids acid 
that is a recognised constituent of human bile. It is present in many organ systems but 
has particular importance in the cardiovascular system as a moderator of both 
muscular development and function. Whilst this molecule is important in reducing 
oxidative stress, providing cardiomyocyte osmoregulation and membrane 
stabilisation, it also has a key role in cardiac calcium regulation.[369] Despite these 
beneficial roles, early evidence identified that elevated levels of taurine were 
associated with cardiac pathophysiology[370]. Human patients who die as a result of 
congestive cardiac failure demonstrate dramatically increased levels of taurine[371] 
whilst this molecule also demonstrates higher levels in heart tissue in the context of 
hypertrophy[372] and systemic hypertension[373]. The powerful effects of Roux-en-
Y gastric bypass procedures on cardiac tissue have been demonstrated to offer a 
beneficial reduction in cardiac failure with an improvement in cardiac geometry and 
long-term risk. Disordered taurine levels can be associated with contractile cardiac 
dysfunction,[374] and the decreased levels in the post-operative stages of bariatric 
surgery may therefore represent a protective biochemical environment after surgery. 
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Optimisation of the levels of cardiac taurine after bariatric procedures may also 
contribute to the improved electrophysiological status of heart tissue after surgery. 
 
In summary, these results suggest that in my rodent model, key metabolic 
intermediaries involved in cardiac energy metabolism may be modulated by Roux-en-
Y gastric bypass surgery. Furthermore, these metabolic changes may, in part, account 
for some of the beneficial effects of these operations, including weight loss through 
increased mitochondrial energy production and cardioprotectivity through increased 
cardiac energy efficiency a reduction in myocardial hypoxia and reactive oxygen 
species generation. It is however important to note that despite these experimental 
findings, the mechanism by which these metabolic shifts give rise to or result from the 
aforementioned beneficial effects of RYGB surgery remains speculatory. As a result, 
further research is now required to better establish the upstream mechanistic changes 
associated with these findings in order to better define the metabolic map of the 
entero-cardiac axis.  	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Chapter	  7	  –	  Conclusions	  
	  
7.1	  Overall	  Discussion	  of	  Results	  
The results from these studies reveal the profound metabolic effects of bariatric 
surgery in both the specifically designed experimental rodent model of Roux-en-Y 
gastric bypass and in humans. It confirms that these procedures offer more than 
‘simply’ weight loss, and are associated with a powerful metabolic effect, so that 
these operations deserve their title of ‘metabolic operations”.  There is no doubt that 
the weight loss does offer its own recognised metabolic effects that carry beneficial 
(weight-dependent) effects on type 2 diabetes, metabolic syndrome heart disease and 
cancer. However these procedures also demonstrate immediate weight-independent 
effects that help set-off the cascade toward weight loss through a gut-brain axis acting 
on appetite and behavior, an entero-insular axis acting on the pancreas, an entero-
cardiac axis acting on the heart, and an entero-renal axis effecting the kidneys. As 
such, disease resolution on these organ systems occurs through multifactorial 
mechanisms. 
 
Considering the effects of obesity and its co-morbidities on the heart, I initially 
hypothesized the existence of an entero-cardiac axis that beneficially modulated the 
heart though gut hormonal and post-bariatric modulation. Using a systems biology 
approach, I have demonstrated significant metabolic changes after RYGB surgery 
which suggest the possible existence of such an entero-cardiac axis. Furthermore, 
added support for this theory has since been confirmed by other groups who have 
shown the powerful effects of gut hormones such as GLP-1 on cardiac function 
through such a gut-heart dialogue.[375] 
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As bariatric surgery employs several physiological and molecular systems, I aimed to 
classify its immediate post-operative effects as a method to explain the biologically 
influential actions of these procedures. As a consequence, I developed the notion of 
the BRAVE framework as a possible classification system for the effects of bariatric 
surgery ((i) bile flow alteration, (ii) reduction of gastric size, (iii) anatomical gut 
rearrangement and altered flow of nutrients, (iv) vagal manipulation and (v) enteric 
gut hormone modulation [105]), and speculated as to the potential way in which these 
anatomical changes may beneficially modulate systems-wide cellular and molecular 
physiology. 
 
One novel finding presented here is the fact the most pronounced metabolic 
modulation of bariatric surgical procedures derived from changes in gut microbial 
metabolites. Whilst the evidence for causation remains speculative and still requires 
further confirmation, the association between gut microbial changes and bariatric 
surgery has opened a new field enhancing bariatric operations. This involves not only 
understanding the mechanisms by which these procedures produce weight 
independent metabolic changes, but also importantly highlighting a route through 
which the next generation of treatments for obesity and its escalating co-morbidities 
may be developed. 
 
To-date the majority of bariatric research has predominantly focused on the putative 
role of malabsorption from the gastrointestinal tract versus the restriction of stomach 
size in resolving obesity and its comorbidities. Whilst my research and those of other 
studies identifies the powerful effect of stomach size restriction, the role of 
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malabsorption in procedures such as adjustable gastric banding is non-existent and the 
Roux-en-Y gastric bypass (the most common bypass procedure) reveals only an 
approximate 5-10% malabsorption rate based on stool calorimetry studies. 
Furthermore, a bottom-up approach of the scientific paradigm identifying putative 
proteins in the beneficial effect of these operations has presented the potential of 
individual gut hormones in acting as intermediaries in metabolic pathways. Two 
hormones have predominated which have anti-appetite effects (GLP-1 and PYY) 
although a myriad of the ever-increasing number of gut hormones have yet to be 
studied through this approach. Based on the data currently available, the beneficial 
effects of these operations were largely classified into foregut or hindgut effects. The 
hindgut hypothesis is now well established and focused on altered foodstuffs reaching 
the hindgut to release hormones such as GLP-1, however, the putative foregut 
hypothesis relies on early data that excludes a segment of the gastrointestinal foregut 
to achieve diabetes resolution and has largely focused on a possible anti-incretin 
hormone that has not yet been discovered. The foregut hypothesis is complex and 
difficult to prove as its putative mechanism is suggested to derive from a yet 
undiscovered peptide that is continually released in the normal gastrointestinal tract 
that acts as an anti-insulin like hormone. The theory further describes that this anti-
incretin hormone is somehow decreased after bariatric surgical intervention to the 
foregut so that this putative blockade of insulin release is removed to correct 
underlying insulin resistance and diabetes. As such, the evidence for these hypotheses 
as the sole arbiters of metabolic benefit after bariatric surgery remains lacking and 
requires further substantiation particularly in the case of the foregut theory.  
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My approach was to consider the multiple effects of a single bariatric operation to 
have actions on the whole gut system that would subsequently have impact elsewhere 
in the human body. As such, I considered the whole gastrointestinal tract as a 
potential source of systemic physiological modulation after bariatric surgery. To 
achieve this I classified each bariatric operation into its immediate activities conveyed 
by the acronym ‘BRAVE’ effects. This holistic view allows the variable effects of 
bariatric surgery to be considered together, incorporating foregut, midgut and hindgut 
modulation. Importantly, it also considers the emerging field of bile acid flow in 
systemic metabolism whilst bearing in mind the established factors of stomach size 
restriction, altered anatomy and gut hormone modulation. Furthermore, it identifies 
the role of the vagal nerve which was classically a critical point of upper 
gastrointestinal operations, in relation to the dumping syndrome; but whose role has 
been less recognised in the recent era.  
 
Using a top-down systems biology approach I have been able to derive a new 
appreciation of post bariatric gut physiology that revealed a characteristic pattern of 
gastrointestinal stool metabolites in subjects undergoing surgery. These findings 
identified a characteristic metabolic signature of post bariatric surgery metabolite 
changes, whilst also revealing previously unknown effects on gut microbial ecology. 
The fundamental role of the gut microbiota in the immune system and several 
systemic and gastrointestinal conditions is increasingly being recognised, however its 
role in bariatric surgery was hitherto unknown. The results of my studies have 
identified that one of the most pronounced metabolic effects of these procedures is 
associated with changes in gut microbiota. This may subsequently reveal previously 
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unknown mechanisms that guide the gastrointestinal tract to direct metabolic function, 
for example in the post-operative resolution of pancreatic insufficiency.  
 
Microbial changes after bariatric surgery do not rely on the simple traditional role of 
bacterial translocation in activating disease but are supported by a wealth of recent 
evidence demonstrating the activation of several molecular intermediaries to carry out 
metabolic effects. Importantly, my results have also demonstrated the association 
between gut microbial changes and those of gastrointestinal electrophysiological 
molecules such as GABA. As such, these findings represent a platform on which to 
study not only metabolic shift but also the electromecanical activities of bariatric 
operations, an avenue of growing interest since the publication of early evidence 
demonstrating improved gastrointestinal peristalsis after bypass procedures.  
 
In addition, the results presented in this thesis also reveal significant metabolic shifts 
in urinary metabolites, and effects on distant organ systems such as the heart. My 
early hypothesis that there was a direct communicative dialogue between the 
gastrointestinal system and the heart led to the concept of the entero-cardiac axis 
where the gastrointestinal system was able to offer protective activity to the 
myocardium through its powerful gut humoral actions. I had further hypothesised that 
the profound beneficial effect that has in some instances revealed up to an 89% 
reduction in relative risk of cardiovascular disease, could be a result of the activation 
of the entero-cardiac axis by bariatric operations. This axis has recently been 
validated by several independent laboratories, and my research has also identified a 
direct metabolic effect on the myocardium following bariatric surgery. These early 
findings suggest a number of potential mechanisms whereby these procedures may 
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directly effect cardiac energy metabolism and thus at least in part explain the 
beneficial actions of surgery on cardiac morphology, re-modeling, electrophysiology 
and prevention of heart failure and ischaemic heart disease. 
 
This work emphasises the metabolic surgical paradigm that one-day bariatric surgery 
may even be designed or performed primarily for targeted metabolic indications such 
as diabetes resolution in the absence of weight loss. Consequently, one suggestion is 
that metabolic operations can be used for direct metabolic effects where weight loss is 
a beneficial bystander effect or even not realized if unnecessary. It opens up a new 
umbrella field where terms such as ‘diabetic surgery’ or ‘metabolic cardiac surgery’ 
may be employed. The fact that bariatric operations offer an intervention into the 
gastrointestinal system that then acts elsewhere in the mammalian body can result in 
these operations being considered as remote surgery where gastrointestinal metabolic 
surgery can offer changes in distal organs such as the pancreas (to resolve diabetes), 
heart (to resolve cardiac failure) and even the brain (to alter appetite and neuronal 
function). Although these hypotheses at present remain speculatory, the results of this 
work may in future offer a platform on which the mechanism of these metabolic shifts 
may be better characterised, as well as providing an opportunity for new and 
enhanced interventions to combat the increasing prevalence of obesity and global 
metabolic dysfunction.  
 
7.4	  Future	  Directions	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The future of this field is to delineate the causal relationships between the numerous 
effects of bariatric surgery, its associated gut microbial changes and subsequent 
systemic and local organ physiology. Whilst a top-down systems biology approach 
has identified numerous avenues for further investigation, these results remain 
preliminary and future studies are required to clarify any Bradford-Hill criteria for the 
manipulation of individual surgical effects and subsequent clinical outcomes. This 
will require a myriad of experimental models and clinical trials targeted to not only 
clarify the mechanism of metabolic shift after bariatric surgery but also to translate 
these results into producing the next generation of metabolic enhancing treatments. 
The profound anti-diabetic effect to these operations is yet to be fully elucidated and 
the exact contribution of weight dependent and weight independent effects on 
systemic physiology through bariatric surgery remains unknown. The top-down 
systems biology approach that has been successfully applied in this work must now be 
enhanced through further mechanistic modalities, including genomic, epigenomic and 
microRNA profiling. Transcriptional and other genetic effects will necessitate 
analysis through transgenic models of obesity, its co-morbidities and metabolic 
disease. Furthermore, complex statistical methodology is likely to be required to 
clarify and adequately weight the actions of bariatric procedures. This may include 
hierarchical network accommodating models to demonstrate the role of bariatric 
surgery on network human interactions, altered feeding behaviour and appetite 
changes. On a clinical level, well-designed prospective and translational randomised 
controlled trials are required to better establish the organ-specific effects of bariatric 
procedures on the pancreas, the kidneys, the liver and heart. Furthermore, such trials 
should strive to incorporate the measurement of molecular endpoints so as to truly 
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bridge the translational gap between metabolic profiling and clinical outcomes (figure 
7-4). 
 
 
 
Figure 7-1. Future Directions of Bariatric/Metabolic Surgery 
 
The timeline and global effects of bariatric surgical actions require increased scrutiny 
across various disease processes affecting every organ system in the body. 
Furthermore, there is a direct requirement to compare and contrast each operation 
against other bariatric procedures. This may require a variety of top-down data 
integration methods that include advanced systems biology modeling, multivariate 
hierarchical statistics, multiple-input-multiple-output techniques, the application of 
fuzzy logic to bioinformatics, neural network programming and the utilization of 
computational physiology and biology within the context of bariatric biomedical 
constraints. Furthermore, there will be a wider need to derive evidence from standard, 
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network, panoramic, über and individual-patient-data (IPD) meta-analytical tools to 
demonstrate complex multiple treatment effects. These can contribute to the new 
wave of personalized health care, precision medicine and personal evidence-based 
medicine (pEBM). In terms of laboratory research, there will be an increased drive 
toward the generation of bariatric animal models for a variety of operations such as 
Roux-en-Y gastric bypass, sleeve gastrectomy, adjustable gastric banding and 
billiopancreatic diversion in transgenic mice to appropriately select procedures in 
larger mammals where necessary. Complex genomic, proteomic and transcriptomic 
analysis can strengthen the classical bottom-up approaches to identifying important 
disease phenotypes, mechanistic peptides and therapeutic molecular targets. The 
multiple benefits from all these data-sources will require more in-depth integration to 
correlate disease-resolving mechanism to patient outcomes, quality of life, cost-
effectiveness and policy strategies to demonstrate the accurate impact of metabolic 
procedures. 
 
Clinical trials of bariatric operations will require an increased level of scientific 
robustness, bias minimizing effects and the importance of international multi-center 
collaborative methodologies with long-term follow up to enhance the translational 
impact of these results and data interpretation. These require bariatric scientists to 
apply the most cutting edge evidence synthesis methodologies that also incorporate 
complex decision models and Bayesian techniques. There will also be an increased 
requirement for societal and medical familiarity with bariatric evidence. These 
methods can offer the interpretation of the most up to date bariatric evidence, to 
generate new hypotheses and develop new therapies for obesity and its comorbidities. 
These will be required to differentiate the protective versus the therapeutic effects of 
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each operation and all of the relative contributions in combined operations such as 
carrying out a sleeve gastrectomy and the next generation of duodenal exclusion (for 
example using the novel endobarrier device). If bariatric operations can truly offer an 
autobionic effect, it is required to identify which proportion of the population should 
receive these, in which age groups, for what demographics and for what diseases. 
 
Future studies therefore require both molecular and translational impact to be 
identified but also contextualization in the era of obesity and diabetes driven global 
health crises. Research evidence from bariatric studies requires an increased focus on 
cost-effectiveness models and decision-making capabilities to support policy 
decisions and enhance the understanding of the beneficial effects of these operations 
by policy makers. The strength of future bariatric research requires justification 
through the highest levels of therapeutic impact data to support medical practice and 
both medical and political guidelines.  
 
The progressing avalanche of global obesity will continue to challenge healthcare 
systems despite the worldwide necessity to reduce healthcare costs. The positive 
future for bariatric procedures offers a new paradigm in patient care. These may 
include: 
 
1. Tailor-made metabolic procedures - where interventions can be focused for 
specific diseases such as the resolution of diabetes (weight loss effects would 
not be the primary aim and could act as a beneficial bystander effect). 
2. Procedures that carry simultaneous effects on multiple organs, for example 
current procedures such as the gastric bypass offer concurrent beneficial 
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actions on both the heart and kidney so that these operations act on the 
metabolic cross-talk between these systems identified through cardio-renal 
axis (figure 7-5). As a result, future operations may not only focus on 
individual organ systems but can be optimized to target specific organ 
interactions and systemic metabolic dialogues. 
3. Development of the next generation of metabolic intervention (surgical and 
non-surgical) 
4. Identification of novel mechanisms for non-surgical therapies in managing 
obesity and metabolic dysfunction 
 
 
 
Figure 7-2. The multi-organ systemic effects of bariatric surgery and the cardio-renal dialogue 
 
In summary, bariatric or metabolic operations have demonstrated powerful metabolic 
impact for the past 60 years, and the escalating crisis of toxic obesogenic 
environments and increasing lifespans has revealed a significant rise in adiposity, 
 165 
diabetes and cancer. The broad range of bariatric procedures has offered both 
protective and therapeutic roles against these disorders. The future of bariatric surgery 
remains influential in view of its powerful metabolic impact. However, this can be 
enhanced for the next generation by increasing the precision of patient selection and 
developing bariatric derived novel therapeutic innovations to offer solutions for many 
of these large-scale epidemiological metabolic diseases.  
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